

Botulinum Toxin

- abobotulinumtoxinA (Dysport)
- daxibotulinumtoxinA-lanm (Daxxify)
- incobotulinumtoxinA (Xeomin)
- onabotulinumtoxinA (Botox)
- rimabotulinumtoxinB (Myobloc)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Botulinum Toxin	1
Summary	3
Definitions	4
Clinical Indications	7
Medical Necessity Criteria for Initial Clinical Review	7
Initial Drug and Indication-Specific Criteria	7
OnabotulinumtoxinA (Botox) (J0585)	7
Achalasia	7
Axillary Hyperhidrosis or Palmar Hyperhidrosis	7
Blepharospasm or Hemifacial Spasms	8
Cervical Dystonia (i.e., Spasmodic Torticollis)	8
Chronic Anal Fissure	9
Chronic Migraine Prophylaxis	9
Essential Tremors	10
Oromandibular Dystonias (i.e., Cranial Dystonia)	10

Overactive Bladder with Urge Incontinence	11
Sialorrhea	11
Spasmodic Dysphonia (i.e., Laryngeal Dystonia)	12
Spasticity of the Upper and/or Lower Extremity	12
Strabismus	13
Upper Extremity Focal Dystonia (e.g., Writer's Cramp or Musician's Cramp)	13
Urinary Incontinence due to Detrusor Overactivity (i.e., Detrusor Instability or Detrusor Hyperreflexia) or Detrusor-Sphincter Dyssynergia	13
AbobotulinumtoxinA (Dysport) (J0586)	14
Axillary Hyperhidrosis	14
Blepharospasm or Hemifacial Spasms	15
Cervical Dystonia (i.e., Spasmodic Torticollis)	15
Chronic Anal Fissure	15
Sialorrhea	16
Spasticity of the Upper and/or Lower Extremity	16
Upper Extremity Focal Dystonia (e.g., Writer's Cramp or Musician's Cramp)	17
RimabotulinumtoxinB (Myobloc) (J0587)	17
Cervical Dystonia (i.e., Spasmodic Torticollis)	17
Sialorrhea	18
IncobotulinumtoxinA (Xeomin) (J0588)	18
Blepharospasm or Hemifacial Spasms	18
Cervical Dystonia (i.e., Spasmodic Torticollis)	19
Sialorrhea	19
Spasticity of the Upper Limb	20
DaxibotulinumtoxinA-lanm (Daxxify) (J0589)	20
Cervical dystonia (i.e., spasmodic torticollis)	20
Medical Necessity Criteria for Subsequent Clinical Review	21
Experimental or Investigational / Not Medically Necessary	22
All Botulinum Toxin Preparations	22
OnabotulinumtoxinA (Botox) (J0585)	23
AbobotulinumtoxinA (Dysport) (J0586)	26
RimabotulinumtoxinB (Myobloc) (J0587)	28
IncobotulinumtoxinA (Xeomin) (J0588)	30
DaxibotulinumtoxinA-lanm (Daxxify) (J0589)	31
Applicable Billing Codes	31
References	54
AbobotulinumtoxinA (Dysport)	61
DaxibotulinumtoxinA-lanm (Daxxify)	64
OnabotulinumtoxinA (Botox)	64
IncobotulinumtoxinA (Xeomin)	89
RimabotulinumtoxinB (Myobloc)	92
Appendix A	98
General Recommendations for Time to Retreatment and Dosing	98

Summary

Botulinum toxins are a class of injectable medications that block the nerves responsible for controlling muscle function. The paralysis of targeted muscles typically occurs within 2 to 5 days after administration and can last for 2 to 3 months. There are seven different types (A-G) of Botulinum toxin, but only types A and B are approved for clinical use:

- There are currently five botulinum toxin preparations available in the US, including:
 - Four type A preparations (abobotulinumtoxinA [Dysport®], daxibotulinumtoxinA-lanm [Daxxify®], incobotulinumtoxinA [Xeomin®], and onabotulinumtoxinA [Botox®, Botox® Cosmetic])
 - Two additional forms of botulinum toxin are available for cosmetic purposes only (Jeuveau® [prabotulinumtoxinA-xvfs], and Letybo® [letibotulinumtoxinA-wlbg]).
 - One type B preparation (rimabotulinumtoxinB [Myobloc®])
- Botulinum toxin preparations must be prescribed and administered by a licensed physician or medical provider.

Botulinum toxins have pharmacological uses in the treatment of various medical conditions characterized by muscle spasms or overactivity, such as cerebral palsy, stroke, and spinal cord disorders. In these conditions, Botulinum toxins are used to reduce muscle tone, relieve pain, and improve functional ability. Botulinum toxins are also used to treat other conditions, such as chronic migraine, hyperhidrosis, and strabismus (eye misalignment).

Botulinum toxins can also be used for cosmetic purposes, such as decreasing wrinkles, but such use is not considered medically necessary by the Plan. In cosmetic applications, Botulinum toxins are used to reduce the appearance of wrinkles by relaxing the muscles responsible for facial expressions. The effects of cosmetic Botulinum toxin injections typically last for 3 to 4 months.

NOTE: The Plan may require the use of preferred medications as the first-line treatment. Please refer to the following applicable Plan Clinical Guideline for a comprehensive list of our preferred and non-preferred drugs on the medical benefit:

- Commercial Preferred Physician-Administered Specialty Drugs (CG052).
- Botulinum Toxins - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria (CG088).

Definitions

“Achalasia” is a failed relaxation of the lower esophageal sphincter resulting in painful spasms and/or regurgitation of food.

“Blepharospasm” refers to uncontrolled blinking or spasms of the eyelids.

“Botulinum Toxins” refer to the seven serologically distinct neurotoxins derived from the bacterium *Clostridium botulinum*. These agents differ in their synthesis and the specific bacterium strain from which they are isolated. Botulinum toxins function by inhibiting acetylcholine release at the neuromuscular junction to cause flaccid paralysis of muscles.

“Documentation” refers to written information, including but not limited to:

- Up-to-date chart notes, relevant test results, and/or relevant imaging reports to support diagnoses; or
- Prescription claims records, and/or prescription receipts to support prior trials of formulary alternatives.

“Cervical Dystonia” (also known as “Spasmodic Torticollis”) refers to painful contraction of the neck muscles causing twisting or tilting of the head to one side.

“Chronic anal fissure” is a tear in the skin of the anus that persists for more than 8 weeks.

“Chronic migraine” is a type of migraine headache that occurs at least 15 days per month for more than three months.

“Detrusor Hyperactivity” (also known as “Bladder Overactivity”) refers to spasms of the bladder muscles resulting in urgency, frequency, pain and/or incontinence.

“Detrusor sphincter dyssynergia (DSD)” is a medical condition that affects the coordination between the bladder and the muscles around the urethra, which is called the external urinary sphincter.

“Essential tremors” is a neurological disorder characterized by involuntary shaking or trembling movements, usually affecting the arms and hands but sometimes involving the head and other parts of the body.

“Hyperhidrosis” refers to inappropriate, excessive sweating.

“Hemifacial spasms” is a neurological disorder characterized by involuntary contractions of the facial muscles on one side of the face.

“Hyperhidrosis Disease Severity Scale (HDSS)” is a tool used to assess the severity of hyperhidrosis, a condition characterized by excessive sweating beyond what is necessary for regulating body temperature. The HDSS is a simple and quick questionnaire that consists of only one question and is rated on a scale from 1 to 4:

1. No interference with daily activities

2. Noticeable but not causing interference with daily activities
3. Some interference with daily activities
4. Severe interference with daily activities

The HDSS is used by healthcare professionals to determine the impact of hyperhidrosis on a patient's quality of life and to guide treatment decisions. Patients with HDSS scores of 3 or 4 are considered to have severe hyperhidrosis and may require more aggressive treatment options, such as prescription antiperspirants, oral medications, or minimally invasive procedures like botulinum toxin injections or iontophoresis. Patients with HDSS scores of 1 or 2 may benefit from less invasive treatments like topical antiperspirants or lifestyle modifications.

“Lower extremity” Refers to the leg, knee, ankle, and foot.

“Muscle Spasms” refer to the involuntary contractions of one or more muscles.

“Neurogenic” refers to a condition or disorder that is caused by or related to problems with the nervous system.

“No evidence of” indicates that the reviewer has not identified any records of the specified item or condition within the submitted materials or claims history. In the absence of such evidence, the member is considered eligible. If any evidence of the item or condition is present upon review of the request, the member does not qualify.

“Oromandibular dystonias (OMD)” refer to a group of neurological movement disorders that affect the muscles of the jaw, mouth, and face. OMD can cause involuntary muscle contractions that result in abnormal movements and postures, such as jaw clenching, teeth grinding, lip pursing, or tongue protrusion. OMD can be classified into several types based on the location and pattern of muscle contractions, including jaw-opening, jaw-closing, or mixed OMD.

“Overactive bladder” is a condition in which the muscles in the bladder contract involuntarily and cause a sudden urge to urinate.

“Prophylaxis” is a preventative treatment intended to stop or reduce the recurrence of a disease or condition.

“Sialorrhea” (also known as “Ptyalism”) refers to excess salivation or drooling.

“Spasmodic dysphonia” is a neurological disorder that affects the muscles of the voice box, causing spasms and interruptions in speech.

“Spasticity” is a condition characterized by increased muscle tone, which can cause stiffness, spasms, or involuntary movements.

“Strabismus” is a vision disorder in which the eyes are not properly aligned and point in different directions.

“Temporomandibular disorders (TMD)” refer to a group of conditions that affect the temporomandibular joint (TMJ) and the muscles of the jaw and face.

“Upper extremity” refers to the arm, shoulder, and hand.

“Urge incontinence” is a type of urinary incontinence characterized by the sudden, strong urge to urinate that is followed by an involuntary loss of urine.

“Urinary incontinence” is a condition in which a person cannot control their bladder, leading to the involuntary loss of urine.

“Urodynamic testing” is a medical diagnostic procedure that evaluates how well the lower urinary tract (including the bladder and urethra) is functioning. The test measures various parameters, such as bladder pressure, urine flow rate, and capacity, to help diagnose conditions that affect the urinary system, such as incontinence, urinary tract obstruction, or nerve or muscle problems.

“[s]” indicates state mandates may apply.

Clinical Indications

Medical Necessity Criteria for Initial Clinical Review

Refer to [Continued Care](#) for reauthorization criteria or [Appendix A](#), Table 1 for standard initial/retreatment authorization duration.

Initial Drug and Indication-Specific Criteria

OnabotulinumtoxinA (Botox) (J0585)

Achalasia

The Plan considers onabotulinumtoxinA (Botox) (J0585) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., gastroenterologist, endoscopist, ENT); *AND*
2. The member has a diagnosis of achalasia; *AND*
3. Documented evidence of ALL of the following
 - a. Confirmed diagnosis with esophageal manometry; *and*
 - b. Alternative causes of the symptoms (e.g., esophageal stricture, carcinoma, schatzki's ring, or extrinsic compression), have been ruled out by upper endoscopy and/or adequately treated; *and*
 - c. Presence of progressive dysphagia to solids and liquids; *and*
 - d. The member meets ONE (1) of the following^[5]:
 - i. Pneumatic dilation or surgical myotomy (i.e., laparoscopic Heller myotomy, or peroral endoscopic myotomy (POEM)) has been attempted but was unsuccessful; *or*
 - i. The member was not a good candidate for the procedure; *or*
 - ii. The member refused treatment/surgery.

Axillary Hyperhidrosis or Palmar Hyperhidrosis

The Plan considers onabotulinumtoxinA (Botox) (J0585) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., dermatologist, neurologist); *AND*
2. The member is 18 years of age or older; *AND*
3. The member has a diagnosis of axillary hyperhidrosis or palmar hyperhidrosis; *AND*
4. Documented evidence of ALL of the following:
 - a. Severe hyperhidrosis, defined as ONE (1) of the following:
 - i. A score of 3 or 4 on the Hyperhidrosis Disease Severity Scale; *or*
 - ii. The impact of excessive sweating on quality of life has been significant, causing interference with daily activities (e.g., social, professional) and leading to feelings of anxiety and embarrassment; *and*

- b. Alternative causes of the symptoms (e.g., hyperthyroidism, lifestyle factors), have been ruled out or adequately treated; *and*
- c. The member is unable to use, or has tried and failed first-line management with BOTH of the following^[5]:
 - i. Lifestyle measures such as avoiding known triggers and tight clothing; *and*
 - ii. Using antiperspirants (e.g., aluminum chloride hexahydrate).

Blepharospasm or Hemifacial Spasms

The Plan considers onabotulinumtoxinA (Botox) (J0585) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., ophthalmologist, neurologist, movement disorder specialist); *AND*
2. The member is 12 years of age or older; *AND*
3. The member has a diagnosis of blepharospasm or hemifacial spasms; *AND*
4. Documented evidence of BOTH of the following:
 - a. Diagnosis of ONE (1) or more of the following:
 - i. Benign essential blepharospasm; *or*
 - ii. Blepharospasm associated with dystonia; *or*
 - iii. Blepharospasm associated with facial nerve disorders such as Bell palsy (i.e., cranial nerve VII disorders);
 - iv. Hemifacial spasm in muscles innervated by the facial nerve (e.g., orbicularis oculi muscle, cranial nerve VII); *and*
 - b. Alternative causes of the symptoms have been ruled out or adequately treated, including but not limited to neuromuscular diseases (e.g., myasthenia gravis).

Cervical Dystonia (i.e., Spasmodic Torticollis)

The Plan considers onabotulinumtoxinA (Botox) (J0585) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, movement disorder specialist); *AND*
2. The member is 16 years of age or older; *AND*
3. The member has a diagnosis of cervical dystonia (i.e., spasmodic torticollis); *AND*
4. Documented evidence of ALL of the following:
 - a. Symptoms (e.g., abnormal head positioning, neck pain, limited range of motion, muscle spasms) have been present for at least 6 months; *and*
 - b. Neck pain and abnormal head tilt/torsion adversely affects range of motion and daily functioning; *and*
 - c. Sustained involuntary contractions in the neck muscles (e.g splenius, trapezius, posterior cervical, or sternocleidomastoid); *and*

Alternative causes of the symptoms have been ruled out or adequately treated, including but not limited to neuromuscular disease (e.g., myasthenia gravis), chronic neuroleptic treatment or fixed muscle contractures.

Chronic Anal Fissure

The Plan considers onabotulinumtoxinA (Botox) (J0585) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., gastroenterologist, colon or rectal surgeon); *AND*
2. The member has a diagnosis of chronic anal fissure; *AND*
3. Documented evidence of ALL of the following:
 - a. At least 2 months of symptoms, including ONE (1) or more of the following:
 - i. Anal bleeding; *or*
 - ii. Post-defecation pain; *and*
 - b. The member is unable to use, or has tried and failed ONE (1) of the following^[5]:
 - i. Topical nitrates (e.g., Nitroglycerin 0.2% or 0.4% rectal ointment); *or*
 - ii. Topical calcium channel blockers (e.g., Diltiazem 2% rectal gel, nifedipine 0.2% or 0.5% rectal ointment); *AND*
4. No evidence of ALL of the following:
 - a. Anal fistula; *and*
 - b. Inflammatory bowel disease; *and*
 - c. Prior perianal surgical intervention.

Chronic Migraine Prophylaxis

The Plan considers onabotulinumtoxinA (Botox) (J0585) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, headache specialist); *AND*
2. The member is 18 years of age or older; *AND*
3. The member has a diagnosis of chronic migraine; *AND*
4. Documented evidence of ALL of the following:
 - a. Diagnosis of migraine headache (with or without aura) per International Classification of Headache Disorders criteria (see [Appendix B, Table 1](#)); *and*
 - b. The member has chronic migraines, defined as headache occurring on 15 or more days per month for more than three months, which, on at least 8 days per month, has the features of migraine headache; *and*
 - c. The member is unable to use ALL, or has adequately tried and failed an 8-week trial of at least TWO (2) preventative therapies, each from a different drug class^[5]:
 1. Anticonvulsants (e.g., topiramate, divalproex, sodium valproate); *and/or*
 2. Tricyclic antidepressants (e.g., amitriptyline, nortriptyline); *and/or*

3. Serotonin-norepinephrine reuptake inhibitors (e.g., venlafaxine, duloxetine); *and/or*
 4. Beta blockers (such as propranolol, metoprolol); *and/or*
 5. Other agents defined as ONE (1) of the following: candesartan, frovatriptan, lisinopril, or memantine; *AND*
- d. IF the requested medication will be used concomitantly with calcitonin gene-related peptide (CGRP) antagonist for migraine headache prophylaxis (e.g., Aimovig [erenumab], Ajovy [fremanezumab], Emgality [galcanezumab], Nurtec [rimegepant], Qulipta [atogepant], Vypti [eptinezumab]) the member meets ALL of the following:
- a. The member has previously experienced a positive response (e.g., reduction in migraine days or severity) with botulinum toxin (i.e., onabotulinumtoxinA [Botox]) OR CGRP antagonist for migraine headache prophylaxis (whichever was started first) alone; *and*
 - b. The member continues to experience migraine days, requiring additional therapy for prevention; *AND*
 - e. No evidence of neuromuscular disease (e.g., myasthenia gravis).

Essential Tremors

The Plan considers onabotulinumtoxinA (Botox) (J0585) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, movement disorder specialist, otolaryngology); *AND*
2. The member has a diagnosis of essential tremor(s); *AND*
3. Documented evidence of BOTH of the following:
 - a. The member meets ONE (1) of the following diagnosis:
 - i. Disabling head and neck tremor; *or*
 - ii. Disabling essential hand tremor; *and*
 - b. The member is unable to use, or has tried and failed TWO (2) of the following^[5]:
 - i. Propranolol (immediate-release or extended-release); *and/or*
 - ii. Primidone; *and/or*
 - iii. Gabapentin; *and/or*
 - iv. Topiramate.

Oromandibular Dystonias (i.e., Cranial Dystonia)

The Plan considers onabotulinumtoxinA (Botox) (J0585) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, movement disorder specialist, orofacial pain specialist, otolaryngologist); *AND*
2. The member has a diagnosis of oromandibular dystonias (i.e., cranial dystonia); *AND*

3. Documented evidence of BOTH of the following:
 - a. Characterized by sustained or intermittent involuntary muscle spasms/contractions in the face, jaw, pharynx, and tongue; *and*
 - b. Causing difficulty in jaw closing or opening and interfering with fluid and food intake and speech.

Overactive Bladder with Urge Incontinence

The Plan considers onabotulinumtoxinA (Botox) (J0585) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., urologist); *AND*
2. The member is 18 years of age or older; *AND*
3. The member has a diagnosis of overactive bladder with urge incontinence; *AND*
4. Documented evidence of BOTH of the following:
 - a. Urodynamic testing confirms urinary incontinence with urgency; *and*
 - b. Symptoms had not been adequately managed with BOTH of the following^[s]:
 - i. Behavioral therapies (such as bladder training and pelvic floor muscle therapy), for at least 8 weeks; *and*
 - ii. The member is unable to use, or as tried and failed, a of TWO (2) pharmacologic therapies, for at least 4 weeks each:
 1. Anticholinergic (i.e., antimuscarinics) therapy, such as darifenacin (Enablex), fesoterodine (Toviaz), oxybutynin (Ditropan XL), solifenacin (Vesicare), tolterodine (Detrol/Detrol LA), or trospium (Sanctura/Sanctura XR); *and/or*
 2. Beta-3 Adrenergic Agonists, such as Gemtesa (vibegron) or Myrbetriq (miraberon); *AND*
5. No evidence of ALL of the following:
 - a. Acute urinary retention; *and*
 - b. Acute urinary tract infection.

Sialorrhea

The Plan considers onabotulinumtoxinA (Botox) (J0585) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, physical medicine and rehabilitation (PM&R), or ENT); *AND*
2. The member has a diagnosis of sialorrhea; *AND*
3. Documented evidence of ALL of the following:
 - a. Chronic sialorrhea resulting from a neurological condition (e.g., Parkinson's disease, atypical parkinsonism, stroke, or traumatic brain injury); *and*
 - b. The member has complications such as recurrent infection or chronic skin breakdown OR sialorrhea that impacts quality of life after failing lifestyle modifications; *and*

- c. The member is unable to use ALL, or has adequately tried and failed two (2) months of pharmacotherapy with ONE (1) of the following^[s]:
 - i. Atropine solution; *and/or*
 - ii. Benztropine; *and/or*
 - iii. Glycopyrrolate; *and/or*
 - iv. Methoscopolamine; *and/or*
 - i. Scopolamine.

Spasmodic Dysphonia (i.e., Laryngeal Dystonia)

The Plan considers onabotulinumtoxinA (Botox) (J0585) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., gastroenterologist, endoscopist, ENT); *AND*
2. The member has a diagnosis of spasmodic dysphonia (i.e., laryngeal dystonia); *AND*
3. Documented evidence of BOTH of the following:
 - a. Adductor-type spasmodic dysphonia confirmed by fiberoptic laryngoscopy; *and*
 - b. Moderate to severe phonation difficulties.

Spasticity of the Upper and/or Lower Extremity

The Plan considers onabotulinumtoxinA (Botox) (J0585) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, PM&R); *AND*
2. The member has a diagnosis of spasticity of the upper and/or lower extremity; *AND*
3. The member is characterized by ONE (1) of the following:
 - a. The member is greater than the age of 2 with spasticity due to cerebral palsy or stroke who are receiving ongoing rehabilitation; *or*
 - b. The member is 18 years of age or older with ONE (1) of the following:
 - i. Spasticity secondary to multiple sclerosis or other demyelinating diseases of the central nervous system; *or*
 - ii. Spasticity secondary to spinal cord injury; *or*
 - iii. Post-stroke spasticity; *AND*
4. Documentation of ALL of the following:
 - a. Joint is not affected by fixed contracture; *and*
 - b. Abnormal muscle tone that interferes with daily functioning or is expected to result in joint contracture with further growth; *and*
 - c. Treatment is expected to improve functioning and/or allow for further therapeutic rehabilitation; *and*
 - d. Surgical intervention is the only other alternative option.

Strabismus

The Plan considers onabotulinumtoxinA (Botox) (J0585) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., ophthalmologist); *AND*
2. The member is 12 years of age or older; *AND*
3. The member has a diagnosis of strabismus; *AND*
4. No evidence of ALL of the following
 - a. Likely to have a spontaneous recovery; *or*
 - b. Restrictive strabismus; *or*
 - c. Strabismus secondary to prior surgical over recession of the ocular antagonist muscle.

Upper Extremity Focal Dystonia (e.g., Writer's Cramp or Musician's Cramp)

The Plan considers onabotulinumtoxinA (Botox) (J0585) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, movement disorder specialist); *AND*
2. The member is 16 years of age or older; *AND*
3. The member has a diagnosis of upper extremity focal dystonia; *AND*
4. Documented evidence of ALL of the following:
 - a. Significant pain and/or abnormal hand or forearm positioning that adversely affects daily functioning; *and*
 - b. Failure of at least two months of conservative therapy (e.g., a levodopa trial in those with a family history of dopa-responsive dystonia, Parkinsonism, or in those in which onset of dystonia was during childhood or adolescence) and/or lifestyle modification^[s].

Urinary Incontinence due to Detrusor Overactivity (i.e., Detrusor Instability or Detrusor Hyperreflexia) or Detrusor-Sphincter Dyssynergia

The Plan considers onabotulinumtoxinA (Botox) (J0585) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., urologist); *AND*
2. The member is 5 years of age or older; *AND*
3. The member has a diagnosis of urinary incontinence due to detrusor overactivity (i.e., detrusor instability or detrusor hyperreflexia) OR detrusor-sphincter dyssynergia; *AND*
4. Documented evidence of ALL of the following:
 - a. The condition is associated with a neurologic condition (e.g., spinal cord injury, multiple sclerosis, Parkinson's disease, cerebral palsy, stroke); *and*
 - b. Symptoms had not been adequately managed with ALL of the following^[s]:

- i. Behavioral therapies (such as bladder training and pelvic floor muscle therapy) for 8 to 12 weeks; *and*
 - ii. IF the member is 18 years of age or older, the member is unable to use, or has tried and failed ONE (1) anticholinergic (i.e. antimuscarinic) therapy such as darifenacin (Enablex), fesoterodine (Toviaz), oxybutynin (Ditropan XL), solifenacin (Vesicare), tolterodine (Detrol/Detrol LA), or trospium (Sanctura/Sanctura XR) for 4 to 8 weeks (inadequate response or intolerable adverse effects); *and*
 - iii. IF the member is 6 years of age or older, the member is unable to use, or has tried and failed ONE (1) of the following:
 - 1. Fesoterodine (Toviaz); *or*
 - 2. Oxybutynin (Ditropan XL); *or*
 - iv. Solifenacin (Vesicare), and the member weighs at least 9kg; *AND*
5. No evidence of ALL of the following:
- a. Urinary tract infection (UTI); *or*
 - b. Urinary retention or postvoid residuals (PVR) greater than 200 mL unless the patient is receiving intermittent catheterization as part of the overall treatment plan.

AbobotulinumtoxinA (Dysport) (J0586)

Axillary Hyperhidrosis

The Plan considers abobotulinumtoxinA (Dysport) (J0586) medically necessary when ALL of the following criteria are met:

- 1. The request is by a provider specialist who will administer botulinum toxin (e.g., dermatologist, neurologist); *AND*
- 2. The member is 18 years of age or older; *AND*
- 3. The member has a diagnosis of axillary hyperhidrosis; *AND*
- 4. Documented evidence of ALL of the following:
 - a. Severe primary axillary hyperhidrosis, defined as ONE (1) of the following:
 - i. A score of 3 or 4 on the Hyperhidrosis Disease Severity Scale; *or*
 - ii. The impact of excessive sweating on quality of life has been significant, causing interference with daily activities (e.g., social, professional) and leading to feelings of anxiety and embarrassment; *and*
 - b. Alternative causes of the symptoms (e.g., hyperthyroidism, lifestyle factors), have been ruled out or adequately treated; *and*
 - c. The member is unable to use, or has tried and failed first-line management with BOTH of the following^[6]:
 - i. Lifestyle measures such as avoiding known triggers and tight clothing; *and*
 - ii. Using antiperspirants (e.g., aluminum chloride hexahydrate)

Blepharospasm or Hemifacial Spasms

The Plan considers abobotulinumtoxinA (Dysport) (J0586) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., ophthalmologist, neurologist, movement disorder specialist); *AND*
2. The member is 18 years of age or older; *AND*
3. The member has a diagnosis of blepharospasm or hemifacial spasms; *AND*
4. Documented evidence of BOTH of the following:
 - a. Diagnosis of ONE (1) or more of the following:
 - i. Benign essential blepharospasm; *or*
 - ii. Blepharospasm associated with dystonia; *or*
 - iii. Blepharospasm associated with facial nerve disorders such as Bell palsy (i.e., cranial nerve VII disorders); *or*
 - iv. Hemifacial spasm involving the orbicularis oculi muscle; *and*
 - b. Alternative causes of the symptoms have been ruled out or adequately treated, including but not limited to neuromuscular diseases (e.g., myasthenia gravis).

Cervical Dystonia (i.e., Spasmodic Torticollis)

The Plan considers abobotulinumtoxinA (Dysport) (J0586) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, movement disorder specialist); *AND*
2. The member is 16 years of age or older; *AND*
3. The member has a diagnosis of cervical dystonia (i.e., spasmodic torticollis); *AND*
4. Documented evidence of ALL of the following:
 - a. Symptoms (e.g., abnormal head positioning, neck pain, limited range of motion, muscle spasms) have been present for at least 6 months; *and*
 - b. Neck pain and abnormal head tilt/torsion adversely affects range of motion and daily functioning; *and*
 - c. Sustained involuntary contractions in the neck muscles (e.g., splenius, trapezius, posterior cervical, or sternocleidomastoid); *and*
 - d. Alternative causes of the symptoms have been ruled out or adequately treated, including but not limited to neuromuscular disease (e.g., myasthenia gravis), chronic neuroleptic treatment, fixed muscle contractures.

Chronic Anal Fissure

The Plan considers abobotulinumtoxinA (Dysport) (J0586) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., gastroenterologist, colon or rectal surgeon); *AND*

2. The member has a diagnosis of chronic anal fissure; *AND*
3. Documented evidence of ALL of the following:
 - a. At least 2 months of symptoms, including ONE (1) or more of the following:
 - i. Anal bleeding; *or*
 - ii. Post-defecation pain; *and*
 - b. The member is unable to use, or has tried and failed ONE (1) of the following^[s]:
 - v. Topical nitrates (e.g., Nitroglycerin 0.2% or 0.4% rectal ointment); *or*
 - vi. Topical calcium channel blockers (e.g., Diltiazem 2% rectal ointment, nifedipine 0.2% or 0.5% rectal ointment); *AND*
4. No evidence of ALL of the following:
 - d. Anal fistula; *and*
 - e. Inflammatory bowel disease; *and*
 - f. Prior perianal surgical intervention.

Sialorrhea

The Plan considers abobotulinumtoxinA (Dysport) (J0586) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, PM&R, or ENT); *AND*
2. The member has a diagnosis of sialorrhea; *AND*
3. Documented evidence of ALL of the following:
 - a. Chronic sialorrhea resulting from a neurological condition (e.g., Parkinson's disease, atypical parkinsonism, stroke, or traumatic brain injury); *and*
 - b. The member has complications such as recurrent infection or chronic skin breakdown OR sialorrhea that impacts quality of life after failing lifestyle modifications; *and*
 - c. The member is unable to use ALL, or has adequately tried and failed TWO (2) months of pharmacotherapy with ONE (1) of the following^[s]:
 - i. Atropine solution; *and/or*
 - ii. Benztropine; *or*
 - iii. Glycopyrrolate; *or*
 - iv. Methoscopolamine; *and/or*
 - v. Scopolamine.

Spasticity of the Upper and/or Lower Extremity

The Plan considers abobotulinumtoxinA (Dysport) (J0586) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, PM&R); *AND*
2. The member has a diagnosis of spasticity of the upper and/or lower extremity; *AND*
3. The member is characterized by ONE (1) of the following:

- a. The member is greater than the age of 2 with spasticity due to cerebral palsy or stroke who are receiving ongoing rehabilitation; *or*
- b. The member is 18 years of age or older with ONE (1) of the following:
 - i. Spasticity secondary to multiple sclerosis or other demyelinating diseases of the central nervous system; *or*
 - ii. Spasticity secondary to spinal cord injury; *or*
 - iii. Post-stroke spasticity; *AND*
- 4. Documentation of ALL of the following:
 - a. Joint is not affected by fixed contracture; *and*
 - b. Abnormal muscle tone that interferes with daily functioning or is expected to result in joint contracture with further growth; *and*
 - c. Treatment is expected to improve functioning and/or allow for further therapeutic rehabilitation; *and*
 - d. Surgical intervention is the only alternative option.

Upper Extremity Focal Dystonia (e.g., Writer’s Cramp or Musician’s Cramp)

The Plan considers abobotulinumtoxinA (Dysport) (J0586) medically necessary when ALL of the following criteria are met:

- 1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, movement disorder specialist); *AND*
- 2. The member has a diagnosis of upper extremity focal dystonia; *AND*
- 3. The member is 16 years of age or older; *AND*
- 4. Documented evidence of ALL of the following:
 - a. Significant pain and/or abnormal hand or forearm positioning that adversely affects daily functioning; *and*
 - b. Failure of at least two months of conservative therapy (e.g., a levodopa trial in those with a family history of dopa-responsive dystonia, Parkinsonism, or in those in which onset of dystonia was during childhood or adolescence) and/or lifestyle modification.

RimabotulinumtoxinB (Myobloc) (J0587)

Cervical Dystonia (i.e., Spasmodic Torticollis)

The Plan considers rimabotulinumtoxinB (Myobloc) (J0587) medically necessary when ALL of the following criteria are met:

- 1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, movement disorder specialist); *AND*
- 2. The member is 18 years of age or older; *AND*
- 3. The member has a diagnosis of cervical dystonia (i.e., spasmodic torticollis); *AND*
- 4. Documented evidence of ALL of the following:

- a. Symptoms (e.g., abnormal head positioning, neck pain, limited range of motion, muscle spasms) have been present for at least 6 months; *and*
- b. Neck pain and abnormal head tilt/torsion adversely affects range of motion and daily functioning; *and*
- c. Sustained involuntary contractions in the neck muscles (e.g splenius, trapezius, posterior cervical, or sternocleidomastoid); *and*

Alternative causes of the symptoms have been ruled out or adequately treated, including but not limited to neuromuscular disease (e.g., myasthenia gravis), chronic neuroleptic treatment, or fixed muscle contractures.

Sialorrhea

The Plan considers rimabotulinumtoxinB (Myobloc) (J0587) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, PM&R, or ENT); *AND*
2. The member has a diagnosis of sialorrhea; *AND*
3. Documented evidence of ALL of the following:
 - a. Chronic sialorrhea resulting from a neurological condition (e.g., Parkinson's disease, atypical parkinsonism, stroke, or traumatic brain injury); *and*
 - b. The member has complications such as recurrent infection or chronic skin breakdown OR sialorrhea that impacts quality of life after failing lifestyle modifications; *and*
 - c. The member is unable to use, or has adequately tried and failed two (2) months of pharmacotherapy with ONE (1) of the following^[s]:
 - i. Atropine solution; *or*
 - ii. Benztropine; *or*
 - iii. Glycopyrrolate; *or*
 - iv. Methoscopolamine; *or*
 - v. Scopolamine.

IncobotulinumtoxinA (Xeomin) (J0588)

Blepharospasm or Hemifacial Spasms

The Plan considers incobotulinumtoxinA (Xeomin) (J0588) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., ophthalmologist, neurologist, movement disorder specialist); *AND*
2. The member is 18 years of age or older; *AND*
3. The member has a diagnosis of blepharospasm or hemifacial spasms; *AND*
4. Documented evidence of BOTH of the following:
 - a. Diagnosis of ONE (1) or more of the following:

- i. Benign essential blepharospasm; *or*
 - ii. Blepharospasm associated with dystonia; *or*
 - iii. Blepharospasm associated with facial nerve disorders such as Bell palsy; *or*
 - iv. Hemifacial spasm involving the orbicularis oculi muscle; *and*
- b. Alternative causes of the symptoms have been ruled out or adequately treated, including but not limited to neuromuscular diseases (e.g., myasthenia gravis).

Cervical Dystonia (i.e., Spasmodic Torticollis)

The Plan considers incobotulinumtoxinA (Xeomin) (J0588) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, movement disorder specialist); *AND*
2. The member is 18 years of age or older; *AND*
3. The member has a diagnosis of cervical dystonia (i.e., spasmodic torticollis); *AND*
4. Documented evidence of ALL of the following:
 - a. Symptoms (e.g., abnormal head positioning, neck pain, limited range of motion, muscle spasms) have been present for at least 6 months; *and*
 - b. Neck pain and abnormal head tilt/torsion adversely affects range of motion and daily functioning; *and*
 - c. Sustained involuntary contractions in the neck muscles (e.g splenius, trapezius, posterior cervical, or sternocleidomastoid); *and*
 - d. Alternative causes of the symptoms have been ruled out or adequately treated, including but not limited to neuromuscular disease (e.g., myasthenia gravis), chronic neuroleptic treatment, or fixed muscle contractures.

Sialorrhea

The Plan considers incobotulinumtoxinA (Xeomin) (J0588) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, PM&R, or ENT); *AND*
2. The member is 2 years of age or older; *AND*
3. The member has a diagnosis of sialorrhea; *AND*
4. Documented evidence of ALL of the following:
 - a. Chronic sialorrhea resulting from a neurological condition (e.g., Parkinson's disease, atypical parkinsonism, stroke, or traumatic brain injury); *and*
 - b. The member has complications such as recurrent infection or chronic skin breakdown OR sialorrhea that impacts quality of life after failing lifestyle modifications; *and*
 - c. The member is unable to use, or has adequately tried and failed two (2) months of pharmacotherapy with ONE (1) of the following^[s]:
 - i. Atropine solution; *or*

- ii. Bzotropine; *or*
- iii. Glycopyrrolate; *or*
- iv. Methoscopolamine; *or*
- v. Scopolamine.

Spasticity of the Upper Limb

The Plan considers incobotulinumtoxinA (Xeomin) (J0588) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, PM&R); *AND*
2. The member has a diagnosis of spasticity of the upper limb; *AND*
3. The member is characterized by ONE (1) of the following:
 - a. The member is 2 to 17 years of age and meets ONE (1) of the following:
 - i. The spasticity is not caused by cerebral palsy; *or*
 - ii. With spasticity due to cerebral palsy who are receiving ongoing rehabilitation; *or*
 - b. The member is 18 years of age or older and meets ONE (1) of the following:
 - i. Spasticity secondary to multiple sclerosis or other demyelinating diseases of the central nervous system; *or*
 - ii. Spasticity secondary to spinal cord injury; *or*
 - iii. Post-stroke spasticity; *AND*
4. Documentation of ALL of the following:
 - a. Joint is not affected by fixed contracture; *and*
 - b. Abnormal muscle tone that interferes with daily functioning or is expected to result in joint contracture with further growth; *and*
 - c. Treatment is expected to improve functioning and/or allow for further therapeutic rehabilitation; *and*
 - e. Surgical intervention is the only alternative option.

DaxibotulinumtoxinA-lanm (Daxxify) (J0589)

Cervical dystonia (i.e., spasmodic torticollis)

The Plan considers daxibotulinumtoxinA-lanm (Daxxify) (J0589) medically necessary when ALL of the following criteria are met:

1. The request is by a provider specialist who will administer botulinum toxin (e.g., neurologist, movement disorder specialist); *AND*
2. The member is 18 years of age or older; *AND*
3. The member has a diagnosis of cervical dystonia (i.e., spasmodic torticollis); *AND*
4. Documented evidence of ALL of the following:
 - a. Symptoms (e.g., abnormal head positioning, neck pain, limited range of motion, muscle spasms) have been present for at least 6 months; *and*

- b. Neck pain and abnormal head tilt/torsion adversely affects range of motion and daily functioning; *and*
- c. Sustained involuntary contractions in the neck muscles (e.g., splenius, trapezius, posterior cervical, or sternocleidomastoid); *and*
- d. Alternative causes of the symptoms have been ruled out or adequately treated, including but not limited to neuromuscular disease (e.g., myasthenia gravis), chronic neuroleptic treatment, or fixed muscle contractures.

Continued Care

Medical Necessity Criteria for Subsequent Clinical Review

Subsequent Medical Necessity Criteria for Botulinum Toxin (abobotulinumtoxinA [Dysport], daxibotulinumtoxinA-ianm [Daxxify], incobotulinumtoxinA [Xeomin], onabotulinumtoxinA [Botox], or rimabotulinumtoxinB [Myobloc])

The Plan considers botulinum toxin medically necessary at the end of the initial trial period when ALL of the following criteria are met:

- 1. A positive response is documented in the medical record, which should typically last for 3 months; *AND*
- 2. The member would continue to meet the initial applicable clinical criteria for the specific botulinum toxin agent in the absence of further treatment; *AND*
- 3. The prescribing clinician provides an expected duration and frequency of ongoing treatment, which may require ongoing approval; *AND*

NOTE: Treatment with botulinum toxin more frequently than every 3 months for a covered condition, regardless of diagnosis, is generally not considered medically necessary.

- 4. IF the request is for chronic migraine prophylaxis with OnabotulinumtoxinA (Botox), after the initial trial period, which is defined as 6 months or a maximum of 2 treatments, the Plan considers continuing treatment medically necessary when the member meets ALL of the following:

- a. The member experiences ONE (1) of the following:
 - i. At least a 50% reduction in monthly migraine days; *or*
 - ii. At least 2 fewer migraine days per month; *or*
 - iii. At least a reduction of 7 headache days over a one-month period compared to the pre-treatment average; *or*
 - iv. A clinically meaningful improvement in ANY of the following validated migraine-specific patient-reported outcome measures:
 - 1. Migraine Disability Assessment (MIDAS)
 - a. Reduction of ≥ 5 points when baseline score is 11-20; *or*
 - b. Reduction of $\geq 30\%$ when baseline score is >20 ; *or*
 - 2. Migraine Physical Function Impact Diary (MPFID)
 - a. Reduction of ≥ 5 points; *or*
 - 3. Headache Impact Test (HIT-6)

- a. Reduction of ≥ 5 points; AND
- b. IF botulinum toxin (i.e., onabotulinumtoxinA [Botox]) will be used concomitantly with a CGRP antagonist for migraine headache prophylaxis (e.g., Aimovig [erenumab], Ajovy [fremanezumab], Emgality [galcanezumab], Nurtec [rimegepant], Qulipta [atogepant], Vyepti [eptinezumab]) the member has had further reduction in migraines days or severity compared to either drug alone.

See [Appendix A](#) for General Recommendations for Time to Retreatment and Dosing

Experimental or Investigational / Not Medically Necessary

All Botulinum Toxin Preparations

Botulinum Toxin for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, unproven, or not medically necessary. Non-covered indications include, but are not limited to, the following:

NOTE: if a rationale is not provided, there were no studies identified to support the safety and/or efficacy for that indication.

1. All botulinum toxin preparations (regardless of type) are considered contraindicated, experimental, investigational, or unproven in the following cases:
 - a. Infection at the proposed injection site; *or*
 - b. Known hypersensitivity to any botulinum toxin preparation or the components in the formulation; *or*
 - c. Retreatment of a condition with the same or different agent after a failed initial trial, regardless of if the member continues to meet clinical criteria; *or*

NOTE: If the member initially failed therapy due to an agent-specific intolerance or reaction, rather than a clinical feature, then this statement may not apply.
2. The Plan deems the use of botulinum toxin for ALL cosmetic purposes as not medically necessary. Such cosmetic purposes include, but are not limited to:
 - a. chin dimpling; *or*
 - b. eyebrow elevation/shaping ("brow lift"); *or*
 - c. flaring nostrils (nasal flare); *or*
 - d. forehead lines; *or*
 - e. glabellar facial ("frown") lines; *or*
 - f. labiomandibular grooves; *or*
 - g. lateral brow lift; *or*
 - h. lateral canthal lines ("crow's feet"); *or*
 - i. lip lines; *or*
 - j. radial lines on the dorsum of the nose (bunny lines); *or*
 - k. to treat prominent platysma muscle bands (age-related neck degeneration).

3. Botulinum toxin antibody assays are considered experimental or investigational and are therefore not covered by the Plan.

OnabotulinumtoxinA (Botox) (J0585)

OnabotulinumtoxinA (Botox) (J0585) for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, unproven, or not medically necessary. Non-covered indications include, but are not limited to, the following:

- A. Acute and chronic back pain
- B. Acute and chronic shoulder pain
 - a. *Rationale:* only one study (n=37) participants assessed shoulder pain at 4 weeks in those with post-stroke shoulder spasticity. However, there was no difference found in pain scores between OnabotulinumtoxinA and placebo.
- C. Anal sphincter achalasia
 - a. *Rationale:* A 2012 meta-analysis on 16 nonrandomized studies examining Botox for internal anal sphincter achalasia revealed significantly higher rates of non-response and adverse outcomes when compared to myectomy. Further evidence is required to determine a potential benefit of Botox therapy in this patient population.
- D. Benign prostatic hyperplasia (BPH, benign prostatic hypertrophy) with lower urinary tract symptoms (LUTS)
 - a. *Rationale:* There is insufficient evidence to support the use of OnabotulinumtoxinA for men with lower urinary tract symptoms caused by benign prostatic hyperplasia. Currently, no guidelines in the field endorse OnabotulinumtoxinA as a potential treatment option. To fully evaluate the short- and long-term efficacy, including the need for repeated injections in patients with LUTS due to BPH, large-scale, placebo-controlled randomized trials are necessary. Furthermore, given the availability of several effective treatments for BPH, the potential role of BoNT-A should be examined in further randomized trials that compare it to α -blockers, 5- α reductase inhibitors, minimally invasive treatments, and even traditional surgery.
- E. Carpal tunnel syndrome
- F. Chronic idiopathic constipation (CIC)
- G. Chronic pain, including, but not limited to: myofascial pain syndrome, inflammatory pain, knee osteoarthritis, musculoskeletal pain (including acute shoulder and back pain), neuropathic pain, postoperative pain, post-herpetic neuralgia, gynecologic pain syndromes, fibromyalgia.
 - a. *Rationale:* Multiple systematic reviews and meta-analyses have concluded that the current evidence is inadequate to support the use of Botox in chronic pain syndromes.
- H. Chronic paralytic strabismus, except when used in conjunction with surgical repair to reduce ocular antagonist muscle contracture.
- I. Club foot (e.g. talipes equinovarus)
 - a. *Rationale:* The existing evidence consists of a small (n=20) randomized trial showing no benefit with Botox in reducing cast time, need for further procedural intervention, or risk for relapse. A small (n=62) study found there was no difference between Botox and

placebo in infants with clubfoot when administered at hindfoot stall. A separate, larger study with 239 patients found some evidence of efficacy for Botox, however the study was designed as a retrospective case series. Further randomized, prospective evidence is needed to determine a potential benefit of Botox for this indication.

- J. Cosmetic strabismus, defined as adults with congenital strabismus without binocular fusion.
- K. Depression
 - a. *Rationale:* while small studies (n=29-225) have shown efficacy for Botox in the management of depression, larger high quality studies are not available to support the safety and efficacy of Botox for depression. One large study (n=715) did show a benefit in depression and anxiety scoring in Botox compared to placebo, however the study was powered originally for the outcome of headache management, not depression.
- L. First-bite syndrome, with or without pain that has failed traditional analgesics
- M. Frey Syndrome (i.e. Gustatory sweating)
 - a. *Rationale:* A 2013 evidence-based review concluded that the lack of randomized clinical evidence for Botox in Frey's syndrome limits the support for clinical use.
- N. Gastroparesis
 - a. *Rationale:* There is limited evidence to support the use of OnabotulinumtoxinA for gastroparesis. Some small studies have suggested potential benefit in reducing symptoms and improving gastric emptying, but larger randomized controlled trials are needed to further evaluate its efficacy and safety for this condition. Therefore, more research is needed before making a definitive conclusion about the effectiveness of OnabotulinumtoxinA for gastroparesis.
- O. Hyperhidrosis of the face/neck
 - a. *Rationale:* more high-quality studies are needed to further evaluate the safety and efficacy of Botox in the treatment of craniofacial hyperhidrosis.
- P. Migraines or other headaches (e.g. tension, cluster, chronic daily) that do not meet the above criteria for chronic migraine prophylaxis
 - a. *Rationale:* OnabotulinumtoxinA has been used with varying degrees of success in a small number of patients suffering from headaches other than chronic migraine, including post-whiplash (cervicogenic) headache, tension-type headache, and cluster headache. The manufacturer cautions that the safety and effectiveness of onabotulinumtoxinA for prophylaxis of episodic migraine (less than or equal to 14 headache days per month) have not been established. The American Academy of Neurology (AAN) does not endorse the use of onabotulinumtoxinA as a treatment for headaches other than chronic migraine.
- Q. Obesity
- R. Painful bruxism
 - a. *Rationale:* while a small (n=23) randomized controlled trial found promising results for Botox over placebo for the management of sleep bruxism, larger, higher quality studies are required to support the safety and efficacy of Botox in this population.
- S. Palatal myoclonus

- T. Phonic tics
- U. Plantar fasciitis
- V. Postnatal brachial plexus injury
- W. Post-radiation myokymia, including facial myokymia and trismus
- X. Raynaud's Phenomenon
 - a. *Rationale:* Limited studies, including small non-controlled trials, case series, and retrospective reviews, have suggested some potential benefits of using onabotulinumtoxinA (botulinum toxin A) for severe symptoms associated with primary or secondary Raynaud phenomenon (RP). While a small randomized, double-blind, placebo-controlled trial in patients with scleroderma-associated RP also showed some positive effect in patient-reported clinical measures, it did not demonstrate significant improvements in blood flow as measured by laser Doppler imaging, which was the primary outcome. A systemic review found insufficient evidence to assess the efficacy of onabotulinumtoxinA in severe RP, and experts recommend reserving its use for patients who have not tolerated or have failed initial conventional therapy. Further trials may be necessary to determine the role of onabotulinumtoxinA in this condition.
- Y. Refractory interstitial cystitis
 - a. *Rationale:* in a small (n=47) randomized controlled trial in those with interstitial cystitis (IC)/bladder pain syndrome (BPS), Botox was found to be more effective than placebo at 2 months post injection, but no different than placebo at months 6 to 9 post injection. Additionally, 8% of those on Botox experienced urinary retention requiring self-catheterization, and no improvement in patient satisfaction, perception of treatment convenience or willingness to undergo re-treatment. Additional studies (n=19-81) have been published with highly variable results in cases of refractory IC/BPS, indicating larger, higher quality studies are need to support the safety and efficacy of Botox in this population.
- Z. Tardive dyskinesia
 - a. *Rationale:* Small noncontrolled trials suggest that botulinum toxin A may be beneficial for treating localized tardive dyskinesia, such as orofacial, head and neck, and cervical symptoms. However, the evaluation of the data is limited due to several studies not specifying the type of botulinum toxin A product used. Case reports primarily evaluating onabotulinumtoxinA have demonstrated benefits in most patients. However, the American Academy of Neurology clinical practice guidelines consider the data inadequate to support or refute the use of botulinum toxin type A for treating tardive dyskinesia.
- AA. Temporomandibular Disorders (TMD)
 - a. *Rationale:* There is limited evidence supporting the use of botulinum toxin A (BTX-A) for the treatment of Temporomandibular Disorders (TMD). Some small randomized controlled trials and case reports have suggested that BTX-A injections may provide pain relief and improve jaw function in patients with TMD. However, the evidence is not

conclusive and larger, more rigorous studies are needed to determine the effectiveness and safety of BTX-A in the treatment of TMD.

BB. Thoracic outlet syndrome

CC. Trigeminal neuralgia

- a. *Rationale:* The current evidence is either uncontrolled or nonrandomized with small (n=9-20) patient samples. Review articles have suggested there may be some efficacy for Botox in trigeminal neuralgia but indicate that further study is needed.

DD. Upper esophageal sphincter dysfunction

AbobotulinumtoxinA (Dysport) (J0586)

AbobotulinumtoxinA (Dysport) (J0586) for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, unproven, or not medically necessary. Non-covered indications include, but are not limited to, the following:

- A. AbobotulinumtoxinA (Dysport) is contraindicated in members with allergy to cow's milk protein, per FDA guidelines
- B. Achalasia or upper esophageal sphincter dysfunction
- C. Benign prostatic hypertrophy (BPH)
 - a. *Rationale:* A 2011 review article on abobotulinumtoxinA for lower urinary tract symptoms related to BPH concluded that the level of evidence is low and further randomized controlled trials are necessary.
- D. Carpal tunnel syndrome
- E. Charcot-Marie-Tooth disease
- F. Chronic migraine prevention
- G. Chronic musculoskeletal and myofascial pain
 - a. *Rationale:* A systematic review of the available randomized trials found lack of efficacy for Dysport in myofascial pain syndromes. A small (n=18) randomized controlled trial found improvement between Dysport and placebo in chronic back pain at 4 weeks, quality of life and a higher proportion of those reporting their low back pain was "much improved;" however, there was no difference in the primary outcome measure. A small (n=14) study found improvement in knee pain upon kneeling, squatting and level walking in those with anterior knee pain with Dysport versus placebo. No high quality, large randomized controlled trials have supported the efficacy and safety of Dysport in those with chronic pain syndromes.
- H. Gastroparesis
 - a. *Rationale:* There is currently insufficient evidence to support the use of AbobotulinumtoxinA (Dysport) for gastroparesis. While botulinum toxin type A has been studied in the treatment of gastroparesis, most studies have focused on the use of onabotulinumtoxinA (Botox) and there is limited research on the efficacy of abobotulinumtoxinA for this indication. More research is needed to determine the safety and effectiveness of abobotulinumtoxinA in the treatment of gastroparesis.

- I. Headaches, including migraines, tension headaches, or headaches secondary to cranial neuralgia
 - a. *Rationale:* A prospective, multi-center, randomized, double-blind placebo-controlled trial found no significant difference between placebo and Dysport in headache free days (primary outcome) among patients suffering from chronic migraine.⁵⁻⁶
- J. Hyperhidrosis, other than axillary hyperhidrosis
 - a. *Rationale:* An expert review by the American Academy of Neurology concluded that the evidence for Dysport in palmar hyperhidrosis was inadequate to guide clinical decision making.
- K. Lateral epicondylitis
 - a. *Rationale:* Only one small (n=60) single-center, randomized controlled trial found improvement with pain intensity at 90 days and quality of life in those receiving Dysport versus placebo; however, larger studies are needed to support these findings.
- L. Obesity
- M. Plantar fasciitis
- N. Postnatal brachial plexus injury
- O. Raynaud's Phenomenon
 - a. *Rationale:* There is limited evidence to support the use of Dysport (abobotulinumtoxinA) in the treatment of Raynaud's Phenomenon (RP). Some small studies and case reports have suggested that botulinum toxin A (BTX-A) injections, including Dysport, may have some benefit for the treatment of severe RP symptoms. However, the evidence is not yet strong enough to make definitive recommendations for the use of Dysport in RP treatment. More studies are needed to determine the optimal dose, injection sites, and duration of effect for BTX-A in the treatment of RP.
- P. Refractory interstitial cystitis
 - a. *Rationale:* only one double-blind small (n=54) study assessed Dysport versus placebo in those with IC/bladder pain syndrome (BPS). They found no improvement in refractory IC/BPS scoring between Dysport and placebo.
- Q. Shoulder pain
- R. Strabismus
- S. Temporomandibular Disorders (TMD)
 - a. *Rationale:* There is limited evidence to support the use of Dysport (abobotulinumtoxinA) in the treatment of Temporomandibular Disorders (TMD). Some small studies and case reports have suggested that botulinum toxin A (BTX-A) injections, including Dysport, may have some benefit for the treatment of certain types of TMD, however, the evidence is not yet strong enough to make definitive recommendations for the use of Dysport in TMD treatment. More studies are needed to determine the optimal dose, injection sites, and duration of effect for BTX-A in the treatment of TMD.
- T. Tourette Syndrome
 - a. *Rationale:* There is currently insufficient evidence to support the use of Dysport (abobotulinumtoxinA) in the treatment of Tourette Syndrome. While some small studies

and case reports have shown promise, larger, well-designed clinical trials are needed to fully evaluate the safety and efficacy of this treatment approach. The American Academy of Neurology's clinical practice guidelines currently do not recommend the use of botulinum toxin for the treatment of tics in Tourette Syndrome.

U. Trigeminal neuralgia

RimabotulinumtoxinB (Myobloc) (J0587)

RimabotulinumtoxinB (Myobloc) (J0587) for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, unproven, or not medically necessary. Non-covered indications include, but are not limited to, the following:

- A. Bladder dysfunction (e.g. overactive bladder, detrusor hyperreflexia)
 - a. *Rationale:* The evidence has been contradictory or inconclusive, with some studies showing RimabotulinumtoxinB efficacy while others have demonstrated a lack of benefit. A 2011 Cochrane review (updating the previous 2007 review) identified 19 studies meeting inclusion criteria, and found that the efficacy of RimabotulinumtoxinB was inferior to that of type A toxins with a substantially shorter duration of benefit across randomized trials for bladder dysfunction.
- B. Blepharospasm and Associated Facial Nerve Disorders (e.g., hemifacial spasm)
 - a. *Rationale:* RimabotulinumtoxinB is limited in efficacy and experience, but has been used for blepharospasm or hemifacial spasm, mainly in patients who have responded to onabotulinumtoxinA. The American Academy of Neurology recommends onabotulinumtoxinA and incobotulinumtoxinA as treatment options, and abobotulinumtoxinA may be considered for blepharospasm, but does not make a recommendation for rimabotulinumtoxinB due to insufficient data.
- C. Disabling headaches (e.g., chronic migraines, cluster headache)
- D. Gastroparesis
 - a. *Rationale:* There is limited evidence to support the use of RimabotulinumtoxinB (Myobloc) in the treatment of gastroparesis. Some small studies have suggested potential benefit in improving symptoms such as nausea and vomiting, but more research is needed to establish the safety and effectiveness of this treatment for gastroparesis.
- E. Hyperhidrosis (including primary axillary hyperhidrosis and focal palmar hyperhidrosis)
 - a. *Rationale:* Although RimabotulinumtoxinB has been utilized for symptomatic management of primary axillary and focal palmar hyperhidrosis characterized by excessive glandular secretion, its efficacy evidence and experience are less extensive when compared to OnabotulinumtoxinA.
- F. Incontinence after spinal cord injury
- G. Involuntary (smooth) muscle overactivity (e.g., neurogenic voiding dysfunction, anal sphincter disorders)
- H. Musculoskeletal pain disorders (e.g., myofascial pain syndrome, chronic low back pain, pain associated with brachial plexopathy)

- I. Raynaud's Phenomenon
 - a. *Rationale:* There is currently insufficient evidence to support the use of RimabotulinumtoxinB (Myobloc) in the treatment of Raynaud's Phenomenon. While one small (n=45) study found improvement in pain/numbness scores, skin temperature recovery and digital ulcer improvement with Myobloc versus placebo, larger studies are needed to support the safety and efficacy of Myobloc in this population.
- J. Spasmodic dysphonia
 - a. *Rationale:* only one preliminary, dose-finding, open-label, small (n=13) study has assessed the safety and efficacy of Myobloc in those with spasmodic dysphonia. Larger, high quality studies will be needed to support the safety and efficacy of Myobloc in this population.
- K. Spasticity in adults, including post-stroke spasticity and spasticity of the upper and/or lower extremities associated with other neurological disorders
 - a. *Rationale:* The clinical evidence for RimabotulinumtoxinB (type b agent) is substantially limited compared to type A agents. A single randomized trial on 24 patients showed possible improvements with RimabotulinumtoxinB but concluded that larger studies with long-term follow up were needed for further evidence. The US Pharmacopeial Convention has stated that off-label use of RimabotulinumtoxinB for spasticity secondary to stroke or brain injury may be indicated, however updated data has failed to demonstrated the statistically significant benefit seen in earlier studies. The American Academy of Neurology currently states (per 2016 guidelines), that the data is insufficient to determine the efficacy of Myobloc in lower limb spasticity, and the evidence is limited to a single Class I study for upper limb spasticity.
- L. Spasticity in children with cerebral palsy (CP)
 - a. *Rationale:* A review by the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society concluded that the evidence was limited in children with CP, and that the existing evidence on RimabotulinumtoxinB showed inferior efficacy compared to type A toxins.
- M. Temporomandibular Disorders (TMD)
 - a. *Rationale:* There is currently insufficient evidence to support the use of RimabotulinumtoxinB (Myobloc) in the treatment of Temporomandibular Disorders (TMD). While there are some studies investigating the use of botulinum toxin in TMD, the evidence is limited and conflicting, with some studies reporting positive outcomes and others reporting no significant benefit. Further research is needed to determine the efficacy of RimabotulinumtoxinB in the treatment of TMD.
- N. Tourette Syndrome
 - a. *Rationale:* There is currently limited evidence on the use of RimabotulinumtoxinB (Myobloc) in the treatment of Tourette Syndrome. While some small studies have shown potential benefit, further research is needed to determine its efficacy and safety for this indication.
- O. Upper esophageal dysfunction or achalasia

- a. *Rationale:* A 2014 Cochrane review revealed no randomized clinical trials on RimabotulinumtoxinB for upper esophageal dysfunction.

IncobotulinumtoxinA (Xeomin) (J0588)

IncobotulinumtoxinA (Xeomin) (J0588) for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, unproven, or not medically necessary. Non-covered indications include, but are not limited to, the following:

- A. Atrial fibrillation
 - a. *Rationale:* while one study (n=60) found improvement in both early and sustained (at 1 year) atrial fibrillation/tachyarrhythmia suppression in those receiving Xeomin in the epicardial fat pads during coronary artery bypass graft surgery, larger, higher quality studies will be needed to support the safety and efficacy of Xeomin in those with atrial fibrillation.
- B. Detrusor hyperactivity (e.g. bladder overactivity)
 - a. *Rationale:* There is limited evidence on Xeomin in patients with overactive bladder. Preliminary results on 95 patients from a double-blinded study on Xeomin and Botox in bladder overactivity were presented at the 27th Annual Congress of the European Association of Urology. However, further peer-reviewed randomized evidence is currently lacking, limiting guidance for clinical application.
- C. Hyperhidrosis, including axillary, palmar, and craniofacial
 - a. *Rationale:* Xeomin and Botox were compared in a double-blind trial in treating palmar hyperhidrosis. There were no significant differences in short- or long-term efficacy outcomes, however only 25 patients were included in the study. Given the small sample size and lack of confirmatory studies, further evidence is required. Similar limitations are present in comparable studies on axillary hyperhidrosis. Further evidence is needed to determine a potential benefit of Xeomin for this indication.
- D. Gastroparesis
 - a. *Rationale:* There is currently insufficient evidence to support the use of IncobotulinumtoxinA (Xeomin) for gastroparesis. While some small studies have shown promising results, larger randomized controlled trials are needed to establish its efficacy and safety in this condition. The use of botulinum toxin for gastroparesis is still considered investigational and not recommended for routine clinical use.
- E. Migraine prophylaxis
 - a. *Rationale:* The evidence for Xeomin in migraine prophylaxis comes from small, retrospective case series and poster presentations, indicating further prospective, randomized evidence is required to guide any potential clinical application.
- F. Parkinson disease with tremor
 - a. *Rationale:* There is insufficient, conflicting, or poor evidence regarding the use of incobotulinumtoxinA for Parkinson disease with tremor, and more research is needed.
- G. Plantar fasciitis
 - a. *Rationale:* There is a lack of sufficient, conflicting, or poor evidence regarding the use of incobotulinumtoxinA for plantar fasciitis. Only one randomized controlled trial (n=50) found improvement in the foot and ankle ability measures (FAAM) tool and reduction in

pain in those with plantar fasciitis. However, larger, high quality studies are needed to support the safety and efficacy of Xeomin for plantar fasciitis.

H. Post-stroke lower limb spasticity

- a. *Rationale:* A prospective, open label study on 71 patients demonstrated safety and efficacy of Xeomin in post-stroke lower limb spasticity, however further randomized studies are required to establish clinical use. Furthermore, the 2016 American Academy of Neurology Guidelines state that there “is insufficient evidence to support or refute the use of incoBoNT-A for the treatment of lower limb spasticity.” Efficacy for the management of upper-lib spasticity has been sufficient to support use of Xeomin in this population (see medical necessity criteria for this above)

I. Raynaud’s Phenomenon

- a. *Rationale:* There is currently insufficient evidence to support the use of IncobotulinumtoxinA (Xeomin) for Raynaud's Phenomenon.

J. Temporomandibular Disorders (TMD)

- a. *Rationale:* There is limited evidence to support the use of IncobotulinumtoxinA for the treatment of Temporomandibular Disorders (TMD). While some studies have shown potential benefits, more research is needed to establish its efficacy and safety in this context. Only small studies (n=15-20) have supported the efficacy of Xeomin in those with TMD.

K. Tourette Syndrome

- a. *Rationale:* There is insufficient evidence to support the use of IncobotulinumtoxinA (Xeomin) for Tourette Syndrome.

DaxibotulinumtoxinA-lanm (Daxxify) (J0589)

DaxibotulinumtoxinA-lanm (Daxxify) (J0589) for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, unproven, or not medically necessary. Non-covered indications include, but are not limited to, the following:

- A. Chronic migraine prevention
- B. Pancreatic Carcinoma
- C. Plantar fascial fibromatosis
- D. Spasmodic Dysphonia

[Applicable Billing Codes](#)

Codes considered medically necessary if clinical criteria are met:

CPT/HCPCS Codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
J0585	Injection, onabotulinumtoxinA, 1 unit (Botox®)
J0586	Injection, abobotulinumtoxinA, 5 units (Dysport®)

J0587	Injection, rimabotulinumtoxinB, 100 units (Myobloc®)
J0588	Injection, incobotulinumtoxinA, 1 unit (Xeomin®)
J0589	Injection, daxibotulinumtoxina-lanm, 1 unit (Daxxify®)
ICD-10 codes considered medically necessary if criteria are met for onabotulinumtoxinA (J0585):	
F95.2	Tourette's disorder
G04.1	Tropical spastic paraplegia
G11.4	Hereditary spastic paraplegia
G12.21	Amyotrophic lateral sclerosis
G20	Parkinson's disease
G24.01	Drug induced subacute dyskinesia
G24.3	Spasmodic torticollis
G24.4	Idiopathic orofacial dystonia
G24.5	Blepharospasm
G24.8	Other dystonia
G25.0	Essential tremor
G35	Multiple sclerosis
G36.0	Neuromyelitis optica
G36.1	Acute and subacute hemorrhagic leukoencephalitis
G36.8	Other specified acute disseminated demyelination
G36.9	Acute disseminated demyelination, unspecified
G37.0	Diffuse sclerosis of central nervous system
G37.1	Central demyelination of corpus callosum
G37.2	Central pontine myelinolysis
G37.3	Acute transverse myelitis in demyelinating disease of central nervous system
G37.4	Subacute necrotizing myelitis of central nervous system
G37.5	Concentric sclerosis [Balo] of central nervous system
G37.8	Other specified demyelinating diseases of central nervous system
G37.81	Myelin oligodendrocyte glycoprotein antibody disease
G37.89	Other specified demyelinating diseases of central nervous system
G37.9	Demyelinating disease of central nervous system, unspecified
G43.101	Migraine with aura, not intractable, with status migrainosus
G43.109	Migraine with aura, not intractable, without status migrainosus

G43.111	Migraine with aura, intractable, with status migrainosus
G43.119	Migraine with aura, intractable, without status migrainosus
G43.701	Chronic migraine without aura, not intractable with status migrainosus
G43.709	Chronic migraine without aura, not intractable without status migrainosus
G43.711	Chronic migraine without aura, intractable, with status migrainosus
G43.719	Chronic migraine without aura, intractable, without status migrainosus
G43.E01	Chronic Migraine With Aura, Not Intractable, With Status Migrainosus
G43.E09	Chronic Migraine With Aura, Not Intractable, Without Status Migrainosus
G43.E11	Chronic Migraine With Aura, Intractable, With Status Migrainosus
G43.E19	Chronic Migraine With Aura, Intractable, Without Status Migrainosus
G51.0	Bell's palsy
G51.1	Geniculate ganglionitis
G52.2	Melkersson's syndrome
G51.3	Clonic hemifacial spasm
G51.31	Clonic hemifacial spasm, right
G51.32	Clonic hemifacial spasm, left
G51.33	Clonic hemifacial spasm, bilateral
G51.39	Clonic hemifacial spasm, unspecified
G51.54	Facial myokymia
G51.58	Other disorders of facial nerve
G51.9	Disorder of facial nerve, unspecified
G80.0	Spastic quadriplegic cerebral palsy
G80.1	Spastic diplegic cerebral palsy
G80.2	Spastic hemiplegic cerebral palsy
G80.8	Other cerebral palsy
G80.9	Cerebral palsy, unspecified
G81.10	Spastic hemiplegia affecting unspecified side
G81.11	Spastic hemiplegia affecting right dominant side
G81.12	Spastic hemiplegia affecting left dominant side
G81.13	Spastic hemiplegia affecting right nondominant side
G81.14	Spastic hemiplegia affecting left nondominant side
G82.20	Paraplegia, unspecified
G82.21	Paraplegia, complete
G82.22	Paraplegia, incomplete
G82.50	Quadriplegia, unspecified
G82.51	Quadriplegia, C1-C4 complete

G82.52	Quadriplegia, C1-C4 incomplete
G82.53	Quadriplegia, C5-C7 complete
G82.54	Quadriplegia, C5-C7 incomplete
G83.10	Monoplegia of lower limb affecting unspecified side
G83.11	Monoplegia of lower limb affecting right dominant side
G83.12	Monoplegia of lower limb affecting left dominant side
G83.13	Monoplegia of lower limb affecting right nondominant side
G83.14	Monoplegia of lower limb affecting left nondominant side
G83.31	Monoplegia, unspecified affecting right dominant side
G83.32	Monoplegia, unspecified affecting left dominant side
G83.33	Monoplegia, unspecified affecting right nondominant side
G83.34	Monoplegia, unspecified affecting left nondominant side
H49.881	Other paralytic strabismus, right eye
H49.882	Other paralytic strabismus, left eye
H49.883	Other paralytic strabismus, bilateral
H49.889	Other paralytic strabismus, unspecified eye
H49.9	Unspecified paralytic strabismus
H50.21	Vertical strabismus, right eye
H50.22	Vertical strabismus, left eye
H50.60	Mechanical strabismus, unspecified
H50.69	Other mechanical strabismus
H50.89	Other specified strabismus
H50.9	Unspecified strabismus
I69.031	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right dominant side
I69.032	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left dominant side
I69.033	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
I69.034	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side
I69.039	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting unspecified side
I69.041	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right dominant side
I69.042	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left dominant side

l69.043	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
l69.044	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side
l69.049	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting unspecified side
l69.051	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right dominant side
l69.052	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left dominant side
l69.053	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
l69.054	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left non-dominant side
l69.059	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting unspecified side
l69.131	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right dominant side
l69.132	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left dominant side
l69.133	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side
l69.134	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side
l69.139	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting unspecified side
l69.141	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right dominant side
l69.142	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left dominant side
l69.143	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side
l69.144	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side
l69.149	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting unspecified side
l69.151	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right dominant side
l69.152	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left dominant side
l69.153	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right non-dominant side

l69.154	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left non-dominant side
l69.159	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting unspecified side
l69.231	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right dominant side
l69.232	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left dominant side
l69.233	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side
l69.234	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side
l69.239	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting unspecified side
l69.241	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right dominant side
l69.242	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left dominant side
l69.243	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side
l69.244	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side
l69.251	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right dominant side
l69.252	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left dominant side
l69.253	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right non-dominant side
l69.254	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left non-dominant side
l69.259	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting unspecified side
l69.331	Monoplegia of upper limb following cerebral infarction affecting right dominant side
l69.332	Monoplegia of upper limb following cerebral infarction affecting left dominant side
l69.333	Monoplegia of upper limb following cerebral infarction affecting right non-dominant side
l69.334	Monoplegia of upper limb following cerebral infarction affecting left non-dominant side

I69.339	Monoplegia of upper limb following cerebral infarction affecting unspecified side
I69.341	Monoplegia of lower limb following cerebral infarction affecting right dominant side
I69.342	Monoplegia of lower limb following cerebral infarction affecting left dominant side
I69.343	Monoplegia of lower limb following cerebral infarction affecting right non-dominant side
I69.344	Monoplegia of lower limb following cerebral infarction affecting left non-dominant side
I69.351	Hemiplegia and hemiparesis following cerebral infarction affecting right dominant side
I69.352	Hemiplegia and hemiparesis following cerebral infarction affecting left dominant side
I69.353	Hemiplegia and hemiparesis following cerebral infarction affecting right non-dominant side
I69.354	Hemiplegia and hemiparesis following cerebral infarction affecting left non-dominant side
I69.359	Hemiplegia and hemiparesis following cerebral infarction affecting unspecified side
I69.831	Monoplegia of upper limb following other cerebrovascular disease affecting right dominant side
I69.832	Monoplegia of upper limb following other cerebrovascular disease affecting left dominant side
I69.833	Monoplegia of upper limb following other cerebrovascular disease affecting right non-dominant side
I69.834	Monoplegia of upper limb following other cerebrovascular disease affecting left non-dominant side
I69.839	Monoplegia of upper limb following other cerebrovascular disease affecting unspecified side
I69.841	Monoplegia of lower limb following other cerebrovascular disease affecting right dominant side
I69.842	Monoplegia of lower limb following other cerebrovascular disease affecting left dominant side
I69.843	Monoplegia of lower limb following other cerebrovascular disease affecting right non-dominant side
I69.844	Monoplegia of lower limb following other cerebrovascular disease affecting left non-dominant side
I69.849	Monoplegia of lower limb following other cerebrovascular disease affecting unspecified side
I69.851	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right dominant side

l69.852	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left dominant side
l69.853	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right non-dominant side
l69.854	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left non-dominant side
l69.859	Hemiplegia and hemiparesis following other cerebrovascular disease affecting unspecified side
l69.861	Other paralytic syndrome following other cerebrovascular disease affecting right dominant side
l69.862	Other paralytic syndrome following other cerebrovascular disease affecting left dominant side
l69.863	Other paralytic syndrome following other cerebrovascular disease affecting right non-dominant side
l69.864	Other paralytic syndrome following other cerebrovascular disease affecting left non-dominant side
l69.865	Other paralytic syndrome following other cerebrovascular disease, bilateral
l69.869	Other paralytic syndrome following other cerebrovascular disease affecting unspecified side
l69.931	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right dominant side
l69.932	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left dominant side
l69.933	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right non-dominant side
l69.934	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left non-dominant side
l69.939	Monoplegia of upper limb following unspecified cerebrovascular disease affecting unspecified side
l69.941	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right dominant side
l69.942	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left dominant side
l69.943	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right non-dominant side
l69.944	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left non-dominant side
l69.949	Monoplegia of lower limb following unspecified cerebrovascular disease affecting unspecified side
l69.951	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right dominant side

I69.952	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left dominant side
I69.953	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right non-dominant side
I69.954	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left non-dominant side
I69.959	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting unspecified side
J38.5	Laryngeal spasm
K11.7	Disturbances of salivary secretion
K22.0	Achalasia of cardia
K60.0	Acute anal fissure
K60.1	Chronic anal fissure
K60.2	Anal fissure, unspecified
L74.510	Primary focal hyperhidrosis, axilla
L74.512	Primary focal hyperhidrosis, palms
L98.8	Other specified disorders of the skin and subcutaneous tissue
M62.40	Contracture of muscle, unspecified site
M62.411	Contracture of muscle, right shoulder
M62.412	Contracture of muscle, left shoulder
M62.419	Contracture of muscle, unspecified shoulder
M62.421	Contracture of muscle, right upper arm
M62.422	Contracture of muscle, left upper arm
M62.429	Contracture of muscle, unspecified upper arm
M62.431	Contracture of muscle, right forearm
M62.432	Contracture of muscle, left forearm
M62.439	Contracture of muscle, unspecified forearm
M62.441	Contracture of muscle, right hand
M62.442	Contracture of muscle, left hand
M62.449	Contracture of muscle, unspecified hand
M62.451	Contracture of muscle, right thigh
M62.452	Contracture of muscle, left thigh
M62.459	Contracture of muscle, unspecified thigh
M62.461	Contracture of muscle, right lower leg
M62.462	Contracture of muscle, left lower leg
M62.469	Contracture of muscle, unspecified lower leg
M62.471	Contracture of muscle, right ankle and foot

M62.472	Contracture of muscle, left ankle and foot
M62.479	Contracture of muscle, unspecified ankle and foot
M62.48	Contracture of muscle, other site
M62.49	Contracture of muscle, multiple sites
M62.830	Muscle spasm of back
M62.831	Muscle spasm of calf
M62.838	Other muscle spasm
N31.0	Uninhibited neuropathic bladder, not elsewhere classified
N31.1	Reflex neuropathic bladder, not elsewhere classified
N31.2	Flaccid neuropathic bladder, not elsewhere classified
N31.8	Other neuromuscular dysfunction of bladder
N31.9	Neuromuscular dysfunction of bladder, unspecified
N32.81	Overactive bladder
N36.44	Muscular disorders of urethra [bladder sphincter dyssynergy] [due to spinal cord injury, bladder-hyphensphincter dyssynergia]
N39.3	Stress incontinence (female) (male)
N39.41	Urge incontinence
N39.42	Incontinence without sensory awareness
N39.43	Post-void dribbling
N39.44	Nocturnal enuresis
N39.45	Continuous leakage
N39.46	Mixed incontinence
N39.490	Overflow incontinence
N39.491	Coital incontinence
N39.492	Postural (urinary) incontinence
N39.498	Other specified urinary incontinence
R13.10	Dysphagia, unspecified
R13.11	Dysphagia, oral phase
R13.12	Dysphagia, oropharyngeal phase
R13.13	Dysphagia, pharyngeal phase
R13.14	Dysphagia, pharynoesophageal phase
R13.19	Other dysphagia
R25.2	Cramp and spasm
R32	Unspecified urinary incontinence
R39.81	Functional urinary incontinence
R49.0	Dysphonia
R61	Generalized hyperhidrosis

ICD-10 codes considered medically necessary if criteria are met for abobotulinumtoxinA (J0586) :	
G11.4	Hereditary spastic paraplegia
G24.01	Drug induced subacute dyskinesia
G24.3	Spasmodic torticollis
G24.5	Blepharospasm
G24.8	Other dystonia
G35	Multiple sclerosis
G36.0	Neuromyelitis optica
G36.1	Acute and subacute hemorrhagic leukoencephalitis
G36.8	Other specified acute disseminated demyelination
G36.9	Acute disseminated demyelination, unspecified
G37.0	Diffuse sclerosis of central nervous system
G37.1	Central demyelination of corpus callosum
G37.2	Central pontine myelinolysis
G37.3	Acute transverse myelitis in demyelinating disease of central nervous system
G37.4	Subacute necrotizing myelitis of central nervous system
G37.5	Concentric sclerosis [Balo] of central nervous system
G37.8	Other specified demyelinating diseases of central nervous system
G37.81	Myelin oligodendrocyte glycoprotein antibody disease
G37.89	Other specified demyelinating diseases of central nervous system
G37.9	Demyelinating disease of central nervous system, unspecified
G51.3	Clonic hemifacial spasm
G51.31	Clonic hemifacial spasm, right
G51.32	Clonic hemifacial spasm, left
G51.33	Clonic hemifacial spasm, bilateral
G51.39	Clonic hemifacial spasm, unspecified
G51.8	Other disorders of facial nerve
G51.9	Disorder of facial nerve, unspecified
G80.0	Spastic quadriplegic cerebral palsy
G80.1	Spastic diplegic cerebral palsy
G80.2	Spastic hemiplegic cerebral palsy
G80.8	Other cerebral palsy
G80.9	Cerebral palsy, unspecified
G81.10	Spastic hemiplegia affecting unspecified sideSpastic hemiplegia
G81.11	Spastic hemiplegia affecting right dominant side
G81.12	Spastic hemiplegia affecting left dominant side

G81.13	Spastic hemiplegia affecting right nondominant side
G81.14	Spastic hemiplegia affecting left nondominant side
G82.20	Paraplegia, unspecified
G82.21	Paraplegia, complete
G82.22	Paraplegia, incomplete
G82.50	Quadriplegia, unspecified
G82.51	Quadriplegia, C1-C4 complete
G82.52	Quadriplegia, C1-C4 incomplete
G82.53	Quadriplegia, C5-C7 complete
G82.84	Quadriplegia, C5-C7 incomplete
G83.0	Diplegia of upper limbs, Diplegia (Upper), Paralysis of both upper limbs
G83.10	Monoplegia of lower limb affecting unspecified side
G83.11	Monoplegia of lower limb affecting right dominant side
G83.12	Monoplegia of lower limb affecting left dominant side
G83.13	Monoplegia of lower limb affecting right nondominant side
G83.14	Monoplegia of lower limb affecting left nondominant side
G83.20	Monoplegia of upper limb affecting unspecified side
G83.21	Monoplegia of upper limb affecting right dominant side
G83.22	Monoplegia of upper limb affecting left dominant side
G83.23	Monoplegia of upper limb affecting right nondominant side
G83.24	Monoplegia of upper limb affecting left nondominant side
G83.30	Monoplegia, unspecified affecting unspecified side
G83.31	Monoplegia, unspecified affecting right dominant side
G83.32	Monoplegia, unspecified affecting left dominant side
G83.33	Monoplegia, unspecified affecting right nondominant side
G83.34	Monoplegia, unspecified affecting left nondominant side
I69.031	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right dominant side
I69.032	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left dominant side
I69.033	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
I69.034	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side
I69.039	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting unspecified side
I69.041	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right dominant side

I69.042	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left dominant side
I69.043	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
I69.044	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side
I69.049	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting unspecified side
I69.051	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right dominant side
I69.052	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left dominant side
I69.053	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
I69.054	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left nondominant side
I69.0541	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left non-dominant side Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage
I69.059	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting unspecified side
I69.131	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right dominant side
I69.132	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left dominant side
I69.133	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side
I69.134	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side
I69.139	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting unspecified side
I69.141	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right dominant side
I69.142	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left dominant side
I69.143	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side
I69.144	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side
I69.149	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting unspecified side
I69.098	Other sequelae following nontraumatic subarachnoid hemorrhage

l69.151	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right dominant side Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage
l69.152	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left dominant side
l69.153	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right non-dominant side
l69.154	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left non-dominant side
l69.159	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting unspecified side
l69.231	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right dominant side
l69.232	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left dominant side
l69.233	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side
l69.234	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side
l69.239	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting unspecified side
l69.241	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right dominant side
l69.242	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left dominant side
l69.243	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side
l69.244	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side
l69.249	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting unspecified side
l69.251	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right dominant side
l69.252	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left dominant side Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage
l69.253	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right non-dominant side
l69.254	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left non-dominant side
l69.259	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting unspecified side

I69.331	Monoplegia of upper limb following cerebral infarction affecting right dominant side
I69.332	Monoplegia of upper limb following cerebral infarction affecting left dominant side
I69.333	Monoplegia of upper limb following cerebral infarction affecting right non-dominant side
I69.334	Monoplegia of upper limb following cerebral infarction affecting left non-dominant side
I69.339	Monoplegia of upper limb following cerebral infarction affecting unspecified side
I69.341	Monoplegia of lower limb following cerebral infarction affecting right dominant side
I69.342	Monoplegia of lower limb following cerebral infarction affecting left dominant side
I69.343	Monoplegia of lower limb following cerebral infarction affecting right non-dominant side
I69.344	Monoplegia of lower limb following cerebral infarction affecting left non-dominant side
I69.349	Monoplegia of lower limb following cerebral infarction affecting unspecified side
I69.351	Hemiplegia and hemiparesis following cerebral infarction affecting right dominant side
I69.352	Hemiplegia and hemiparesis following cerebral infarction affecting left dominant side
I69.353	Hemiplegia and hemiparesis following cerebral infarction affecting right non-dominant side
I69.354	Hemiplegia and hemiparesis following cerebral infarction affecting left non-dominant side
I69.359	Hemiplegia and hemiparesis following cerebral infarction affecting unspecified side
I69.831	Monoplegia of upper limb following other cerebrovascular disease affecting right dominant side
I69.832	Monoplegia of upper limb following other cerebrovascular disease affecting left dominant side
I69.833	Monoplegia of upper limb following other cerebrovascular disease affecting right non-dominant side
I69.834	Monoplegia of upper limb following other cerebrovascular disease affecting left non-dominant side
I69.839	Monoplegia of upper limb following other cerebrovascular disease affecting unspecified side
I69.841	Monoplegia of lower limb following other cerebrovascular disease affecting right dominant side
I69.842	Monoplegia of lower limb following other cerebrovascular disease affecting left dominant side

169.843	Monoplegia of lower limb following other cerebrovascular disease affecting right non-dominant side
169.844	Monoplegia of lower limb following other cerebrovascular disease affecting left non- dominant side
169.849	Monoplegia of lower limb following other cerebrovascular disease affecting unspecified side
169.851	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right dominant side Hemiplegia and hemiparesis following other cerebrovascular disease
169.852	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left dominant side
169.853	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right non-dominant side
169.854	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left non-dominant side
169.859	Hemiplegia and hemiparesis following other cerebrovascular disease affecting unspecified side
169.931	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right dominant side
169.932	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left dominant side
169.933	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right non-dominant side
169.934	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left non-dominant side
169.939	Monoplegia of upper limb following unspecified cerebrovascular disease affecting unspecified side
169.941	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right dominant side
169.942	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left dominant side
169.943	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right non-dominant side
169.944	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left non-dominant side
169.949	Monoplegia of lower limb following unspecified cerebrovascular disease affecting unspecified side
169.951	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right dominant side Hemiplegia and hemiparesis following unspecified cerebrovascular disease
169.952	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left dominant side

I69.953	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right non-dominant side
I69.954	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left non-dominant side
I69.959	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting unspecified side
H49.9	Unspecified paralytic strabismus
K11.7	Disturbances of salivary secretion
K60.0	Acute anal fissure
K60.1	Chronic anal fissure
K60.2	Anal fissure, unspecified
L74.510	Primary focal hyperhidrosis, axilla
L98.8	Other specified disorders of the skin and subcutaneous tissue
M62.40	Contracture of muscle, unspecified site
M62.411	Contracture of muscle, right shoulder
M62.412	Contracture of muscle, left shoulder
M62.419	Contracture of muscle, unspecified shoulder
M62.421	Contracture of muscle, right upper arm
M62.422	Contracture of muscle, left upper arm
M62.429	Contracture of muscle, unspecified upper arm
M62.431	Contracture of muscle, right forearm
M62.432	Contracture of muscle, left forearm
M62.439	Contracture of muscle, unspecified forearm
M62.441	Contracture of muscle, right hand
M62.442	Contracture of muscle, left hand
M62.449	Contracture of muscle, unspecified hand
M62.451	Contracture of muscle, right thigh
M62.452	Contracture of muscle, left thigh
M62.459	Contracture of muscle, unspecified thigh
M62.461	Contracture of muscle, right lower leg
M62.462	Contracture of muscle, left lower leg
M62.469	Contracture of muscle, unspecified lower leg
M62.471	Contracture of muscle, right ankle and foot
M62.472	Contracture of muscle, left ankle and foot
M62.479	Contracture of muscle, unspecified ankle and foot
M62.48	Contracture of muscle, other site
M62.49	Contracture of muscle, multiple sites

M62.831	Muscle spasm of calf
M62.838	Other muscle spasm
R25.2	Cramp and spasm
ICD-10 codes considered medically necessary if criteria are met for rimabotulinumtoxinB (J0587):	
G12.21	Amyotrophic lateral sclerosis
G20	Parkinson's disease
G24.3	Spasmodic torticollis
G24.4	Idiopathic orofacial dystonia
G24.8	Other dystonia
G80.0	Spastic quadriplegic cerebral palsy
G80.1	Spastic diplegic cerebral palsy
G80.2	Spastic hemiplegic cerebral palsy
G80.8	Other cerebral palsy
G80.9	Cerebral palsy, unspecified
K11.7	Disturbances of salivary secretion
R25.2	Cramp and spasm
ICD-10 codes considered medically necessary if criteria are met for incobotulinumtoxinA (J0588):	
G24.3	Spasmodic torticollis
G24.4	Idiopathic orofacial dystonia
G24.5	Blepharospasm
G51.3	Clonic hemifacial spasm
G51.8	Other disorders of facial nerve
G51.9	Disorder of facial nerve, unspecified
G80.0	Spastic quadriplegic cerebral palsy
G80.1	Spastic diplegic cerebral palsy
G80.2	Spastic hemiplegic cerebral palsy
G81.10	Spastic hemiplegia affecting unspecified sideSpastic hemiplegia
G81.11	Spastic hemiplegia affecting right dominant side
G81.12	Spastic hemiplegia affecting left dominant side
G81.13	Spastic hemiplegia affecting right nondominant side
G81.14	Spastic hemiplegia affecting left nondominant side
G82.53	Quadriplegia, C5-C7 complete
G82.84	Quadriplegia, C5-C7 incomplete
G83.0	Diplegia of upper limbs
G83.20	Monoplegia of upper limb affecting unspecified side

G83.21	Monoplegia of upper limb affecting right dominant side
G83.22	Monoplegia of upper limb affecting left dominant side
G83.23	Monoplegia of upper limb affecting right nondominant side
G83.24	Monoplegia of upper limb affecting left nondominant side
I69.031	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right dominant side
I69.032	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left dominant side
I69.033	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
I69.034	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side
I69.039	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting unspecified side
I69.051	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right dominant side
I69.052	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left dominant side
I69.053	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
I69.0541	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left non-dominant side Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage
I69.059	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting unspecified side
I69.131	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right dominant side
I69.132	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left dominant side
I69.133	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side
I69.134	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side
I69.139	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting unspecified side
I69.151	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right dominant side Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage
I69.152	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left dominant side

I69.153	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right non-dominant side
I69.154	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left non-dominant side
I69.231	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right dominant side
I69.232	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left dominant side
I69.233	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side
I69.234	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side
I69.239	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting unspecified side
I69.251	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right dominant side
I69.252	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left dominant side Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage
I69.253	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right non-dominant side
I69.254	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left non-dominant side
I69.259	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting unspecified side
I69.331	Monoplegia of upper limb following cerebral infarction affecting right dominant side
I69.332	Monoplegia of upper limb following cerebral infarction affecting left dominant side
I69.333	Monoplegia of upper limb following cerebral infarction affecting right non-dominant side
I69.334	Monoplegia of upper limb following cerebral infarction affecting left non-dominant side
I69.339	Monoplegia of upper limb following cerebral infarction affecting unspecified side
I69.351	Hemiplegia and hemiparesis following cerebral infarction affecting right dominant side
I69.352	Hemiplegia and hemiparesis following cerebral infarction affecting left dominant side

I69.353	Hemiplegia and hemiparesis following cerebral infarction affecting right non-dominant side
I69.354	Hemiplegia and hemiparesis following cerebral infarction affecting left non-dominant side
I69.359	Hemiplegia and hemiparesis following cerebral infarction affecting unspecified side
I69.831	Monoplegia of upper limb following other cerebrovascular disease affecting right dominant side
I69.832	Monoplegia of upper limb following other cerebrovascular disease affecting left dominant side
I69.833	Monoplegia of upper limb following other cerebrovascular disease affecting right non-dominant side
I69.834	Monoplegia of upper limb following other cerebrovascular disease affecting left non-dominant side
I69.839	Monoplegia of upper limb following other cerebrovascular disease affecting unspecified side
I69.851	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right dominant side Hemiplegia and hemiparesis following other cerebrovascular disease
I69.852	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left dominant side
I69.853	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right non-dominant side
I69.854	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left non-dominant side
I69.859	Hemiplegia and hemiparesis following other cerebrovascular disease affecting unspecified side
I69.931	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right dominant side
I69.932	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left dominant side
I69.933	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right non-dominant side
I69.934	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left non-dominant side
I69.939	Monoplegia of upper limb following unspecified cerebrovascular disease affecting unspecified side
I69.951	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right dominant side Hemiplegia and hemiparesis following unspecified cerebrovascular disease

I69.952	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left dominant side
I69.953	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right non-dominant side
I69.954	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left non-dominant side
I69.959	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting unspecified side
K11.7	Disturbances of salivary secretion
L98.8	Other specified disorders of the skin and subcutaneous tissue
M62.40	Contracture of muscle, unspecified siteContracture of muscle
M62.411	Contracture of muscle, right shoulder
M62.412	Contracture of muscle, left shoulder
M62.419	Contracture of muscle, unspecified shoulder
M62.421	Contracture of muscle, right upper arm
M62.422	Contracture of muscle, left upper arm
M62.429	Contracture of muscle, unspecified upper arm
M62.431	Contracture of muscle, right forearm
M62.432	Contracture of muscle, left forearm
M62.439	Contracture of muscle, unspecified forearm
M62.441	Contracture of muscle, right hand
M62.442	Contracture of muscle, left hand
M62.449	Contracture of muscle, unspecified hand
M62.451	Contracture of muscle, right thigh
M62.452	Contracture of muscle, left thigh
M62.459	Contracture of muscle, unspecified thigh
M62.461	Contracture of muscle, right lower leg
M62.462	Contracture of muscle, left lower leg
M62.469	Contracture of muscle, unspecified lower leg
M62.471	Contracture of muscle, right ankle and foot
M62.472	Contracture of muscle, left ankle and foot
M62.479	Contracture of muscle, unspecified ankle and foot
M62.48	Contracture of muscle, other site
M62.49	Contracture of muscle, multiple sites
ICD-10 codes considered medically necessary if criteria are met for daxibotulinumtoxinA-lanm (Daxxify) (J0589):	
G24.3	Spasmodic torticollis

L98.8	Other specified disorders of the skin and subcutaneous tissue
-------	---

CPT/HCPCS Codes considered medically necessary but may be subject to medical necessity review:

<i>Code</i>	<i>Description</i>
31513	Laryngoscopy, indirect; with vocal cord injection
31570	Laryngoscopy, direct, with injection into vocal cord(s), therapeutic;
31571	Laryngoscopy, direct, with injection into vocal cord(s), therapeutic; with operating microscope or telescope
31573	Laryngoscopy, flexible; with therapeutic injection(s) (eg, chemodenevation agent or corticosteroid, injected percutaneous, transoral, or via endoscope channel), unilateral
31574	Laryngoscopy, flexible; with injection(s) for augmentation (eg, percutaneous, transoral), unilateral
43192	Esophagoscopy, rigid, transoral; with directed submucosal injection(s), any substance
43201	Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance
43236	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance
43253	Esophagoscopy, rigid, transoral; with directed submucosal injection(s), any substance
46505	Chemodenevation of internal anal sphincter [covered for anal fissure only]
52287	Cystourethroscopy, with injection(s) for chemodenevation of the bladder
64611	Chemodenevation of parotid and submandibular salivary glands, bilateral
64612	Chemodenevation of muscle(s); muscle(s) innervated by facial nerve, unilateral (eg, for blepharospasm, hemifacial spasm)
64615	Chemodenevation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)
64616	Chemodenevation of muscle(s); neck muscle(s), excluding muscles of the larynx, unilateral (eg, for cervical dystonia, spasmodic torticollis)
64617	Chemodenevation of muscle(s); larynx, unilateral, percutaneous (eg, for spasmodic dysphonia), includes guidance by needle electromyography, when performed
64642	Chemodenevation of one extremity; 1-4 muscle(s)

64643	Chemodenervation of one extremity; each additional extremity, 1-4 muscle(s) (List separately in addition to code for primary procedure)
64644	Chemodenervation of one extremity; 5 or more muscles
64645	Chemodenervation of one extremity; each additional extremity, 5 or more muscles (List separately in addition to code for primary procedure)
64646	Chemodenervation of trunk muscle(s); 1-5 muscle(s)
64647	Chemodenervation of trunk muscle(s); 6 or more muscles
64650	Chemodenervation of eccrine glands; both axillae
64653	Chemodenervation of eccrine glands; other area(s) (e.g., scalp, face, neck), per day
67345	Chemodenervation of extraocular muscle
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
95873	Electrical stimulation for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure)
95874	Needle electromyography for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure)
S2340	Chemodenervation of abductor muscle(s) of vocal cord
S2341	Chemodenervation of adductor muscle(s) of vocal cord

CPT/HCPCS codes considered experimental or investigational or *not* considered medically necessary

<i>Code</i>	<i>Description</i>
86609	Antibody; bacterium, not elsewhere specified [neutralizing antibodies to botulinum toxin]

References

1. 2019 surveillance of lower urinary tract symptoms in men: management (NICE guideline CG97) [Internet]. London: National Institute for Health and Care Excellence (NICE); 2019 Nov 14.
2. 2019 surveillance of urinary incontinence in neurological disease: assessment and management (NICE guideline CG148) [Internet]. London: National Institute for Health and Care Excellence (NICE); 2019 Jan 31.
3. Abdel-Fattah M, Chapple C, Guerrero K, et al., Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness

and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms. *Trials*. 2021 Oct 26;22(1):745. doi: 10.1186/s13063-021-05661-3.

4. Adam B et al: Botulinum toxin injection for treatment of chronic anal fissure: is there any dose-dependent efficiency? A meta-analysis. *World J Surg*. 40(12):3064-72, 2016
5. Adler CH, Factor SA, Brin M et al. Secondary nonresponsiveness to in patients with oromandibular dystonia. *Mov Disord*. 2002; 17:158-61.
6. Ailani J., Burch R., & Robbins M.S. (2021). The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. *The Journal of Head and Face Pain*, 61 (7), 1021-1039. Doi: <https://doi.org/10.1111/head.14153>
7. AIMOVIG(R) subcutaneous injection, erenumab-aooe subcutaneous injection. Amgen Inc (per FDA), Thousand Oaks, CA, 2021.
8. AJOVY(TM) subcutaneous injection, fremanezumab-vfrm subcutaneous injection. Teva Pharmaceuticals USA Inc (per FDA), North Wales, PA, 2021.
9. Albanese A, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. *European Journal of Neurology* 2011;18(1):5-18.
10. Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. *JAMA*. 2011; 305:89-90.
11. American Academy of Neurology. (May 2019). Practice Guideline Recommendations Summary: Treatment of Tics in People with Tourette Syndrome and Chronic Tic Disorders. <https://www.aan.com/Guidelines/home/GuidelineDetail/958>
12. Anon. Botox for overactive bladder. *Med Lett Drugs Ther*. 2013; 55(Apr 15):31-2.
13. Anon. Botulinum toxin (Botox Cosmetic) for frown lines. *Med Lett Drugs Ther*. 2002; 44:47-8.
14. Anon. Botulinum toxin for cervical dystonia. *Med Lett Drugs Ther*. 2001; 43:63-4.
15. Anon. Clinical use of botulinum toxin. NIH Consensus Statement Online 1990 Nov 12-14
16. Anon. Cosmetic use of botulinum toxin. *Med Lett Drugs Ther*. 1999; 41:63-4.
17. Anon. FDA approves Botox to treat severe underarm sweating. FDA talk paper. Rockville, MD: Food and Drug Administration; 2004 Jul 20.
18. Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the Use of Botulinum Toxin in the Treatment of Lower Urinary Tract Disorders and Pelvic Floor Dysfunctions: A European Consensus Report. *Eur Urol*. 2009;55(1):100-20.
19. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. *Clin J Pain*. 2002; 18(Suppl):S177-S181.
20. Armanious, M., Khalil, N., Lu, Y., & Jimenez-Sanders, R. (2021). Erenumab and OnabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: A retrospective analysis. *Journal of Pain & Palliative Care Pharmacotherapy*, 35(1), 1-6.
21. Arnon SS, Schechter R, Inglesby TV et al for the Working Group on Civilian Biodefense. Botulinum toxin as a biologic weapon: medical and public health management. *JAMA*. 2001; 285:1059-70.

22. Bai Y, et al. A systematic review on intrapyloric botulinum toxin injection for gastroparesis. *Digestion* 2010;81(1):27-34
23. Benson RA, Palin R, Holt PJ, Loftus IM. Diagnosis and management of hyperhidrosis. *British Medical Journal* 2013;347:f6800.
24. Berardelli A, Abbruzzese G, Bertolasi L et al. Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology. *Ital J Neurol Sci.* 1997; 18:261-9.
25. Bleday, R. Anal fissure: Medical management. UpToDate.com.
https://www.uptodate.com/contents/anal-fissure-medical-management?search=chronic%20anal%20fissure%20treatment&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H3548935 Last updated Feb. 2020.
26. Blumenfeld AM, Binder W, Silberstein SD. Procedures for administering for migraine and tension-type headache. *Headache.* 2003; 43:884-91.
27. Chapman MA, Barron R, Tanis DC et al. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. *Clin Ther.* 2007; 29:1325-37.
28. Cipullo LM, et al. Pharmacological approach to overactive bladder and urge urinary incontinence in women: an overview. *European Journal of Obstetrics, Gynecology, and Reproductive Biology* 2014;174:27-34.
29. Coeytaux RR, Kaufman JS, Chao R, Mann JD, Devellis RF. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. *J Clin Epidemiol.* 2006 Apr;59(4):374–380.
30. Contarino MF, Van Den Dool J, Balash Y, et al. Clinical practice: evidence-based recommendations for the treatment of cervical dystonia with botulinum toxin. *Front Neurol.* 2017;8:35. doi:10.3389/fneur.2017.00035[PubMed 28286494]
31. Cohen F, Armand C, Lipton RB, Vollbracht S. Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine. *Pain Med* 2021; 22:1857.
32. Cohen S, Parkman HP. Treatment of achalasia—from whalebone to botulinum toxin. *N Engl J Med.* 1995; 332:815-6.
33. Cruccu G, Truini A. Refractory trigeminal neuralgia. Non surgical treatment options. *CNS Drugs* 2013;27(2):91-6.
34. Cvach K, Rosamilia A. Review of intravesical therapies for bladder pain syndrome/interstitial cystitis. *Transl Androl Urol.* 2015;4(6):629-37.
35. Davids JS, Hawkins AT, Bhamra AR, et al., The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anal Fissures. *Dis Colon Rectum.* 2023 Feb 1;66(2):190-199. doi: 10.1097/DCR.0000000000002664. Epub 2022 Nov 1.
36. Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology.* 2010;74(4):336-43.

37. Desloovere K, Molenaers G, Jonkers I et al. A randomized study of combined and casting in the ambulant child with cerebral palsy using objective outcome measures. *Eur J Neurol.* 2001; 8 Suppl 5:75-87.
38. Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. *Cochrane Database Syst Rev.* 2011;(12):CD005493.
39. EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3.
40. Ferreira JJ, Costa J, Coelho M et al. The management of cervical dystonia. *Expert Opin Pharmacother.* 2007; 8:129-40.
41. Ferreira JJ, Mestre TA, Lyons KE, et al.,. MDS evidence-based review of treatments for essential tremor. *Mov Disord.* 2019 Jul;34(7):950-958. doi: 10.1002/mds.27700. Epub 2019 May 2.
42. Foxx-Orenstein AE et al: Common anorectal disorders. *Gastroenterol Hepatol (N Y).* 10(5):294-301, 2014
43. Goldman JG. Writer's cramp. *Toxicon.* 2015;107(Pt A):98-104
44. Graham HK, Aoki KR, Autti-Ramo I et al. Recommendations for the use of in the management of cerebral palsy. *Gait Posture.* 2000; 11:67-79.
45. Greene P, Fahn S, Diamond B. Development of resistance to in patients with torticollis. *Mov Disord.* 1994; 9:213-7.
46. Hartmann A, Worbe Y. Pharmacological treatment of Gilles de la Tourette syndrome. *Neuroscience and Bio-behavioral Reviews* 2013;37(6):1157 61.
47. Hayes, Inc. Health Technology Assessment. Botulinum Toxin for Treatment of Pain Associated with Temporomandibular Disorders. Lansdale, PA: Hayes, Inc.,; May 28 2021.
48. Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives NJ, Clarke CE, Sinclair AJ. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. *BMJ Open.* 2019 Jul 16;9(7):e027953. Jinnah HA. Medical and Surgical Treatments for Dystonia. *Neurol Clin.* 2020;38:325-348.
49. Herzig DO, Lu KC. Anal fissure. *Surgical Clinics of North America* 2010;90(1):33 44, Table of Contents
50. Higuero T: Update on the management of anal fissure. *J Visc Surg.* 152(2 suppl):S37-43, 2015
51. Johnson EA. Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. *Annu Rev Microbiol.* 1999; 53:551-75.
52. Karp BI, Adler K. Muscle Selection for Focal Limb Dystonia. *Toxins (Basel).* 2018;10(1):20. doi: 10.3390/toxins10010020
53. Khan A, Frazer-Green L, Amin R, et al.,. Respiratory Management of Patients With Neuromuscular Weakness: An American College of Chest Physicians Clinical Practice Guideline and Expert Panel Report. *Chest.* 2023 Aug;164(2):394-413. doi: 10.1016/j.chest.2023.03.011. Epub 2023 Mar 13.
54. Khashab MA, Vela MF, Thosani N, et al. ASGE guideline on the management of achalasia. *Gastrointest Endosc.* 2020 Feb;91(2):213-227.e6. doi: 10.1016/j.gie.2019.04.231. Epub 2019 Dec 13.
55. Koman LA, Smith BP, Balkrishnan R. Spasticity associated with cerebral palsy in children. *Pediatr Drugs.* 2003; 5:11-23.

56. Lakraj AA, Moghimi N, Jabbari B. Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. *Toxins (Basel)* 2013;5(4):821-40.
57. Lakraj AA, Moghimi N, Jabbari B. Sialorrhea: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. *Toxins (Basel)* 2013;5(5):1010-31.
58. Li L, Liu QS, Liu WH, et al. Treatment of obesity by endoscopic gastric intramural injection of botulinum toxin A: a randomized clinical trial. *Hepatogastroenterology*. 2012;59(118):2003-7.
59. Madoff RD, Fleshman JW. AGA technical review on the diagnosis and care of patients with anal fissure. *Gastroenterology*. 2003; 124:235-45.
60. Madoff RD. Pharmacologic therapy for anal fissure. *N Engl J Med*. 1998; 338:257-9.
61. Magoon EH. Chemodenervation of strabismic children. *Ophthalmology*. 1989; 96:931-4.
62. McCann JD, Ugurbas SH, Goldberg RA. Benign essential blepharospasm. *Int Ophthalmol Clin*. 2002; 42:113-21.
63. Molenaers G, Eyssen M, Desloovere K et al. A multilevel approach to treatment of the (ilio)psaos in spasticity in cerebral palsy. *Eur J Neurol*. 1999; 6(Suppl 4):S59-2.
64. Moonen AJ, Boeckstaens GE. Management of achalasia. *Gastroenterology Clinics of North America* 2013;42(1):45-55.
65. Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. *Neurology*. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124[PubMed 33144515]
66. Naumann M, So Y, Argoff CE, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2008;70(19):1707-14.
67. Nelson RL, Thomas K, Morgan J, Jones A. Non-surgical therapy for anal fissure. *Cochrane Database of Systematic Reviews* 2012, Issue 2. Art. No.: CD003431.
68. NURTEC(R) ODT orally disintegrating tablets, rimegepant orally disintegrating tablets. Biohaven Pharmaceuticals Inc (per FDA), New Haven, CT, 2021.
69. Pandey S. A practical approach to management of focal hand dystonia. *Ann Indian Acad Neurol*. 2015 Apr-Jun; 18(2): 146–153. doi: 10.4103/0972-2327.156563
70. Perry WB et al: Practice parameters for the management of anal fissures (3rd revision). *Dis Colon Rectum*. 53(8):1110-5, 2010
71. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence -based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology* 2010 (AAN reaffirmed 2013);74(4):336-43.
72. Primary Focal Axillary Hyperhidrosis. Sweathelp.org <https://sweathelp.org/treatments-hcp/clinical-guidelines/primary-focal-hyperhidrosis/primary-focal-axillary.html> Accessed March 23, 2020.
73. Pringsheim T, Davenport W, Mackie G, et al., Canadian Headache Society guideline for migraine prophylaxis. *Can J Neurol Sci*. 2012 Mar;39(2 Suppl 2):S1-59.

74. Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society, Delgado MR, Hirtz D et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology*. 2010; 74:336-43.
75. QULIPTA(TM) oral tablets, atogepant oral tablets. AbbVie Inc (per FDA), North Chicago, IL, 2021.
76. Rosenstengel C, Matthes M, Baldauf J, Fleck S, Schroeder H. Hemifacial spasm: conservative and surgical treatment options. *Deutsches Arzteblatt International* 2012;109(41):667-73.
77. Rowe FJ, Noonan CP. Botulinum toxin for the treatment of strabismus. *Cochrane Database Syst Rev*. 2009;(2):CD006499.
78. Rowe FJ, Noonan CP. Botulinum toxin for the treatment of strabismus. *Cochrane Database Syst Rev*. 2017 Mar 2;3(3):CD006499.
79. Sakzewski L, Ziviani J, Boyd RN. Efficacy of upper limb therapies for unilateral cerebral palsy: a meta-analysis. *Pediatrics* 2014;133(1):e175-204.
80. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2012 Apr 24;78(17):1337-45. doi: 10.1212/WNL.0b013e3182535d20. Erratum in: *Neurology*. 2013 Feb 26;80(9):871.
81. Silberstein S, Tfelt-Hansen P, Dodick DW et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. *Cephalalgia*. 2008; 28:484-95.
82. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2016;86(19):1818-26.
83. Singh S, Davis H, Wilson P. Axillary hyperhidrosis: A review of the extent of the problem and treatment modalities. *Surgeon* 2015;13(5):279-85.
84. Soares A, Andriolo RB, Atallah AN, Da silva EM. Botulinum toxin for myofascial pain syndromes in adults. *Cochrane Database Syst Rev*. 2014;(7):CD007533.
85. Sridharan K, Sivaramakrishnan G. Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network meta-analysis of randomized controlled trials. *J Clin Neurosci*. 2018;51:12-17
86. Stefanidis D, et al. SAGES guidelines for the surgical treatment of esophageal achalasia. *Surgical Endoscopy* 2012;26(2):296-311.
87. Steward D.B., Gaertner W., Glasgow S., Migaly J., Feingold D., & Steele S.R. Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. (2017). Clinical Practice Guideline for the Management of Anal Fissures. *Dis Colon Rectum*, 2017, 60, 7-14. DOI: 10.1097/DCR.0000000000000735

88. Tögel B, Greve B, Raulin C. Current therapeutic strategies for hyperhidrosis: a review. *Eur J Dermatol.* 2002; 12:219-23.
89. Triadafilopoulos G, et al. The Kagoshima consensus on esophageal achalasia. *Diseases of the Esophagus* 2012;25(4):337-48.
90. UBRELVY(TM) oral tablets, ubrogepant oral tablets. Allergan USA Inc (per FDA), Madison, NJ, 2021
91. Utomo E, Groen J, Blok BF. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction. *Cochrane Database of Systematic Reviews* 2014, Issue 5. Art. No.: CD004927.
92. Vaezi MF, Pandolfino JE, Yadlapati RH, Greer KB, Kavitt RT. ACG Clinical Guidelines: Diagnosis and Management of Achalasia. *Am J Gastroenterol.* 2020 Sep;115(9):1393-1411. doi: 10.14309/ajg.0000000000000731.
93. VYEPTI(TM) intravenous injection, eptinezumab-jjmr intravenous injection. Lundbeck Seattle BioPharmaceuticals Inc (per manufacturer), Bothell, WA, 2021.
94. Wald A et al: ACG clinical guideline: management of benign anorectal disorders. *The American Journal of Gastroenterology*: October 2021 - Volume 116 - Issue 10 - p 1987-2008 doi: 10.14309/ajg.0000000000001507
95. Walling HW, Swick BL. Treatment options for hyperhidrosis. *American Journal of Clinical Dermatology* 2011;12(5):285-95.
96. Walshe M, Smith M, Pennington L. Interventions for drooling in children with cerebral palsy. *Cochrane Database Syst Rev.* 2012;11:CD008624.
97. Williams A. Consensus statement for the management of focal dystonias. *Br J Hosp Med.* 1993; 50:655-9.
98. Woodcock J (US Food and Drug Administration). Response to Public Citizen's petition on botulinum toxin re: docket no: FDA-2008-P-0061. Rockville, MD; 2009 April 30. From FDA website.
99. Yang D, Bechara R, Dunst CM, Konda VJA. AGA Clinical Practice Update on Advances in Per-Oral Endoscopic Myotomy (POEM) and Remaining Questions-What We Have Learned in the Past Decade: Expert Review. *Gastroenterology.* 2024 Dec;167(7):1483-1490. doi: 10.1053/j.gastro.2024.08.038. Epub 2024 Oct 16.
100. Zesiewicz TA, Elble RJ, Louis ED, et al,. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. *Neurology.* 2011 Nov 8;77(19):1752-5. doi: 10.1212/WNL.0b013e318236f0fd. Epub 2011 Oct 19.
101. Zesiewicz TA, Elble R, Louis ED, et al,. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology.* 2005 Jun 28;64(12):2008-20. doi: 10.1212/01.WNL.0000163769.28552.CD. Epub 2005 Jun 22.

AbobotulinumtoxinA (Dysport)

1. Franco I, Landau-Dyer L, Isom-Batz G, Collett T, Reda EF. The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children. *J Urol*. 2007 Oct;178(4 Pt 2):1775-9; discussion 1779-80. doi: 10.1016/j.juro.2007.03.185. Epub 2007 Aug 17. PMID: 17707430.
2. Annese V, Bassotti G, Coccia G, et al. Comparison of two different formulations of botulinum toxin A for the treatment of oesophageal achalasia. The Gismad Achalasia Study Group. *Aliment Pharmacol Ther*. 1999;13(10):1347-50.
3. Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. *Stroke*. 2000;31(10):2402-2406.
4. Boyle MH, McGwin G Jr, Flanagan CE, et al. High versus low concentration botulinum toxin A for benign essential blepharospasm: Does dilution make a difference? *Ophthal Plast Reconstr Surg*. 2009;25(2):81-84
5. Brisinda G, Cadeddu F, Brandara F, et al,. Botulinum toxin for recurrent anal fissure following lateral internal sphincterotomy. *Br J Surg*. 2008 Jun;95(6):774-8. doi: 10.1002/bjs.6080.
6. Brisinda G, Cadeddu F, Brandara F, Marniga G, Maria G. Randomized clinical trial comparing botulinum toxin injections with 0.2 per cent nitroglycerin ointment for chronic anal fissure. *Br J Surg*. 2007;94(2):162-7.
7. Burns J, Scheinberg A, Ryan MM, Rose KJ, Ouvrier RA. Randomized trial of botulinum toxin to prevent pes cavus progression in pediatric Charcot-Marie-Tooth disease type 1A. *Muscle Nerve*. 2010;42(2):262-7.
8. Chankrachang S, Arayawichanont A, Pongvarin N, et al. Prophylactic botulinum type A toxin complex (Dysport®) for migraine without aura. *Headache*. 2011;51(1):52-63.
9. Chartier-kastler E, Mehnert U, Denys P, Giuliano F. Botulinum neurotoxin A for male lower urinary tract symptoms. *Curr Opin Urol*. 2011;21(1):13-21.
10. Creuzé A, Petit H, de Sèze M. Short-Term Effect of Low-Dose, Electromyography-Guided Botulinum Toxin A Injection in the Treatment of Chronic Lateral Epicondylar Tendinopathy: A Randomized, Double-Blinded Study. *J Bone Joint Surg Am*. 2018 May 16;100(10):818-826. doi: 10.2106/JBJS.17.00777. PMID: 29762276.
11. Dashtipour K, Chen JJ, Walker HW, Lee MY. Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Lower Limb Spasticity. *Medicine (Baltimore)*. 2016;95(2):e2468.
12. Desiato MT, Risina B. The role of botulinum toxin in the neuro-rehabilitation of young patients with brachial plexus birth palsy. *Pediatr Rehabil*. 2001;4(1):29-36.
13. Duarte GS, Rodrigues FB, Castelão M, Marques RE, Ferreira J, Sampaio C, Moore AP, Costa J. Botulinum toxin type A therapy for hemifacial spasm. *Cochrane Database Syst Rev*. 2020 Nov 19;11:CD004899.
14. Dysport (abobotulinumtoxinA for injection) [prescribing information]. Ipsen Biopharmaceuticals, Inc.), Wrexham, UK. September 2023.

15. Ezzeddine D, Jit R, Katz N, Gopalswamy N, Bhutani MS. Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. *Gastrointest Endosc.* 2002;55:920-923.
16. Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. *Am J Gastroenterol.* 2008;103:416-423.
17. Gómez-Caravaca MT, Cáceres-Redondo MT, Huertas-Fernández I, Vargas-González L, Carrillo F, Carballo M, Mir P. The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders. *Neurol Sci.* 2015;36:275-279.
18. Guarda-Nardini L, Stecco A, Stecco C, Masiero S, Manfredini D. Myofascial pain of the jaw muscles: comparison of short-term effectiveness of botulinum toxin injections and fascial manipulation technique. *Cranio.* 2012 Apr;30(2):95-102. doi: 10.1179/crn.2012.014. PMID: 22606852.
19. Heckmann M, Ceballos-Baumann AO, Plewig G; Hyperhidrosis Study Group. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). *N Engl J Med.* 2001;344:488-93.
20. Hu GC, Chuang YC, Liu JP, et al. Botulinum toxin (Dysport) treatment of the spastic gastrocnemius muscle in children with cerebral palsy: A randomized trial comparing two injection volumes. *Clin Rehabil.* 2009;23(1):64-71.
21. Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: A prospective, randomised, double blind, placebo controlled, dose ranging study. *J Neurol Neurosurg Psychiatry.* 2000;68(6):707-712.
22. Ipsen announces FDA approval of Dysport (abobotulinumtoxinA) for injection for the treatment of lower limb spasticity in children aged two and older. Press Release. Paris, France: Ipsen; August 1, 2016.
23. Jochim A, Meindl T, Huber C, et al. Treatment of blepharospasm and Meige's syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice. *J Neurol.* 2020 Jan;267(1):267-275. doi: 10.1007/s00415-019-09581-w. Epub 2019 Oct 19.
24. Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. *Dermatol Surg.* 2009;35(1):1-8.
25. Kruisdijk JJM, Koelman JHTM, Ongerboer de Visser BW, et al. Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up. *J Neurol Neurosurg Psychiatry.* 2007; 78(3): 264–270. doi:10.1136/jnnp.2005.083170
26. Machado D, Kumar A, Jabbari B. Abobotulinum Toxin A in the Treatment of Chronic Low Back Pain. *Toxins (Basel).* 2016 Dec 15;8(12):374. doi: 10.3390/toxins8120374. PMID: 27983689; PMCID: PMC5198568.
27. Manning J, Dwyer P, Rosamilia A, Colyvas K, Murray C, Fitzgerald E. A multicentre, prospective, randomised, double-blind study to measure the treatment effectiveness of abobotulinum A (AboBTXA) among women with refractory interstitial cystitis/bladder pain syndrome. *Int Urogynecol J.* 2014 May;25(5):593-9. doi: 10.1007/s00192-013-2267-8. Epub 2013 Nov 26. PMID: 24276074.
28. Minguini N, De carvalho KM, Bosso FL, Hirata FE, Kara-josé N. Surgery with intraoperative botulinum toxin-A injection for the treatment of large-angle horizontal strabismus: a pilot study. *Clinics (Sao Paulo).* 2012;67(3):279-82

29. Peterlein CD, Funk JF, Hölscher A, Schuh A, Placzek R. Is botulinum toxin A effective for the treatment of plantar fasciitis?. *Clin J Pain*. 2012;28(6):527-33.
30. Pittcock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. *Cerebrovasc Dis*. 2003;15(4):289-300.
31. Reichenbach ZW, Stanek S, Patel S, Ward SJ, Malik Z, Parkman HP, Schey R. Botulinum Toxin A Improves Symptoms of Gastroparesis. *Dig Dis Sci*. 2020;65:1396-1404.
32. Rodwell K, Edwards P, Ware RS, Boyd R. Salivary gland botulinum toxin injections for drooling in children with cerebral palsy and neurodevelopmental disability: a systematic review. *Dev Med Child Neurol*. 2012;54(11):977-87.
33. Sekmen U, Paksoy M. The Efficacy of Botulinum Toxin Injection Site in Chronic Anal Fissure Healing. *Niger J Clin Pract*. 2020;23:1639-1642.
34. Singer BJ, Silbert PL, Song S, Dunne JW, Singer KP. Treatment of refractory anterior knee pain using botulinum toxin type A (Dysport) injection to the distal vastus lateralis muscle: a randomised placebo controlled crossover trial. *Br J Sports Med*. 2011 Jun;45(8):640-5. doi: 10.1136/bjsm.2009.069781. Epub 2010 Apr 23. PMID: 20418523; PMCID: PMC3106976.
- 35.
36. Straube A, Empl M, Ceballos-Baumann A, et al. Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache - a multicentre, double-blind, randomized, placebo-controlled study. *Eur J Neurol*. 2008;15(3):205-213.
37. Tercica Inc. Dysport for injection (abobotulinumtoxin A). Full Prescribing Information. Brisbane, CA: Tercica; revised November 2018. Available at: https://www.ipsen.com/websites/ipsen_Online/wp-content/uploads/sites/9/2019/01/21084019/Dysport_Full_Prescribing_Information.pdf.
38. Truong D, Comella C, Fernandez HH, Ondo WG; Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: A randomized, placebo-controlled, phase II trial. *Parkinsonism Relat Disord*. 2008;14(5):407-414.
39. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study. *Mov Disord*. 2005;20(7):783-791.
40. Tsai CP, Chiu MC, Yen DJ, et al. Quantitative assessment of efficacy of dysport (botulinum toxin type A) in the treatment of idiopathic blepharospasm and hemifacial spasm. *Acta Neurol Taiwan*. 2005;14(2):61-68.
41. Tsai CP, Liu CY, Lin KP, Wang KC. Efficacy of botulinum toxin type a in the relief of Carpal tunnel syndrome: A preliminary experience. *Clin Drug Investig*. 2006;26(9):511-5.
42. Wong SM, Hui AC, Tong PY, Poon DW, Yu E, Wong LK. Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med*. 2005;143(11):793-7.

43. Yun JY, Kim JW, et al. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study. *Mov Disord*. 2015 Feb;30(2):206-13. doi: 10.1002/mds.26085. Epub 2014 Dec 5.
44. Zhang H, Lian Y, et al. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. *J of Headache and Pain*. 2014; 15:65.

DaxibotulinumtoxinA-lanm (Daxxify)

1. Daxxify (daxibotulinumtoxinA) [prescribing information]. Newark, CA: Revance Therapeutics Inc; August 2023.
2. Solish N, Carruthers J, Kaufman J, Rubio RG, Gross TM, Gallagher CJ: Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A. *Drugs*. 2021 Dec;81(18):2091-2101. doi: 10.1007/s40265-021-01631-w. Epub 2021 Nov 17.

OnabotulinumtoxinA (Botox)

- 1.
2. Agamia NF, Sobhy N, Abd-Elraouf A, Tawfik A. Fractional CO2 Laser for Transcutaneous Drug Delivery of Onabotulinum Toxin in Palmar Hyperhidrosis. *Dermatol Surg*. 2021 May 1;47(5):678-683. doi: 10.1097/DSS.0000000000002901.
3. Ahmadi J, Azary S, Ashjaei B, Paragomi P, Khalifeh-soltani A. Intrasphincteric botulinum toxin injection in treatment of chronic idiopathic constipation in children. *Iran J Pediatr*. 2013;23(5):574-8.
4. Ahn MS, Catten M, Maas CS. Temporal brow lift using botulinum toxin A. *Plast Reconstr Surg*. 2000; 105:1129-35; discussion 1136-9.
5. Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. *Arch Dermatol*. 2002; 138:510-4.
6. Allergan Inc. Botox (onabotulinumtoxin A). Full Prescribing Information. 72284US11B, Irvine, CA: Allergan; revised May 2018. Available at: https://www.allergan.com/assets/pdf/botox_pi.pdf.
7. Allergan. Botox® (onabotulinumtoxinA) for injection prescribing information. Irvine, CA; 2017 Apr.
8. Allergan. Botox® Cosmetic (onabotulinumtoxinA) for injection prescribing information. Irvine, CA; 2017 Oct.
9. Alvarez CM, Wright JG, Chhina H, Howren A, Law P. Botulinum Toxin Type A Versus Placebo for Idiopathic Clubfoot: A Two-Center, Double-Blind, Randomized Controlled Trial. *J Bone Joint Surg Am*. 2018 Sep 19;100(18):1589-1596. doi: 10.2106/JBJS.17.01652.
10. Annese V, Bassotti G, Coccia G, et al. Comparison of two different formulations of botulinum toxin A for the treatment of oesophageal achalasia. The Gismad Achalasia Study Group. *Aliment Pharmacol Ther*. 1999;13(10):1347-50.

11. Annese V, D'Onofrio V, Andriulli A. Botulinum toxin in long-term therapy for achalasia. *Ann Intern Med.* 1998; 128:696.
12. Anon. Assessment: the clinical usefulness of botulinum toxin-A in treating neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology.* 1990; 40:1332-6.
13. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. *Headache.* 2003; 43 (Suppl 1):9-15.
14. Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single dose, placebo controlled trial. *Clinical Journal of Pain* 2013;29(10):857-64.
15. Arad-Cohen A, Blitzer A. Botulinum toxin treatment for symptomatic Frey's syndrome. *Otolaryngol Head Neck Surg.* 2000; 122:237-40.
16. Arezzo JC, Litwak MS, Gasper CA et al. The spread of paralytic activity in juvenile monkeys: a comparison of and botulinum toxin type B. Paper presented at the World Congress of Neurological Rehabilitation, Venice, Italy: 2002 Apr 2-6.
17. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. *Clin J Pain.* 2002; 18(Suppl):S177-S181.
18. Arthurs B, Flanders M, Codere F et al. Treatment of blepharospasm with medication, surgery and type A botulinum toxin. *Can J Ophthalmol.* 1987; 22:24-8.
19. Arts J, Holvoet L, Caenepeel P, Bisschops R, Sifrim D, Verbeke K, Janssens J, Tack J. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. *Aliment Pharmacol Ther.* 2007;26:1251-1258.
20. Aurora SK, Dodick DW, Turkel CC et al, for the PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. *Cephalalgia.* 2010 Jul; 30:793-803.
21. Aurora SK, Winner P, Freeman MC et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results of the 56-week PREEMPT clinical program. *Headache.* 2010; 51:1358-73.
22. Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. *J Neurol Neurosurg Psychiatry.* 1997; 62:198.
23. Bang CS, Baik GH, Shin IS, et al. Effect of intragastric injection of botulinum toxin A for the treatment of obesity: a meta-analysis and meta-regression. *Gastrointest Endosc.* 2015;81(5):1141-9.e1-7.
24. Barbehenn E, Lurie P, Stark S et al. Petition to the FDA requesting regulatory action concerning the possible spread of botulinum toxin (Botox, Myobloc) from the site of injection to other parts of the body. Washington, DC: Public Citizen's Health Research Group; 2008 Jan.
25. Barwood S, Baillieu C, Boyd R et al. Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. *Dev Med Child Neurol.* 2000; 42:116-21.
26. Baumann L, Black L. Botulinum toxin type B (Myobloc). *Dermatol Surg.* 2003; 29:496-500.

27. Baumann L, Frankel S, Welsh E et al. Cryoanalgesia with dichlorotetrafluoroethane lessens the pain of botulinum toxin injections for the treatment of palmar hyperhidrosis. *Dermatol Surg.* 2003; 29:1057-60.
28. Beckmann Y, Çetin Üncü F, Kurt İncesu T, Türe S. Effectiveness, Safety, and Health-Related Quality of Life of Chronic Migraine Patients Treated with Onabotulinum Toxin A. *Eur Neurol.* 2020;83(5):517-522. doi: 10.1159/000509853. Epub 2020 Sep 23.
29. Bell MS, Vermeulen LC, Sperling KB. Pharmacotherapy with botulinum toxin: harnessing nature's most potent neurotoxin. *Pharmacotherapy.* 2000; 20:1079-91.
30. Bhakta BB, Cozens JA, Chamberlain MA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. *J Neurol Neurosurg Psychiatry.* 1996; 61:30-5.
31. Bhatia KP, Munchau A, Thompson PD et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. *J Neurol Neurosurg Psychiatry.* 1999; 67:90-3.
32. Bielamowicz S, Stager SV, Badillo A et al. Unilateral versus bilateral injections of botulinum toxin in patients adductor spasmodic dysphonia. *J Voice.* 2002; 16:117-23.
33. Binder WJ, Brin MF, Blitzer A et al. Botulinum toxin type A (Botox®) for treatment of migraine headaches: an open-label study. *Otolaryngol Head Neck Surg.* 2000; 123:669-76
34. Binder WJ, Brin MF, Blitzer A et al. Botulinum toxin type A (Botox®) for treatment of migraine. *Semin Cutan Med Surg.* 2001; 20:93-100.
35. Bjerkhoel A, Trobbe O. Frey's syndrome: treatment with botulinum toxin. *J Laryngol Otol* 1997; 111:839.
36. Blackie JD, Lees AJ. Botulinum toxin treatment in spasmodic torticollis. *J Neurol Neurosurg Psychiatry.* 1990; 53:640-3.
- 37.
38. Blitzer A, Binder WJ, Aviv JE et al. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. *Arch Otolaryngol Head Neck Surg.* 1997; 123:389-92.
39. Blitzer A, Binder WJ, Brin MF. Botulinum toxin injections for facial lines and wrinkles: technique. In: Blitzer A, Binder WJ, Boyd JB et al., eds. *Management of facial lines and wrinkles.* Lippincott Williams & Wilkins, Philadelphia, PA; 2000:303-13.
40. Blitzer A, Brin MF, Greene PE et al. Botulinum toxin injection for the treatment of oromandibular dystonia. *Ann Otol Rhinol Laryngol.* 1989; 98:93-7.
41. Blitzer A, Brin MF, Stewart C., et al. Abductor laryngeal dystonia: a series treated with botulinum toxin. *Laryngoscope.* 1992; 102:163-7.
42. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. *Laryngoscope.* 1998; 108:1435-41.
43. Blitzer A, Brin MF. Laryngeal dystonia: a series with botulinum toxin therapy. *Ann Otol Rhinol Laryngol.* 1991; 100:85-9.
44. Blitzer A. Botulinum neurotoxin A for the management of lower facial lines and platysmal bands. In: Lowe N, ed. *Textbook of facial rejuvenation.* Martin Dunitz, London; 2002:171-177.
45. Blumenfeld , Andrew. "Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to Onabotulinumtoxina: A Retrospective Chart

- Review." Pain and Therapy, U.S. National Library of Medicine, Dec. 2021, <https://pubmed.ncbi.nlm.nih.gov/33880725/>.
46. Blumenfeld A, Evans RW. OnabotulinumtoxinA for chronic migraine. *Headache*. 2012 Jan; 52:142-8.
 47. Blumenfeld AM, Tepper SJ, Robbins LD, et al. Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. *J Neurol Neurosurg Psychiatry*. 2019 Mar;90(3):353-360. doi: 10.1136/jnnp-2018-319290. Epub 2019 Jan 10.
 48. Böger A, Herath H, Rompel R, Ferbert A. Botulinum toxin for treatment of craniofacial hyperhidrosis. *J Neurol* 2000; 247:857.
 49. BOTOX (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use. [Accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103000s53091bl.pdf). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103000s53091bl.pdf Updated June 2019. Accessed March 23, 2020.
 50. Botox (onabotulinumtoxinA) [prescribing information]. Madison, NJ: Allergan Pharmaceuticals Ireland a subsidiary of: Allergan, Inc.; August 2023.
 51. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. [nice.org.uk](https://www.nice.org.uk/Guidance/ta260). <https://www.nice.org.uk/Guidance/ta260>. Published 2012. Accessed March 23, 2020.
 52. Brandt F, Swanson N, Baumann L et al. Randomized, placebo-controlled study of a new botulinum toxin type A for treatment of glabellar lines: efficacy and safety. *Dermatol Surg*. 2009; 35(12):1893-901.
 53. Brashear A, Gordon MF, Elovic E for the Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. *N Engl J Med*. 2002; 347:395- 400.
 54. Brashear A, Lew MF, Dykstra DD et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. *Neurology*. 1999; 53:1439-46.
 55. Brashear A, McAfee AL, Kuhn ER et al. Treatment with botulinum toxin type B for upper-limb spasticity. *Arch Phys Med Rehabil*. 2003; 84:103-7.
 56. Brin MF, Binder W, Blitzer A et al. Botulinum Toxin Type A Botox® for Pain and Headache. In: Brin MF, Hallett M, Jankovic J, ed. *Scientific and Therapeutic Aspects of Botulinum Toxin*. Lippincott Williams & Wilkins, Philadelphia, PA; 2002.
 57. Brin MF, Blitzer A, Stewart C. Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin. *Adv Neurol*. 1998; 78:237-52.
 58. Brin MF, Fahn S, Moskowitz C et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. *Movement Dis*. 1987; 2:237-54.
 59. Brin MF, Durgam S, Lum A, James L, Liu J, Thase ME, Szegedi A. OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females. *Int Clin Psychopharmacol*. 2020 Jan;35(1):19-28. doi: 10.1097/YIC.0000000000000290. PMID: 31609787; PMCID: PMC6903360.
 60. Brin MF, Vapnek JM. Treatment of vaginismus with botulinum toxin injections. *Lancet*. 1997; 349:252-3.

61. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. *Muscle Nerve Suppl.* 1997; 6:S146-68.
62. Brisinda G, Cadeddu F, Brandara F, et al,. Botulinum toxin for recurrent anal fissure following lateral internal sphincterotomy. *Br J Surg.* 2008 Jun;95(6):774-8. doi: 10.1002/bjs.6080.
63. Brisinda G, Civello IM, Albanese A et al. Gastrointestinal smooth muscles and sphincters spasms: treatment with botulinum neurotoxin. *Curr Med Chem.* 2003; 10:603-23.
64. Brisinda G, Maria G, Bentivoglio AR et al. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. *N Engl J Med.* 1999; 341:65-9.
65. Brown EA, Schutz SG, Simpson DM. Botulinum toxin for neuropathic pain and spasticity: an overview. *Pain Management* 2014;4(2):129 51. DOI: 10.2217/pmt.13.75.
66. Brown M, Williamson PR, Sutton L, et al,. Onabotulinum toxin-A versus extended release tolterodine in the management of idiopathic overactive bladder in children: A pilot randomised controlled trial (OVERT trial). *J Pediatr Urol.* 2021 Feb;17(1):77.e1-77.e12. doi: 10.1016/j.jpuro.2020.10.012. Epub 2020 Oct 19.
67. Bushara KO, Park DM, Jones JC et al. Botulinum toxin—a possible new treatment for axillary hyperhidrosis. *Clin Exp Dermatol.* 1996; 21:276-8.
68. Cady RK, Schreiber CP, Porter JAH et al. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. *Headache.* 2011; 51(1): 21-32.
69. Callaway JE, Arezzo JC, Grethlein AJ. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. *Semin Cutan Med Surg.* 2001; 20:127-36.
70. Campanati A, Giuliadori K, Martina E et al. Onabotulinumtoxin type A (Botox®) versus Incobotulinumtoxin type A (Xeomin®) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial. *J Neural Transm.* 2014 Jan; 121:21-6.
71. Cantarella G, Berlusconi A, Mele V, et al. Treatment of Frey's syndrome with botulinum toxin type B. *Otolaryngol Head Neck Surg.* 2010;143(2):214-218.
72. Carr LJ, Cosgrove AP, Gingras P et al. Position paper on the use of botulinum toxin in cerebral palsy. *Arch Dis Child.* 1998; 79:271-3.
73. Carruthers A, Carruthers J, Cohen J. A prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. *Dermatol Surg.* 2003; 29:461-7.
74. Carruthers J, Carruthers A. Aesthetic botulinum A toxin in the mid and lower face and neck. *Dermatol Surg.* 2003; 29:468-76.
75. Carruthers JA, Lowe NJ, Menter MA et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. *J Am Acad Dermatol.* 2002; 46:840-9.
76. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. *J Dermatol Surg Oncol.* 1992; 18:17-21.

77. Carruthers JDA, Carruthers A. Botulinum toxin and laser resurfacing for lines around the eyes. In: Blitzer A, Binder WJ, Boyd JB et al., eds. Management of facial lines and wrinkles. Lippincott Williams & Wilkins, Philadelphia, PA; 2000:315-32.
78. Carruthers JDA, Kennedy RA, Bagaric D. Botulinum vs adjustable suture surgery in the treatment of horizontal misalignment in adult patients lacking fusion. Arch Ophthalmol. 1990; 108:1432-5.
79. Carruthers JDA. Ophthalmologic use of botulinum A exotoxin. Can J Ophthalmol. 1985; 20:135-41.
80. Centeno RF, Boswell CB, Matarasso A. Botulinum toxin for managing focal hyperhidrosis. Aesthetic Surg J. 2003; 23:67-9.
81. Ceolato-Martin C, Chevallier-Collins C, Clément JP, Charles E, Lacroix A, Ranoux D. OnabotulinumtoxinA in Resistant Depression: A Randomized Trial Comparing Two Facial Injection Sites (OnaDEP Study). *Depress Anxiety*. 2024 Sep 12;2024:1177925. doi: 10.1155/2024/1177925.
82. Chancellor MB, et al. Evidence based review and assessment of botulinum neurotoxin for the treatment of urologic conditions. *Toxicon* 2013;67:129 40.
83. Chapman MA, Barron R, Tanis DC et al. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. *Clin Ther*. 2007; 29:1325-37.
84. Chapple C, Sievert KD, MacDiarmid S et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. *Eur Urol*. 2013 Aug; 64:249-56.
85. Chartier-Kastler E, Mehnert U, Denys P, Giuliano F. Botulinum neurotoxin A for male lower urinary tract symptoms. *Current Opinion in Urology* 2011;21(1):13 21.
86. Chen HL, et al. Botulinum toxin injection versus lateral internal sphincterotomy for chronic anal fissure: a meta- analysis of randomized control trials. *Techniques in Coloproctology* 2014;18(8):693 8.
87. Chen RS, Lu CS, Tsai CH. Botulinum toxin A injection in the treatment of hemifacial spasm. *Acta Neurol Scand*. 1996; 94:207-11.
88. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part 1. *Am J Health Syst Pharm*. 2006; 63:145-52.
89. Chertow DS, Tan ET, Maslanka SE et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. *JAMA*. 2006; 296:2476-9.
90. Chhina H, Howren A, Simmonds A, Alvarez CM. Onabotulinumtoxin A injections: A safety review of children with clubfoot under 2 years of age at BC Children's Hospital. *European Journal of Paediatric Neurology* 2014;18(2):171 5
91. Childers MK, Brashear A, Jozefczyk P at al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. *Arch Phys Med Rehabil*. 2004 Jul; 85:1063-9.
92. Ching J, Tinsley A, Rothrock J. Prognosis Following Discontinuation of OnabotulinumA Therapy in "Super-responding" Chronic Migraine Patients. *Headache*. 2019 Sep;59(8):1279-1285. doi: 10.1111/head.13630. Epub 2019 Sep 9.

93. Chiu SY, Patel B, Burns MR, et al. High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy. *Tremor Other Hyperkinet Mov (N Y)*. 2020 Feb 27;10. doi: 10.7916/tohm.v0.749.
94. Chuang YC, Kuo HC. A Prospective, Multicenter, Double-Blind, Randomized Trial of Bladder Instillation of Liposome Formulation OnabotulinumtoxinA for Interstitial Cystitis/Bladder Pain Syndrome. *J Urol*. 2017 Aug;198(2):376-382. doi: 10.1016/j.juro.2017.02.021. Epub 2017 Feb 12. PMID: 28202358.
95. Chughtai B, et al. Randomized, double-blind, placebo controlled pilot study of intra-detrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia. *Canadian Journal of Urology* 2014;21(2):7217 21.
96. Chung SD, Kuo YC, Kuo HC. Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. *Pain Physician*. 2012 May-Jun;15(3):197-202. PMID: 22622903.
97. Cobb DB, Watson WA, Fernandez MC. Botulism-like syndrome after injections of botulinum toxin. *Vet Hum Toxicol*. 2000 Jun; 42:163.
98. Cohen, F., Armand, C., Lipton, R. B., & Vollbracht, S. (2021). Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to onabotulinumtoxinA in patients with chronic migraine. *Pain Medicine*, 22(9), 1857-1863.
99. Cohen DA, Savino PJ, Stern MB et al. Botulinum injection therapy for blepharospasm: review and report of 75 patients. *Clin Neuropharmacol*. 1986; 9:415-29.
100. Corry IS, Cosgrove AP, Duffy CM et al. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. *J Pediatr Orthop*. 1998; 18:304-11.
101. Corry IS, Cosgrove AP, Walsh EG et al. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. *Dev Med Child Neurol*. 1997; 39:185-93.
102. Costa J, Espirito-Santo CC, Borges AA et al. Botulinum toxin type A therapy for cervical dystonia (review). *Cochrane Database of Systematic Reviews*. 2005, Issue 1. Article No: CD003633.
103. Coté TR, Mohan AK, Polder JA et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. *J Am Acad Dermatol*. 2005; 53:407-15.
104. Cox L, Cameron AP. OnabotulinumtoxinA for the treatment of overactive bladder. *Research and Reports in Urology* 2014;6:79 89.
105. Crawford ED, Hirst K, Kusek JW et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: A phase II randomized clinical trial. *J Urol*. 2011 Sep; 186: 965–70.
106. Crespi J, Bratbak D, Dodick DW, Matharu M, Jamtøy KA, Tronvik E. Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia. *Headache*. 2019 Sep;59(8):1229-1239. doi: 10.1111/head.13608. Epub 2019 Jul 25. PMID: 31342515; PMCID: PMC6771650.

107. Cummings RJ. The effectiveness of botulinum A toxin as an adjunct to the treatment of clubfeet by the Ponseti method: a randomized, double blind, placebo controlled study. *Journal of Pediatric Orthopedics* 2009;29(6):564-9.
108. Davies J, Duffy D, Boyt N et al. Botulinum toxin (Botox) reduces pain after hemorrhoidectomy. *Dis Colon Rectum*. 2003; 46:1097-1102.
109. Demiryurek BE. Botulinum Toxin Monotherapy for the Treatment of Essential Tremor: Life Quality Effect. *Clin Neuropharmacol*. 2021 Jan-Feb 01;44(1):1-4. doi: 10.1097/WNF.0000000000000428.
110. de Seze M, Petit H, Gallien P et al. Botulinum A toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. *Eur Urol*. 2002; 42:56-62.
111. Desiato MT, Risina B. The role of botulinum toxin in the neuro-rehabilitation of young patients with brachial plexus birth palsy. *Pediatr Rehabil*. 2001 Jan-Mar;4(1):29-36. doi: 10.1080/13638490151068456.
112. Diener HC, Dodick DW, Aurora SK et al, for the PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. *Cephalalgia*. 2010; 30:804-14.
113. Dodick DW, Silberstein SD, Lipton RB, DeGryse RE, Adams AM, Diener HC. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data. *Cephalalgia*. 2019 Jul;39(8):945-956. doi: 10.1177/0333102418825382. Epub 2019 May 21.
114. Dodick DW, Turkel CC, Degryse RE et al. OnabotulinumtoxinA for treatment of chronic migraine: a response. *Headache*. 2011 Jun; 51(6):1005-8. Reply.
115. Donahue SP. Botulinum toxin treatment for esotropia. *American Orthoptic Journal* 2013;63:29-31.
116. Dressler D, Adib Saberi F, Benecke R. Botulinum toxin type B for treatment of axillar hyperhidrosis. *J Neurol*. 2002; 249:1729-32.
117. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. *Eur Neurol*. 2003; 49:34-8.
118. Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced therapy failure. *J Neurol*. 2003; 250:967-9.
119. Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. *Eur J Neurol*. 2009; 16 Suppl 2:2-5.
120. Drobik C, Laskawi R. Frey's syndrome: treatment with botulinum toxin. *Acta Otolaryngol*. 1995; 115:459-61.
121. Duarte A, Coutinho L, Germiniani FMB, Teive HAG. Effects of onabotulinum toxin type A injections in patients with Meige's syndrome. *Arq Neuropsiquiatr*. 2024 Apr;82(4):1-7. doi: 10.1055/s-0044-1785691. Epub 2024 Apr 19.
122. Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. *Cochrane Database of Systematic Reviews* 2011, Issue 12. Art. No.: CD005493.
123. Elia AE, Filippini G, Calandrella D et al. Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. *Movement Disorders*. 2009; 24(6):801-12.

124. Elston JS, Russell RWR. Effect of treatment with botulinum toxin on neurogenic blepharospasm. *BMJ*. 1985; 290:1857-9.
125. EMGALITY(TM) subcutaneous injection, galcanezumab-gnlm subcutaneous injection. Eli Lilly and Company (per manufacturer), Indianapolis, IN, 2021.
126. Eslamian F, Dolatkah N, Fallah L, Jahanjoo F, Toopchizadeh V, Talebi M. Effectiveness of Botulinum Toxin on Hand Tremor Intensity and Upper Limb Function in Patients with Parkinson's Disease: Results of a Systematic Review. *Tremor Other Hyperkinet Mov (N Y)*. 2023 Aug 24;13:27. doi: 10.5334/tohm.773.
127. Evers S, Rahmann A, Vollmer-Haase J et al. Treatment of headache with botulinum toxin A--a review according to evidence-based medicine criteria. *Cephalalgia*. 2002; 22:699-710.
128. Fagien S, Cohen JL, Coleman W et al. Forehead line treatment with onabotulinumtoxinA in subjects with forehead and glabellar facial rhytids: a phase 3 study. *Dermatol Surg*. 2017; 43:S274-S284.
129. Fehlings D, et al. Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement. *European Journal of Neurology* 2010;17 Suppl 2:38 56.
130. Fehlings D, Rang M, Glazier J et al. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. *J Pediatr*. 2000; 137:331-7.
131. Figgitt DP, Noble S. Botulinum toxin B: A review of its therapeutic potential in the management of cervical dystonia. *Drugs*. 2002; 62:705-2.
132. Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial. *J Psychiatr Res*. 2014 May;52:1-6. doi: 10.1016/j.jpsychires.2013.11.006. Epub 2013 Dec 1. PMID: 24345483.
133. Fishman VM, Parkman HP, Schiano TD et al. Symptomatic improvement in achalasia after botulinum toxin injection of the lower esophageal sphincter. *Am J Gastroenterol*. 1996; 91:1724-30.
134. Flett PJ, Stern LM, Waddy H et al. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. *J Paediatr Child Health*. 1999; 35:71-7.
135. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain. *Neurology*. 2001;56:1290-1293.
136. Fowler CJ, et al. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36 week, double =blind, placebo-controlled, randomized, dose- ranging trial. *European Urology* 2012;62(1):148 57.
137. Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study. *Headache*. 2000; 40:231-6.
138. Freund BJ, Schwartz M. Use of botulinum toxin in chronic whiplash-associated disorder. *Clin J Pain*. 2002; 18:S163-8.
139. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?. *Biologics*. 2010; 4:325-32.

140. Friedmacher F, Puri P. Comparison of posterior internal anal sphincter myectomy and intrasphincteric botulinum toxin injection for treatment of internal anal sphincter achalasia: a meta analysis. *Pediatric Surgery International* 2012;28(8):765-71.
141. Gallien P, Robineau S, Verin M et al. Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. *Arch Phys Med Rehabil.* 1998; 79:715-7.
142. Garcia A, Fulton JE Jr. Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study. *Dermatol Surg.* 1996; 22:39-43.
143. Gassner HG, Sherris DA. Addition of an anesthetic agent to enhance the predictability of the effects of injections: a randomized controlled study. *Mayo Clin Proc.* 2000; 75:701-4.
144. George SM, Atkinson LR, Farrant PB, Shergill BS. Botulinum toxin for focal hyperhidrosis of the face. *Br J Dermatol* 2014; 170:211.
145. Gerwin R. Botulinum toxin treatment of myofascial pain: a critical review of the literature. *Current Pain and Headache Reports* 2012;16(5):413-22.
146. Ginsberg D, Gousse A, Keppenne V et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. *J Urol.* 2012; 187:2131-9.
147. Giordano CN, Matarasso SL, Ozog DM. Injectable and topical neurotoxins in dermatology: Indications, adverse events, and controversies. *J Am Acad Dermatol.* 2017; 76:1027-1042.
148. Glogau RG. Botulinum A neurotoxin for axillary hyperhidrosis. No sweat Botox. *Dermatol Surg.* 1998; 24:817-9.
149. Glogau RG. Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes. *Clin J Pain.* 2002; 18(6 Suppl):S191-7.
150. Gordon JM, Eaker EY. Prospective study of esophageal botulinum toxin injection in high-risk achalasia patients. *Am J Gastroenterol.* 1997; 92:1812-7.
151. Gordon K, Cadera W, Hinton G. Successful treatment of hereditary trembling chin with botulinum toxin. *J Child Neurol.* 1993; 8:154-6.
152. Gordon MF, Brashear A, Elovic E et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. *Neurology.* 2004; 63:1971-3.
153. Grazi L. Onabotulinum toxin A for treatment of chronic migraine with medication overuse. *Neurol Sci.* 2013 May;34 Suppl 1:S27-8. doi: 10.1007/s10072-013-1381-1.
154. Greene P, Kang U, Fahn S et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. *Neurology.* 1990; 40:1213-8.
155. Grosse J, Kramer G, Stöhrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. *Eur Urol.* 2005; 47:653-9.
156. Guerrissi JO. Intraoperative injection of botulinum toxin A into orbicularis oculi muscle for the treatment of crow's feet. *Plast Reconstr Surg.* 2000; 105:2219-25; discussion 2226-8.
157. Guyuron B, Huddleston SW. Aesthetic indications for botulinum toxin injection. *Plast Reconstr Surg.* 1994; 93:913-8.
158. Hallett M, et al. Evidence based review and assessment of botulinum neurotoxin for the treatment of movement disorders. *Toxicon* 2013;67:94-114.

159. Hallett M. One man's poison—clinical applications of botulinum toxin. *N Engl J Med.* 1999; 341:118-20.
160. Heckmann M, Heyer GH, Brunner B et al. Botulinum toxin type A injection in the treatment of lichen simplex: an open pilot study. *J Am Acad Dermatol.* 2002; 46:617-9.
161. Hellman A, Torres -Russotto D. Botulinum toxin in the management of blepharospasm: current evidence and recent developments. *Therapeutic Advances in Neurological Disorders* 2015;8(2):82-91.
162. Hermanowicz N, Truong DD. Treatment of oromandibular dystonia with botulinum toxin. *Laryngoscope.* 1991; 101:1216-8.
163. Hesse S, Krajnik J, Luecke D et al. Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. *Stroke.* 1996; 27:455-60.
164. Hesse S, Reiter F, Konrad M et al. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. *Clin Rehabil.* 1998; 12:381-8.
165. Hexsel DM, Trindade de Almeida T, Rutowitsch M et al. Multicenter, double-blind study of the efficacy of injections of reconstituted up to six weeks before application. *Dermatol Surg.* 2003; 29:523-9.
166. Hoare BJ, Wallen MA, Imms C, Villanueva E, Rawicki HB, Carey L. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). *Cochrane Database of Systematic Reviews* 2010, Issue 1. Art. No.: CD003469
167. Hosp C, Naumann MK, Hamm H. Botulinum toxin treatment of autonomic disorders: Focal hyperhidrosis and sialorrhea. *Seminars in Neurology* 2016;36(1):20-8.
168. Houltram J, Noble I, Boyd RN et al. Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence-based economic evaluation. *Eur J Neurol.* 2001; 8 Suppl 5:194-202.
169. Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. *J Am Acad Dermatol.* 2000; 43:249-59.
170. Ipsen Biopharmaceuticals, Inc. Dysport® for injection (abobotulinumtoxinA) prescribing information. Basking Ridge, NJ; 2017 Sep.
171. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta analysis. *Journal of the American Medical Association* 2012;307(16):1736-45.
172. Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. *Muscle Nerve Suppl.* 1997; 6:129-45.
173. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. *N Engl J Med.* 1991; 324:1186-94.
174. Jankovic J, et al. Primary results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE). *Journal of the Neurological Sciences* 2015;349(1-2):84-93.
175. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: double-blind, placebo-controlled study. *Neurology.* 1987; 37:616-23.

176. Jankovic J, Schwartz K, Clemence W et al. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. *Mov Disord.* 1996; 11:250-256.
177. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. *J Neurol Neurosurg Psychiatry.* 1990; 53:633-9.
178. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. *Neurology.* 1990; 40:277-80.
179. Jankovic J, Schwartz K. Botulinum toxin treatment of tremors. *Neurology.* 1991; 41:1185-8.
180. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. *Neurology.* 1995; 45:1743-6.
181. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. *Neurology.* Sep; 45:1743-6.
182. Jankovic J, Schwartz KS. Clinical correlates of response to botulinum toxin injections. *Arch Neurol.* 1991; 48:1253-6.
183. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. *Neurology.* 2003; 60:1186-8.
184. Jesitus J. Bogus Botox sounds wake-up call. *Cosm Surg Times*
185. Jiang YH, Jhang JF, Lee CL, Kuo HC. Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxinA injection in the treatment of interstitial cystitis refractory to conventional treatment-A prospective, randomized, clinical trial. *Neurourol Urodyn.* 2018 Apr;37(4):1467-1473. doi: 10.1002/nau.23475. Epub 2018 Jan 13. PMID: 29331031.
186. Jochim A, Meindl T, Huber C, et al. Treatment of blepharospasm and Meige's syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice. *J Neurol.* 2020 Jan;267(1):267-275. doi: 10.1007/s00415-019-09581-w. Epub 2019 Oct 19.
187. Jost WH, Schimrigk K. Therapy of anal fissure using botulin toxin. *Dis Colon Rectum.* 1994; 37:1321-4.
188. Jost WH, Schrank B. Repeat botulin toxin injections in anal fissure: in patients with relapse and after insufficient effect of first treatment. *Dig Dis Sci.* 1999; 44:1588-9.
189. Joyce KE, Beyer F, Thomson RG, Clarke MP. A systematic review of the effectiveness of treatments in altering the natural history of intermittent exotropia. *British Journal of Ophthalmology* 2015;99(4):440-50
190. Kaji R, Osako Y, Suyama K et al. Botulinum toxin type A in post-stroke upper limb spasticity. *Curr Med Res Opin.* 2010; 26:1983-92.
191. Kaji R, Osako Y, Suyama K et al. Botulinum toxin type A in post-stroke upper limb spasticity. *Curr Med Res Opin.* 2010; 8:1983-92.
192. Kalra HK, Magoon EH. Side effects of the use of botulinum toxin for treatment of benign essential blepharospasm and hemifacial spasm. *Ophthalmic Surg.* 1990; 21:335-8.
193. Kane MA, Rohrich RJ, Narins RS et al. Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase 3, randomized, double-blind, placebo-controlled study. *Plast Reconstr Surg.* 2009; 124(5):1619-29.

194. Karamfilov T, Konrad H, Karte K et al. Lower relapse rate of botulinum toxin A therapy for axillary hyperhidrosis by dose increase. *Arch Dermatol.* 2000; 136:487-90.
195. Kawata AK, Hareendran A, Poon J-L. Evaluating clinically meaningful within-subject change in functioning associated with migraine prevention using the migraine physical function impact diary (MPFID). *Cephalalgia* 2017;37:344–5
196. Kayikcioglu A, Erk Y, Mavili E. Botulinum toxin in the treatment of zygomatic fractures. *Plast Reconstr Surg.* 2003; 111:341-6.
197. Keen M, Blitzer A, Aviv J et al. Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study. *Plast Reconstr Surg.* 1994; 94:94-9.
198. Keizer SB, Rutten HP, Pilot P et al. Botulinum toxin injection versus surgical treatment for tennis elbow: a randomized pilot study. *Clin Orthop.* 2002; 401:125-31.
199. Kirazli Y, On AY, Kismali B et al. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke. *Am J Phys Med Rehabil.* 1998; 77:510-5.
200. Klein AW, Glogau RG. Botulinum toxin: beyond cosmesis. *Arch Dermatol.* 2000; 136:539-41.
201. Klein AW. Complications and adverse reactions with the use of botulinum toxin. *Semin Cutan Med Surg.* 2001; 20:109-20.
202. Klein AW. Dilution and storage of botulinum toxin. *Dermatol Surg.* 1998; 24:1179-80.
203. Klein AW. Treatment of wrinkles with Botox. *Curr Probl Dermatol.* 2002; 30:188-217.
204. Kolbasnik J, Waterfall WE, Fachnie B, Chen Y, Tougas G. Long-term efficacy of Botulinum toxin in classical achalasia: a prospective study. *Am J Gastroenterol.* 1999 Dec;94(12):3434-9. doi: 10.1111/j.1572-0241.1999.01605.x.
205. Kollewe K, Mohammadi B, Dengler R, Dressler D. Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport. *Journal of Neural Transmission* 2010;117(6):759 63.
206. Koman LA, Brashear A, Rosenfeld S et al. Botulinum toxin type A neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. *Pediatrics.* 2001 Nov; 108:1062-71.
207. Koman LA, Mooney JF III, Smith B et al. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. *J Pediatr Orthop.* 1993; 13:489-95.
208. Koman LA, Mooney JF III, Smith BP et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. *BOTOX Study Group. J Pediatr Orthop.* 2000; 20:108-15.
209. Koman LA, Mooney JF III, Smith BP et al. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. *J Pediatr Orthop.* 1994; 14:299-303.
210. Koog YH, Min BI. Effects of botulinum toxin A on calf muscles in children with cerebral palsy: a systematic review. *Clinical Rehabilitation* 2010;24(8):685 700
211. Krack P, Deuschl G, Benecke R et al. Dose standardization of botulinum toxin. *Mov Disord.* 1998; 13:749-51.
212. Kraft SP, Lang AE. Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations. *Can J Neurol Sci.* 1988; 15:276-80.

213. Kuo HC. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. *J Urol.* 2003; 170:1908-12.
214. Kuo HC. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. *Urology.* 2003; 61:550-4.
215. Kuo HC. Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome. *Pain Physician.* 2013 Jan;16(1):E15-23. PMID: 23340540.
216. Kuo HC. Repeated intravesical onabotulinumtoxinA injections are effective in treatment of refractory interstitial cystitis/bladder pain syndrome. *Int J Clin Pract.* 2013 May;67(5):427-34. doi: 10.1111/ijcp.12113. PMID: 23574103.
217. Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment - A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. *Neurourol Urodyn.* 2016 Jun;35(5):609-14. doi: 10.1002/nau.22760. Epub 2015 Apr 24. PMID: 25914337.
218. Kuo YC, Kuo HC. O'Leary-Sant Symptom Index Predicts the Treatment Outcome for OnabotulinumtoxinA Injections for Refractory Interstitial Cystitis/Bladder Pain Syndrome. *Toxins (Basel).* 2015 Jul 30;7(8):2860-71. doi: 10.3390/toxins7082860. PMID: 26264022; PMCID: PMC4549729.
219. L'Hommedieu C, Stough R, Brown L et al. Potentiation of neuromuscular weakness in infant botulism by aminoglycosides. *J Pediatr.* 1979; 95:1065-70.
220. Laccourreye O, Akl E, Gutierrez-Fonseca R et al. Recurrent gustatory sweating (Frey syndrome) after intracutaneous injection of botulinum toxin type A: incidence, management, and outcome. *Arch Otolaryngol Head Neck Surg.* 1999; 125:283-6.
221. Lang AM. Botulinum toxin therapy for myofascial pain disorders. *Curr Pain Headache Rep.* 2002; 6:355-60.
222. Lange DJ, Rubin M, Greene PE et al. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. *Muscle Nerve.* 1991; 14:672-5.
223. Latimer PR, Hodgkins PR, Vakalis AN et al. Necrotising fasciitis as a complication of botulinum toxin injection. *Eye.* 1998; 12(Part 1):51-3.
224. Leyden JE, Moss AC, MacMathuna P. Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. *Cochrane Database of Systematic Reviews* 2014, Issue 12. Art. No.: CD005046.
225. Linsenmeyer TA. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: State of the art review. *J Spinal Cord Med.* 2013; 36:402-19.
226. Linsenmeyer TA. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. *Journal of Spinal Cord Medicine* 2013;36(5):402 19.
227. Lipton RB, Varon SF, Grosberg B et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. *Neurology.* 2011; 77:1465-72.
228. Long H, Liao Z, Wang Y, Liao L, Lai W. Efficacy of botulinum toxins on bruxism: an evidence-based review. *Int Dent J.* 2012;62(1):1-5.
229. Love SC, et al. Botulinum toxin assessment, intervention and aftercare for lower limb spasticity in children with cerebral palsy: international consensus statement. *European Journal of Neurology* 2010;17 Suppl 2:9 37.
230. Love SC, Valentine JP, Blair EM et al. The effect of on the functional ability of the child with spastic hemiplegia: a randomized controlled trial. *Eur J Neurol.* 2001; 8 (Suppl 5):50-8.
231. Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52 week multicenter double-blind, randomized,

- placebo-controlled study of efficacy and safety. *Journal of the American Academy of Dermatology* 2007;56(4):604-11.
232. Lowe NJ, Lask G, Yamauchi P et al. Bilateral, double-blind, randomized comparison of 3 doses of and placebo in patients with crow's feet. *J Am Acad Dermatol.* 2002; 47:834-40.
 233. Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique. *J Am Acad Dermatol.* 1996; 35:569-72.
 234. Lowe NJ, Yamauchi PS, Lask GP et al. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. *J Cosmet Laser Ther.* 2002; 4:15-8.
 235. Lowe NJ, Yamauchi PS, Lask GP, et al. Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. *Dermatol Surg* 2002; 28:822.
 236. Lyseng-Williamson KA, Frampton JE. OnabotulinumtoxinA (BOTOX®): A guide to its use in preventing headaches in adults with chronic migraine. *CNS Drugs.* 2012; 26(8):717-23.
 237. MacDiarmid S, Glazier DB, McCrery RJ, et al. Efficacy and safety of an alternative onabotulinumtoxinA injection paradigm for refractory overactive bladder. *Neurourol Urodyn.* 2024 Jan;43(1):31-43. doi: 10.1002/nau.25290. Epub 2023 Sep 25.
 238. Magid M, Reichenberg JS, Poth PE, Robertson HT, LaViolette AK, Kruger TH, Wollmer MA. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. *J Clin Psychiatry.* 2014 Aug;75(8):837-44. doi: 10.4088/JCP.13m08845. PMID: 24910934.
 239. Magoon E, Dakoske C. Botulinum toxin injection for vertical strabismus. *Am Orthop J.* 1985; 35:48-52.
 240. Mall V, Glocker FX, Frankenschmidt A et al. Treatment of neuropathic bladder using botulinum toxin A in a 1-year-old child with myelomeningocele. *Pediatr Nephrol.* 2001; 16:1161-2.
 241. Mangera A, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. *European Urology* 2014;65(5):981-990.
 242. Mangera A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). *European Urology* 2011;60(4):784-95
 243. Marberger M, et al. A randomized double-blind placebo controlled phase 2 dose ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. *European Urology* 2013;63(3):496-503
 244. Marchal C, Perez JE, Herrera B, Machuca FJ, Redondo M. The use of botulinum toxin in benign prostatic hyperplasia. *Neurourology and Urodynamics* 2012;31(1):86-92
 245. Marciniak CM, Harvey RL, Gagnon CM, et al. Does botulinum toxin type A decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity?: a randomized, double-blind, placebo-controlled trial. *Am J Phys Med Rehabil.* 2012 Dec;91(12):1007-19. doi: 10.1097/PHM.0b013e31826ecb02.

246. Maria G, Brisinda G, Civello IM et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. *Urology*. 2003; 62:264-5. Reply.
247. Maria G, Cassetta E, Gui D et al. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. *N Engl J Med*. 1998; 338:217-20.
248. Markert RJ, Solomon GD. OnabotulinumtoxinA for treatment of chronic migraine. *Headache*. 2011; 51:1002-3. Letter.
249. Markey AC. Botulinum A exotoxin in cosmetic dermatology. *Clin Exp Dermatol*. 2000; 25:173-5.
250. Martinelli D, Arceri S, De Icco R, et al,. BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm. *Cephalalgia*. 2022 Feb;42(2):170-175. doi: 10.1177/03331024211034508. Epub 2021 Aug 18.
251. Matarasso A, Deva AK. Botulinum toxin. *Plast Reconstr Surg*. 2002; 109:1191-7.
252. Matarasso A, Matarasso SL, Brandt FS et al. Botulinum A exotoxin for the management of platysma bands. *Plast Reconstr Surg*. 2003; 112:127-34S.
253. Matarasso A, Matarasso SL. Botulinum A exotoxin for the management of platysma bands. *Plast Reconstr Surg*. 2003; 112:138-140S.
254. Matarasso SL, Matarasso A. Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. *Plast Reconstr Surg*. 2001; 108:208-14,215-7.
255. Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. *Dermatol Surg*. 2003; 29:7-13.
256. Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxinA (BOTOX®) and topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: a pilot study. *Headache*. 2009; 49: 1466-78.
257. Mauriello JA Jr, Coniaris H, Haupt EJ. Use of botulinum toxin in the treatment of one hundred patients with facial dyskinesias. *Ophthalmology*. 1987; 94:976-9.
258. Mehta S, et al. Meta- analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury. *Archives of Physical Medicine and Rehabilitation* 2013;94(8):1473 81.
259. Montes BB, Irkorucu O, Akin M et al. Comparison of botulinum toxin injection and lateral internal sphincterotomy for the treatment of chronic anal fissure. *Dis Colon Rectum*. 2003; 46:232-7.
260. Minguez M, Melo F, Espi A et al. Therapeutic effects of different doses of botulinum toxin in chronic anal fissure. *Dis Colon Rectum*. 1999; 42:1016-21.
261. Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach. *Parkinsonism Relat Disord*. 2018 Nov;56:65-69. doi: 10.1016/j.parkreldis.2018.06.019. Epub 2018 Jun 12. PMID: 29929813.
262. Modugno N, Priori A, Berardelli A et al. Botulinum toxin restores presynaptic inhibition of group Ia afferents in patients with essential tremor. *Muscle Nerve*. 1998; 21:1701-5.

263. Molenaers G, Desloovere K, Eyssen M et al. Botulinum toxin type A treatment of cerebral palsy: an integrated approach. *Eur J Neurol*. 1999; 6 Suppl 4:S51-7.
264. Monheit GD, Cohen JL, the Reloxin Investigational Group. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: Interim analysis from an open-label extension study. *J Am Acad Dermatol*. 2009; 61(3):421-5.
265. Moore AP. Botulinum toxin A (BoNT-A) for spasticity in adults. What is the evidence? *Eur J Neurol*. 2002; 9(Suppl 1):42-7.
266. Morre HH, Keizer SB, Os JJ. Treatment of chronic tennis elbow with botulinum toxin. *Lancet*. 1997; 349:1746.
267. Moy R, Maas C, Monheit G et al. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. *Arch Facial Plast Surg*. 2009 Mar-Apr; 11:77-83.
268. Naumann M, Boo LM, Ackerman AH et al. Immunogenicity of botulinum toxins. *J Neural Transm*. 2013; 120(2):275-90.
269. Naumann M, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 2008;70(19):1707-14.
270. Naumann M, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. *Toxicon* 2013;67:141-52.
271. Naumann M, Flachenecker P, Brocker EB et al. Botulinum toxin for palmar hyperhidrosis. *Lancet*. 1997; 349:252.
272. Naumann M, Hofmann U, Bergmann I et al. Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. *Arch Dermatol*. 1998; 134:301-4.
273. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. *BMJ*. 2001; 323:596-9.
274. Naver H, Swartling C, Aquilonius SM. Palmar and axillary hyperhidrosis treated with botulinum toxin: one-year clinical follow-up. *Eur J Neuro*. 2000; 7:55-62.
275. Niemann N, Jankovic J. Botulinum Toxin for the Treatment of Hand Tremor. *Toxins (Basel)*. 2018 Jul 19;10(7):299. doi: 10.3390/toxins10070299.
276. Nitti VW, Dmochowski R, Herschorn S et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. *J Urol*. 2013; 189:2186-93.
277. Nitti V, Haag-Molkenteller C, Kennelly M, Chancellor M, Jenkins B, Schurch B. Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact. *Medicine (Baltimore)*. 2023 Jul 1;102(S1):e32377. doi: 10.1097/MD.00000000000032377.
278. O'Brien CF. Treatment of spasticity with botulinum toxin. *Clin J Pain*. 2002; 18: S182-90.
279. Odderson IR. Hyperhidrosis treated by botulinum A exotoxin. *Dermatol Surg* 1998; 24:1237.

280. Odderson IR. Long-term quantitative benefits of in the treatment of axillary hyperhidrosis. *Dermatol Surg.* 2002; 28:480-3.
281. Odergren T, Hjaltason H, Kaakkola S et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. *J Neurol Neurosurg Psychiatry.* 1998; 64:6-12.
282. Ondo WG, Simmons JH, Shahid MH, Hashem V, Hunter C, Jankovic J. Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study. *Neurology.* 2018 Feb 13;90(7):e559-e564. doi: 10.1212/WNL.0000000000004951. Epub 2018 Jan 17.
283. Pacchetti C, Albani G, Martignoni E et al. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. *Mov Disord.* 1995; 10:333-6.
284. Pandey S, Srivanitchapoom P, Kirubakaran R, Berman BD. Botulinum toxin for motor and phonic tics in Tourette's syndrome. *Cochrane Database of Systematic Reviews* 2018, Issue 1. Art. No.: CD012285. DOI: 10.1002/14651858.CD012285.pub2.
285. Pasricha PJ, Rai R, Ravich WJ et al. Botulinum toxin for achalasia: long- term outcome and predictors of response. *Gastroenterology.* 1996; 110:1410-5.
286. Pasricha PJ, Ravich WJ, Hendrix TR et al. Intrasphincteric botulinum toxin for the treatment of achalasia. *N Engl J Med.* 1995; 332:774-8.
287. Patel PN, Kabagambe EK, Starkweather JC, et al,. Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor. *JAMA Otolaryngol Head Neck Surg.* 2018 Apr 1;144(4):293-299. doi: 10.1001/jamaoto.2017.3088. Patel S, Martino D. Cervical dystonia: from pathophysiology to pharmacotherapy. *Behavioural Neurology* 2013;26(4):275-82.
288. Pearce LB, Borodic GE, Johnson EA et al. The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin. *Toxicon.* 1995; 33:217-27.
289. *Pediatr Rehabil.* 2001;4(1):29-36.
290. Pero R, Coretti L, Lembo F. Botulinum Toxin A for Controlling Obesity. *Toxins (Basel).* 2016;8(10)
291. Peterlein CD, Funk JF, Hölscher A, Schuh A, Placzek R. Is botulinum toxin A effective for the treatment of plantar fasciitis?. *Clin J Pain.* 2012;28(6):527-33.
292. Petracca M, et al. Botulinum Toxin A and B in sialorrhoea: Long-term data and literature overview. *Toxicon* 2015;107(Pt A):129-40.
293. Phelan MW, Franks M, Somogyi GT et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. *J Urol.* 2001; 165:1107-10.
294. Pinto RA, Costa D, Morgado A, Pereira P, Charrua A, Silva J, Cruz F. Intratriganal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind, Placebo Controlled Trial. *J Urol.* 2018 Apr;199(4):998-1003. doi: 10.1016/j.juro.2017.10.018. Epub 2017 Oct 13. PMID: 29031769.

295. Poewe W. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. Clinically appropriate conversion factor may be less than three. *J Neurol Neurosurg Psychiatry*. 2002; 72:430.
296. Porta M, Maggioni G, Ottaviani F, Schindler A. Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A. *Neurol Sci*. 2004;24(6):420-3.
297. Pribitkin EA, Greco TM, Goode RL et al. Patient selection in the treatment of glabellar wrinkles with botulinum toxin type A injection. *Arch Otolaryngol Head Neck Surg*. 1997; 123:321-6.
298. Qerama E, Fuglsang Frederiksen A, Jensen TS. The role of botulinum toxin in management of pain: an evidence based review. *Current Opinion in Anaesthesiology* 2010;23(5):602 10.
- 299.
300. Racette BA, Good L, Sagitto S et al. Botulinum toxin B reduces sialorrhea in parkinsonism. *Mov Disord*. 2003; 18:1059-61.
301. Racette BA, Lopate G, Good L et al. Ptosis as a remote effect of therapeutic botulinum toxin B injection. *Neurology*. 2002; 59:1445-7.
302. Racette BA, Stambuk M, Perlmutter JS. Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024). *Mov Disord*. 2002; 17:1098-100.
303. Raj PP. Botulinum toxin in the treatment of pain associated with musculoskeletal hyperactivity. *Curr Rev Pain*. 1997; 1:403- 16.
304. Ramirez -Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. *Toxins (Basel)* 2013;5(2):249 66.
305. Ramirez AL, Reeck J, Maas CS. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. *Otolaryngol Head Neck Surg*. 2002; 126:459-67.
306. Ramzan Z, Nassri AB. The role of Botulinum toxin injection in the management of achalasia. *Current Opinion in Gastroenterology* 2013;29(4):468 .
307. Ranoux D, Gury C, Fondarai J et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. *J Neurol Neurosurg Psychiatry*. 2002; 72:459-62.
308. Rawicki B, et al. Botulinum toxin assessment, intervention and aftercare for paediatric and adult niche indications including pain: international consensus statement. *European Journal of Neurology* 2010;17 Suppl 2:122 34.
309. Reeve GS, Insel O, Thomas C, Houle AN, Miloro M. Does the Use of Botulinum Toxin in Treatment of Myofascial Pain Disorder of the Masseters and Temporalis Muscles Reduce Pain, Improve Function, or Enhance Quality of Life? *J Oral Maxillofac Surg*. 2024 Apr;82(4):393-401. doi: 10.1016/j.joms.2023.12.014. Epub 2023 Dec 28. PMID: 38228287; PMCID: PMC11648603.
310. Restivo DA, Lanza S, Patti F, et al. Improvement of diabetic autonomic gustatory sweating by botulinum toxin type A. *Neurology* 2002; 59:1971.
311. Roche N, Schnitzler A, Genet F F et al. Undesirable distant effects following injection. *Clin Neuropharmacol* 2008; 31:272-80.
312. Rodwell K, Edwards P, Ware RS, Boyd R. Salivary gland botulinum toxin injections for drooling in children with cerebral palsy and neurodevelopmental disability: a systematic review. *Dev Med Child Neurol*. 2012;54(11):977-87.

313. Ron T, Jankovic J. Botulinum Toxin Type A in the Management of Oromandibular Dystonia and Bruxism. In: Brin MF, Hallett M, Jankovic J, ed. *Scientific and therapeutic aspects of botulinum toxin*. Lippincott Williams & Wilkins, Philadelphia, PA; 2002.
314. Rothrock JF, Adams AM, Lipton RB, et al. FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. *Headache*. 2019 Nov;59(10):1700-1713. doi: 10.1111/head.13653. Epub 2019 Sep 26.
315. Rowland LP. Stroke, spasticity, and botulinum toxin. *N Engl J Med*. 2002; 347:382-3.
316. Royal MA. The use of botulinum toxins in the management of myofascial pain and other conditions associated with painful muscle spasm. Available from website.
317. Rubin MG, Dover J, Glogau RG et al. The efficacy and safety of a new U.S. botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. *J Drugs Dermatol*. 2009; 8:439-44.
318. Rudzinska M, Wojcik M, Szczudlik A. Hemifacial spasm non -motor and motor -related symptoms and their response to botulinum toxin therapy. *Journal of Neural Transmission* 2010;117(6):765 72.
319. Russman BS, Tilton A, Gormley ME. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. *Muscle Nerve Suppl*. 1997; 6:181-93S.
320. Ryll U, Bastiaenen C, De Bie R, Staal B. Effects of leg muscle botulinum toxin A injections on walking in children with spasticity -related cerebral palsy: a systematic review. *Developmental Medicine and Child Neurology* 2011;53(3):210 6.
321. Sampaio C, Ferreira JJ, Simoes F. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1. *Mov Disord*. 1997; 12:1013-8.
322. Sandrini G, Perrotta A, Tassorelli C, et al. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. *J Headache Pain*. 2011 Aug;12(4):427-33. doi: 10.1007/s10194-011-0339-z. Epub 2011 Apr 16.
323. Sato H, Watanabe T, Otsuka S, Tsukada S. Short-term Efficacy of Botulinum Toxin A for Refractory Overactive Bladder in Female Patients. *In Vivo*. 2025 Mar-Apr;39(2):942-950. doi: 10.21873/invivo.13899.
324. Sattler G, Callander MJ, Grablowitz D et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. *Dermatol Surg*. 2010; 36 Suppl 4:2146-54.
325. Schaffner R, Kreyden OP. Complications and side-effects of botulinum toxin A. *Curr Probl Dermatol*. 2002; 30:141-8.
326. Schnider P, Binder M, Auff E, et al. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. *Br J Dermatol* 1997; 136:548.
327. Schulte-Baukloh H, Michael T, Schobert J et al. Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. *Urology*. 2002; 59:325-8.

328. Schulte-Baukloh H, Michael T. Botulinum-A toxin in the treatment of neurogenic bladder in children. *Pediatrics*. 2002; 110(2 Part 1):420-1.
329. Schurch B, de Sèze M, Denys P et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. *J Urol*. 2005; 174:196-200.
330. Schurch B, Hauri D, Rodic B et al. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. *J Urol*. 1996; 155:1023-9.
331. Schurch B, Hodler J, Rodic B. Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. *J Neurol Neurosurg Psychiatry*. 1997; 63:474-6.
332. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. *N Engl J Med*. 2000; 342:665.
333. Schwartz M, Freund B. Treatment of temporomandibular disorders with botulinum toxin. *Clin J Pain*. 2002; 18(6 Suppl):S198-203.
334. Scott AB, Magoon EH, McNeer KW et al. Botulinum treatment of childhood strabismus. *Ophthalmology*. 1990; 97:1434-8.
335. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. *Move Dis*. 1988; 3:333-5.
336. Scott AB. Antitoxin reduces botulinum side effects. *Eye*. 1988; 2:29- 32.
337. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. *Ophthalmology*. 1980; 87:1044-9.
338. Scott AB. Botulinum toxin treatment of strabismus. In: *Focal points 1989: clinical modules for ophthalmologists*. American Academy of Ophthalmology. Vol. VII, module 12. 1989:1-11.
339. Scottish Intercollegiate Guidelines Network (SIGN). Pharmacological management of migraine. Edinburgh: SIGN; 2023. (SIGN publication no. 155). [March 2023]. Available from URL: <http://www.sign.ac.uk>
340. Setler PE. Therapeutic use of botulinum toxins: background and history. *Clin J Pain*. 2002; 18(Suppl):S119-24.
341. Sheean G. Botulinum toxin for the treatment of musculoskeletal pain and spasm. *Curr Pain Headache Rep*. 2002; 6:460-9.
342. Shelley WB, Talanin NY, Shelley ED. Botulinum toxin therapy for palmar hyperhidrosis. *J Am Acad Dermatol* 1998; 38:227.
343. Sievert K-D, Chapple C, Herschorn S et al. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. *Int J Clin Pract*. 2014 Oct; 68; 10:1246–56.
344. Silberstein SD, Diener HC, Dodick DW, Sommer K, Lipton RB. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials. *Headache*. 2024 Jul-Aug;64(7):838-848. doi: 10.1111/head.14743. Epub 2024 Jun 22.

345. Silberstein S, Mathew N, Saper J et al for the BOTOX Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. *Headache*. 2000; 40:445-50.
346. Silberstein SD, Blumenfeld AM, Cady RK et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. *J Neurol Sci*. 2013 Aug 15; 331(1-2):48-56.
347. Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. *Br J Dermatol* 2003; 149:1041.
348. Simpson DM, Alexander DN, O'Brien CF et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. *Neurology*. 1996; 46:1306-10.
349. Simpson DM, Blitzer A, Brashear A et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2008; 70:1699-706.
350. Simpson DM, Gracies JM, Yablon SA et al. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. *J Neurol Neurosurg Psychiatry*. 2009; 80:380-5.
351. Simpson DM, Hallett M, Ashman EJ et al. Practice guideline update: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adults spasticity, and headache: report of the guideline development subcommittee of the American Academy of Neurology. 2016. Available from American Academy of Neurology website.
352. Simpson DM. Clinical trials of botulinum toxin in the treatment of spasticity. *Muscle Nerve Suppl*. 1997; 6:S1-7.
353. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic junction. *J Pharmacol Exp Ther*. 1980; 212:16-21.
354. Sloop RR, Cole BA, Escutin RO. Reconstituted does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. *Neurology*. 1997; 48:249-53.
355. Soares A, Andriolo RB, Atallah AN, da Silva EM. Botulinum toxin for myofascial pain syndromes in adults. *Cochrane Database of Systematic Reviews* 2014, Issue 7. Art. No.: CD007533.
356. Solomon BA, Hayman R. Botulinum toxin type A therapy for palmar and digital hyperhidrosis. *J Am Acad Dermatol* 2000; 42:1026.
357. Solomon S. OnabotulinumtoxinA for treatment of chronic migraine: the unblinding problem. *Headache*. 2013; 53:824-6. Commentary.
358. Solstice Neurosciences. Myobloc® (rimabotulinumtoxinB) injection prescribing information. South San Francisco, CA; 2010 May.
359. Souayah N, Karim H, Kamin SS et al. Severe botulism after focal injection of botulinum toxin. *Neurology*. 2006; 67:1855-6.
360. Sposito MM. New indications for botulinum toxin type a in cosmetics: mouth and neck. *Plast Reconstr Surg*. 2003; 112:75-85S.
361. Stein E. Botulinum toxin and anal fissure. *Curr Probl Dermatol*. 2002; 30:218-26.

362. Storr M, Allescher HD, Rosch T et al. Treatment of symptomatic diffuse esophageal spasm by endoscopic injection of botulinum toxin: a prospective study with long term follow-up. *Gastrointest Endosc.* 2001; 54:754-9.
363. Strobl W, et al. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. *Toxins (Basel)* 2015;7(5):1629-48.
364. Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. *Neurourology and Urodynamics* 2013;32(3):242-9.
365. Sutherland DH, Kaufman KR, Wyatt MP et al. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. *Gait Posture.* 1999; 10:1-9.
366. Teive HA, Troiano AR, Robert F, et al. Botulinum toxin for treatment of Frey's syndrome: report of two cases. *Arq Neuropsiquiatr* 2003; 61:256.
367. Thobois S, Broussolle E, Tourelle L et al. Severe dysphagia after botulinum toxin injection for cervical dystonia in multiple system atrophy. *Mov Disord.* 2001 Jul; 16:764-5.
368. Tincello DG, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). *European Urology* 2012;62(3):507-14.
369. Tomsak RL, Remler BF, Averbuch-Heller L et al. Unsatisfactory treatment of acquired nystagmus with retrobulbar injection of botulinum toxin. *Am J Ophthalmol.* 1995; 119:489-96.
370. Toni, T., Tamana, R., Newman, B., Green, L., Katz, E., & Katz, P. (2021). Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: Case series. *Neurological Sciences*, 42(12), 5373-5377.
371. Truong D, Duane DD, Jankovic J et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. *Mov Disord.* 2005; 20:783-91.
372. Tsai CP, Liu CY, Lin KP, Wang KC. Efficacy of botulinum toxin type a in the relief of Carpal tunnel syndrome: A preliminary experience. *Clin Drug Investig.* 2006;26(9):511-5.
373. Tugnoli V, Eleopra R, Quatralo R et al. Botulism-like syndrome after injections for focal hyperhidrosis. *Br J Dermatol.* 2002; 147:808-9.
374. Turkel CC, Dru RM, Simon D et al. Neutralizing antibody formation is rare following repeated injections of a low protein formulation of botulinum toxin type a (BTX-A) in patients with poststroke spasticity. *Neurology.* 2002; 58(Suppl 3):A316.
375. Ubhi T, Bhakta BB, Ives HL et al. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. *Arch Dis Child.* 2000; 83:481-7.
376. Ukleja A, Tandon K, Shah K, Alvarez A. Endoscopic botox injections in therapy of refractory gastroparesis. *World Journal of Gastrointestinal Endoscopy* 2015;7(8):790-8. DOI: 10.4253/wjge.v7.i8.790.
377. Vadoud-Seyedi J, Heenen M, Simonart T. Treatment of idiopathic palmar hyperhidrosis with botulinum toxin. Report of 23 cases and review of the literature. *Dermatology.* 2001; 203:318-21.

378. Valizadeh N, et al. Botulinum toxin injection versus lateral internal sphincterotomy for the treatment of chronic anal fissure: randomized prospective controlled trial. *Langenbecks Archives of Surgery* 2012;397(7):1093-8.
379. Verma G. Role of botulinum toxin type A (BTX A) in the management of trigeminal neuralgia. *Pain Research and Treatment* 2013;2013:831094.
380. Visco AG, et al. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. *New England Journal of Medicine* 2012;367(19):1803-13.
381. Vivancos-Matellano F, Rodríguez-Sanz A, Herrero-Infante Y, Mascías-Cadavid J. Efficacy and Safety of Long-Term Therapy with Type A Botulinum Toxin in Patients with Blepharospasm. *Neuroophthalmology*. 2018 Nov 26;43(5):277-283. doi: 10.1080/01658107.2018.1542009.
382. Wang CC, Chou EC, Chuang YC, et al., Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan-A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study). *Toxins (Basel)*. 2021 Dec 20;13(12):911. doi: 10.3390/toxins13120911.
383. Waseem Z, Boulias C, Gordon A, Ismail F, Sheean G, Furlan AD. Botulinum toxin injections for low-back pain and sciatica. *Cochrane Database of Systematic Reviews* 2011, Issue 1. Art. No.: CD008257.
384. Weckx F, Tutolo M, De Ridder D, Van der Aa F. The role of botulinum toxin A in treating neurogenic bladder. *Translational Andrology and Urology* 2016;5(1):63-71.
385. Wehrmann T, Kokabpick H, Jacobi V et al. Long-term results of endoscopic injection of botulinum toxin in elderly achalasic patients with tortuous megaesophagus or epiphrenic diverticulum. *Endoscopy*. 1999; 31:352-8.
386. Wein T, Esquenazi A, Jost WH et al. OnabotulinumtoxinA for the Treatment of Post-Stroke Distal Lower-Limb Spasticity: A Randomized Trial. *PM R*. 2018;
387. Wein T, Jog M, Bhogal M, Dhani S, Miller R, Ismail F, Beauchamp R, Trentin G. Long-term Safety and Dosing of OnabotulinumtoxinA: A Prospective, Observational Study. *Can J Neurol Sci*. 2019 Nov;46(6):742-752. doi: 10.1017/cjn.2019.238.
388. Welch EK, Dengler KL, DiCarlo-Meacham AM, et al. Bladder instillations vs onabotulinumtoxinA injection for interstitial cystitis/bladder pain syndrome: a randomized clinical trial. *Am J Obstet Gynecol*. 2024 Nov;231(5):528.e1-528.e11. doi: 10.1016/j.ajog.2024.05.027. Epub 2024 May 18.
389. Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers' product summaries. *J Clin Pharm Ther*. 2007; 32:387-402.
390. WH. One hundred cases of anal fissure treated with botulin toxin: early and long-term results. *Dis Colon Rectum*. 1997; 40:1029-32.
391. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. *Spine*. 1998; 23:1662-6.
392. Wheeler AH, Goolkasian P, Gretz SS. Botulinum toxin A for the treatment of chronic neck pain. *Pain*. 2001; 94:255-60.

393. Wheeler AH, Goolkasian P. Open label assessment of botulinum toxin A for pain treatment in a private outpatient setting. *J Musculoskeletal Pain*. 2001; 9:67-82.
394. Wheeler AH. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. *Headache*. 1998; 38:468-71.
395. Wheeler AH. Botulinum toxin injection technique for treatment of headaches. *Aesthetic Surg J*. 2002; 22:65-8.
396. Wheeler AH. Therapeutic uses of botulinum toxin. *Am Fam Physician*. 1997; 55:541-5, 548.
397. Winner PK, Blumenfeld AM, Eross EJ, et al,. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study. *Drug Saf*. 2019 Aug;42(8):1013-1024. doi: 10.1007/s40264-019-00824-3.
398. Winner PK, Kabbouche M, Yonker M, Wangsadipura V, Lum A, Brin MF. A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine. *Headache*. 2020 Mar;60(3):564-575. doi: 10.1111/head.13754. Epub 2020 Feb 9.
399. Wollina U, Karamfilov T, Konrad H. High-dose therapy for axillary hyperhidrosis markedly prolongs the relapse-free interval. *J Am Acad Dermatol*. 2002; 46:536-40.
400. Wollmer MA, de Boer C, Kalak N, Beck J, Götz T, Schmidt T, Hodzic M, Bayer U, Kollmann T, Kollwe K, Sönmez D, Duntsch K, Haug MD, Schedlowski M, Hatzinger M, Dressler D, Brand S, Holsboer-Trachsler E, Kruger TH. Facing depression with botulinum toxin: a randomized controlled trial. *J Psychiatr Res*. 2012 May;46(5):574-81. doi: 10.1016/j.jpsychires.2012.01.027. Epub 2012 Feb 24. PMID: 22364892.
401. Woodcock J (US Food and Drug Administration). Response to Public Citizen's petition on botulinum toxin re: docket no: FDA-2008-P-0061. Rockville, MD; 2009 April 30. From FDA website.
402. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. *Spinal Cord*. 2002; 40:599-600.
403. Xia JH, et al. Botulinum toxin A in the treatment of trigeminal neuralgia. *International Journal of Neuroscience* 2016;126(4):348-53.
404. Yablon SA, Jackkson MS, Daggett S et al. Toxin neutralizing antibody formation with (BoNTA) treatment in neuromuscular disorders. *Neurology*. 2005; 64 (suppl 1); A72. Abstract.
405. Yablon SA. Botulinum neurotoxin intramuscular chemodenervation. Role in the management of spastic hypertonia and related motor disorders. *Phys Med Rehab Clin NA*. 2001; 12:833-74.
406. Yiannakopoulou E. Botulinum toxin and anal fissure: efficacy and safety systematic review. *International Journal of Colorectal Disease* 2012;27(1):1-9.
407. Yoshimura DM, Aminoff MJ, Tami TA et al. Treatment of hemifacial spasm with botulinum toxin. *Muscle Nerve*. 1992; 15:1045-9.
408. Yun JY, Kim JW, et al. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study. *Mov Disord*. 2015 Feb;30(2):206-13. doi: 10.1002/mds.26085. Epub 2014 Dec 5.
409. Żebryk P, Puszczewicz MJ. Botulinum toxin A in the treatment of Raynaud's phenomenon: a systematic review. *Arch Med Sci*. 2016 Aug 1; 12(4): 864–870. doi: 10.5114/aoms.2015.48152
- 410.

411. Zhang T, et al. The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta-analysis. *Inflammopharmacology* 2011;19(1):21-34
412. Zhou X, Yan HL, Cui YS, Zong HT, Zhang Y. Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis. *Chinese Medical Journal* 2015;128(7):963-8.
413. Zimbler MS, Holds JB, Kokoska MS et al. Effect of botulinum toxin pretreatment on laser resurfacing results: a prospective, randomized, blinded trial. *Arch Facial Plast Surg*. 2001; 3:165-9.
414. Zúñiga C, Piedimonte F, Díaz S, Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. *Clin Neuropharmacol*. 2013 Sep-Oct;36(5):146-50. doi: 10.1097/WNF.0b013e31829cb60e. PMID: 24045604.

IncobotulinumtoxinA (Xeomin)

1. Ahmad J, Ahmad SH, Jones K. Treatment of Plantar Fasciitis With Botulinum Toxin. *Foot Ankle Int*. 2017 Jan;38(1):1-7. doi: 10.1177/1071100716666364. Epub 2016 Oct 1. PMID: 27630253.
2. Ângelo DF, Sanz D, Maffia F, Cardoso HJ. Outcomes of IncobotulinumtoxinA Injection on Myalgia and Arthralgia in Patients Undergoing Temporomandibular Joint Arthroscopy: A Randomized Controlled Trial. *Toxins (Basel)*. 2023 Jun 3;15(6):376. doi: 10.3390/toxins15060376. PMID: 37368677; PMCID: PMC10302210.
3. Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. *J Neurol Neurosurg Psychiatry*. 1997; 62:198.
4. Bell MS, Vermeulen LC, Sperling KB. Pharmacotherapy with botulinum toxin: harnessing nature's most potent neurotoxin. *Pharmacotherapy*. 2000; 20:1079-91.
5. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. *Neurology*. 2005;64(11):1949-1951.
6. Benecke R. Xeomin in the treatment of cervical dystonia. *Eur J Neurol*. 2009; 16 Suppl 2:6-10.
7. Bhatia KP, Munchau A, Thompson PD et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. *J Neurol Neurosurg Psychiatry*. 1999; 67:90-3.
8. Campanati A, Giuliadori K, Martina E, et al. Onabotulinumtoxin A (Botox) versus incobotulinum toxin A (Xeomin) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial. *J Neural Transm* 2014;121:21-6.
9. Carraro E, Trevisi E, Martinuzzi A. Safety profile of incobotulinum toxin A [Xeomin®] in gastrocnemius muscles injections in children with cerebral palsy: Randomized double-blind clinical trial. *Eur J Paediatr Neurol*. 2016;20(4):532-7.
10. Castelnovo G, Le Floch A, Campello C, Bouly S. IncobotulinumtoxinA (XEOMIN®) in chronic refractory migraine. Poster presented at the 23rd Meeting of the European Neurological Society (ENS), 8-11 June 2013, Barcelona, Spain [ENS 2013 Abstract]
11. Cobb DB, Watson WA, Fernandez MC. Botulism-like syndrome after injections of botulinum toxin. *Vet Hum Toxicol*. 2000 Jun; 42:163.
12. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S; US XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum

- neurotoxin type A, without accessory proteins) in patients with cervical dystonia. *J Neurol Sci.* 2011;308(1-2):103-109.
13. Costa J, Espirito-Santo CC, Borges AA et al. Botulinum toxin type A therapy for cervical dystonia (review). *Cochrane Database of Systematic Reviews.* 2005, Issue 1. Article No: CD003633. DOI: 10.1002/14651858.CD003633.pub2.
 14. Dressler D, Rychlik R, Kreimendahl F, Schnur N, Lambert-baumann J. Long-term efficacy and safety of incobotulinumtoxinA and conventional treatment of post stroke arm spasticity: a prospective, non-interventional, open-label, parallel-group study. *BMJ Open.* 2015;5(12):e009358.
 15. Dressler D. Comparing Botox and Xeomin for axillar hyperhidrosis. *J Neural Transm* 2010;117:317-19.
 16. Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. *Eur J Neurol.* 2009;16 (Suppl 2):2–5.
 17. Elovic EP, Munin MC, Kaňovský P, Hanschmann A, Hiersemenzel R, Marciniak C. Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity. *Muscle Nerve.* 2016;53(3):415-21
 18. Fezza J, Burns J, Woodward J, Truong D, Hedges T, Verma A. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm. *J Neurol Sci.* 2016;367:56-62.
 19. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?. *Biologics.* 2010; 4:325-32.
 20. Hampel C, D'Andrea D, Gillitzer R, et al. Comparison of two different botulinum toxin A products (Xeomin, Botox) used for detrusor injection in patients with bladder overactivity (BO) – a prospective randomized double-blind study. 27th Annual Congress of the European Association of Urology, February 26th, 2012.
 21. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm—a randomized trial. *Mov Disord.* 2011;26(8):1521-1528.
 22. Jankovic J. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. *Eur J Neurol.* 2009; 16 Suppl 2:14-8.
 23. Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. *Drugs.* 2007; 67:669-83.
 24. Kanovský P, Slawek J, Denes Z et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. *Clin Neuropharmacol.* 2009 Sep-Oct; 32:259-65.
 25. Kanovský P, Slawek J, Denes Z et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. *J Rehabil Med.* 2011; 43:486-92.
 26. Kanovsky P, Slawek J, Denes Z, et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in poststroke upper limb spasticity. *J Rehabil Med* 2011;43:486-92.

27. Kazerooni R, Lim J, Ashley blake P, Lessig S. IncobotulinumtoxinA for Migraine: A Retrospective Case Series. *Clin Ther.* 2015;37(8):1860-4.
28. Lamb YN, Scott LJ. IncobotulinumtoxinA: A Review in Upper Limb Spasticity. *Drugs.* 2016;76(14):1373-9.
29. Matarasso A, Deva AK. Botulinum toxin. *Plast Reconstr Surg.* 2002; 109:1191-7.
30. Merz Pharmaceuticals. Xeomin® (incobotulinumtoxinA) for injection, intramuscular use prescribing information. Raleigh, NC; 2015 Dec.
31. Merz North America, Inc. FDA approves Xeomin (incobotulinumtoxinA) for adult patients with sialorrhea. Press Release. Raleigh, NC: Merz; July 3, 2018. Available at: <https://www.merzusa.com/news/fda-approves-xeomin-incobotulinumtoxina-for-adult-patients-with-sialorrhea/>.
32. Merz Pharmaceuticals, LLC. Xeomin (incobotulinumtoxinA) for injection, for intramuscular or intraglandular use. Prescribing Information. Raleigh, NC: Merz Pharmaceuticals; revised July 2018. Available at: <http://www.xeomin.com/wp-content/uploads/xeomin-full-prescribing-information.pdf>.
33. Merz Pharmaceuticals. Xeomin® incobotulinumtoxinA for injection, for intramuscular use prescribing information. Raleigh, NC; 2015 Dec.
34. Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum Toxin in Parkinson Disease Tremor: A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach. *Mayo Clin Proc.* 2017 Sep;92(9):1359-1367. doi: 10.1016/j.mayocp.2017.06.010. Epub 2017 Aug 5. PMID: 28789780.
35. Narayanaswami P, Geisbush T, Tarulli A, et al. Drooling in Parkinson's disease: A randomized controlled trial of incobotulinum toxin A and meta-analysis of Botulinum toxins. *Parkinsonism Relat Disord.* 2016;30:73-7.
36. Park J, Lee MS, Harrison AR. Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm. *Clin Ophthalmol.* 2011; 5:725-32.
37. Patel AA, Lerner MZ, Blitzer A. IncobotulinumtoxinA Injection for Temporomandibular Joint Disorder. *Ann Otol Rhinol Laryngol.* 2017 Apr;126(4):328-333. doi: 10.1177/0003489417693013. Epub 2017 Feb 1. PMID: 28290229.
38. Pokushalov E, Kozlov B, Romanov A, et al. Long-term suppression of atrial fibrillation by botulinum toxin injection into epicardial fat pads in patients undergoing cardiac surgery: One year follow up of a randomized pilot study. *Circ Arrhythm Electrophysiol.* 2015;8(6):1334-1341.
39. Proietti S, Giovannozzi S, Lepri E, et al. Clinical and urodynamic efficacy of Xeomin in the treatment of neurogenic detrusor overactivity: preliminary results. *Neurol Urodyn.* 2011; 30 (suppl):45-46.
40. Roche N, Schnitzler A, Genet F F et al. Undesirable distant effects following botulinum toxin type A injection. *Clin Neuropharmacol* 2008; 31:272-80.
41. Roggenkämper P, Jost WH, Bihari K et al. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. *J Neural Transm.* 2006; 113:303-12.

42. Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. *J Neural Transm.* 2006;113(3):303-312.
43. Santamato A, Micello MF, Panza F, et al. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower-limb spasticity: a prospective open-label study. *Eur J Phys Rehabil Med* 2013;49:483-9.
44. Sattler G, Callander MJ, Grablowitz D et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. *Dermatol Surg.* 2010; 36 Suppl 4:2146-54.
45. Simpson DM, Gracies JM, Graham K et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review). *Neurology.* 2009; 73:736-7; author reply 737-8.
46. Simpson DM, Hallett M, Ashman EJ et al. Practice guideline update: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adults spasticity, and headache: report of the guideline development subcommittee of the American Academy of Neurology. 2016. Available at: <https://www.neurology.org/doi/10.1212/wnl.0000000000002560>
47. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology* 2016;86:1-9.
48. Tugnoli V, Eleopra R, Quatralo R et al. Botulism-like syndrome after botulinum toxin type A injections for focal hyperhidrosis. *Br J Dermatol.* 2002; 147:808-9.
49. US Food and Drug Administration. Center for Drug Evaluation and Research: Application number 125360: Summary review for incobotulinumtoxinA. From FDA website.
50. Woodcock J (US Food and Drug Administration). Response to Public Citizen's petition on botulinum toxin re: docket no: FDA-2008-P-0061. Rockville, MD; 2009 April 30. From FDA website (https://www-fda-gov.libproxy.unm.edu/cder/drug/early_comm/botulinum_CP_response.pdf)
51. Xeomin (incobotulinumtoxinA) [prescribing information] Raleigh, NC: Merz Pharmaceuticals LLC; September 2023.
52. Zeuner KE, Deuschl G. Pharmacokinetics and pharmacodynamics of incobotulinumtoxinA influencing the clinical efficacy in post-stroke spasticity. *Expert Opin Drug Metab Toxicol.* 2016;12(4):457-66.

RimabotulinumtoxinB (Myobloc)

102. Adler CH, Bansberg SF, Krein-Jones K, Hentz JG. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia. *Mov Disord.* 2004;19(9):1075-1079.
103. Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. *JAMA.* 2011; 305:89-90.

104. An JS, Hyun won C, Si han J, Park HS, Seo KK. Comparison of onabotulinumtoxinA and rimabotulinumtoxinB for the treatment of axillary hyperhidrosis. *Dermatol Surg*. 2015;41(8):960-7.
105. Arezzo JC, Litwak MS, Gasper CA et al. The spread of paralytic activity in juvenile monkeys: a comparison of and botulinum toxin type B. Paper presented at the World Congress of Neurological Rehabilitation, Venice, Italy: 2002 Apr 2-6.
106. Armanious M, Khalil N, Lu Y, Jimenez-Sanders R. Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis. *J Pain Palliat Care Pharmacother* 2021; 35:1.
107. Arnon SS, Schechter R, Inglesby TV et al for the Working Group on Civilian Biodefense. Botulinum toxin as a biologic weapon: medical and public health management. *JAMA*. 2001; 285:1059-70.
108. Barbehenn E, Lurie P, Stark S et al. Petition to the FDA requesting regulatory action concerning the possible spread of botulinum toxin (Botox, Myobloc) from the site of injection to other parts of the body. Washington, DC: Public Citizen's Health Research Group; 2008 Jan.
109. Baumann L, Black L. Botulinum toxin type B (Myobloc). *Dermatol Surg*. 2003; 29:496-500.
110. Baumann L, slezinger A, Halem M et al. Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis. *Dermatol Surg*. 2005; 31:263-70.
111. Baumann L, Slezinger A, Halem M, et al. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis. *Int J Dermatol*. 2005;44(5):418-424.
112. Baumann L, Slezinger A, Vujevich J et al. A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet: a double-blinded, placebo-controlled trial. *Dermatol Surg*. 2003; 29:508-15.
113. Baumann LS, Helam ML. Botulinum toxin-B and the management of hyperhidrosis. *Dermatology*. 2004;22:60-65.
114. Bell MS, Vermeulen LC, Sperling KB. Pharmacotherapy with botulinum toxin: harnessing nature's most potent neurotoxin. *Pharmacotherapy*. 2000; 20:1079-91.
115. Benecke R, Jost WH, Kanovsky P et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. *Neurology*. 2005; 64(11):1949-51.
116. Berardelli A, Abbruzzese G, Bertolasi L et al. Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology. *Ital J Neurol Sci*. 1997; 18:261-9.
117. Berman B, Seeberger L, Kumar R. Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia. *Mov Disord*. 2005;20(2):233-237.
118. Blackie JD, Lees AJ. Botulinum toxin treatment in spasmodic torticollis. *J Neurol Neurosurg Psychiatry*. 1990; 53:640-3.

119. Brandenburg JE, Krach LE, Gormley ME Jr. Use of rimabotulinum toxin for focal hypertonicity management in children with cerebral palsy with non-response to onabotulinum toxin. *Am J Phys Med Rehabil.* 2013;92(10):898-904.
120. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. *Neurology.* 1999;53(7):1439-1446.
121. Brashear A, McAfee AL, Kuhn ER, Ambrosius WT. Treatment with botulinum toxin type B for upper-limb spasticity. *Arch Phys Med Rehabil.* 2003;84(1):103-7.
122. Brashear A, McAfee AL, Kuhn ER, Fyffe J. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. *Arch Phys Med Rehabil.* 2004;85(5):705-9.
123. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. *Neurology.* 1999;53(7):1431-1438.
124. Callaway JE, Arezzo JC, Grethlein AJ. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. *Semin Cutan Med Surg.* 2001; 20:127-36.
125. Callaway JE, Oregozo P, Gore N et al. Long-term stability of a new liquid formulation of botulinum toxin type b (BoNT-B). *Neurology.* 2001; 56(suppl 3): A346.
126. Chapman MA, Barron R, Tanis DC et al. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. *Clin Ther.* 2007; 29:1325-37.
127. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part 1. *Am J Health Syst Pharm.* 2006; 63:145-52.
128. Cobb DB, Watson WA, Fernandez MC. Botulism-like syndrome after injections of botulinum toxin. *Vet Hum Toxicol.* 2000 Jun; 42:163.
129. Colosimo C, Chianese M, Giovannelli M et al. Botulinum toxin type B in blepharospasm and hemifacial spasm. *J Neurol Neurosurg Psychiatry.* 2003; 74:687-91.
- 130.
131. Costa J, Espírito-Santo C, Borges A, et al. Botulinum toxin type B for cervical dystonia. *Cochrane Database Syst Rev.* 2004;(4):CD004315.
132. Cullis PA, O'Brien CF, Truong DD, et al. Botulinum toxin type B: An open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients. *Adv Neurol.* 1998;78:227-230.
133. Dressler D, Adib Saberi F, Benecke R. Botulinum toxin type B for treatment of axillar hyperhidrosis. *J Neurol.* 2002; 249:1729-32.
134. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. *Eur Neurol.* 2003; 49:34- 8.
135. Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced therapy failure. *J Neurol.* 2003; 250:967-9.
136. Dressler D, Saberi FA, Benecke R. Botulinum toxin type B for treatment of axillary hyperhidrosis. *J Neurol.* 2002;249:1729-1732.
137. Dutton JJ, White JJ, Richard MJ. Myobloc for the treatment of benign essential blepharospasm in patients refractory to botox. *Ophthal Plast Reconstr Surg.* 2006;22(3):173-7.

138. Dykstra DD, Pryor J, Goldish G. Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: a case report. *Arch Phys Med Rehabil.* 2003; 84:1399-400.
139. Elan Pharmaceuticals. South San Francisco, CA: Personal communication.
140. Elston JS, Russell RWR. Effect of treatment with botulinum toxin on neurogenic blepharospasm. *BMJ.* 1985; 290:1857-9.
141. Erbguth F, Claus D, Engelhardt A et al. Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. *J Neurol Neurosurg Psychiatry.* 1993; 56:1235- 6.
142. Evers S, Rahmann A, Vollmer-Haase J et al. Treatment of headache with botulinum toxin A--a review according to evidence-based medicine criteria. *Cephalalgia.* 2002; 22:699-710.
143. Fadeyi MO, Adams QM. Use of botulinum toxin type B for migraine and tension headaches. *Am J Health-Syst Pharm.* 2002;59:1860-1862.
144. Figgitt DP, Noble S. Botulinum toxin B: A review of its therapeutic potential in the management of cervical dystonia. *Drugs.* 2002; 62:705-2.
145. Figgitt DP, Noble S. Botulinum toxin B: A review of its therapeutic potential in the management of cervical dystonia. *Drugs.* 2002;62(4):705-722.
146. Ghei M, Maraj BH, Miller R, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. *J Urol* 2005;174(5):1873-7.
147. Glogau RG. Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes. *Clin J Pain.* 2002; 18(6 Suppl):S191-7.
148. Gracies JM, Bayle N, Goldberg S, Simpson DM. Botulinum toxin type B in the spastic arm: a randomized, double-blind, placebo-controlled, preliminary study. *Arch Phys Med Rehabil.* 2014;95(7):1303-11.
149. Guntinas-Lichius O. Injection of botulinum toxin type B for the treatment of otolaryngology patients with secondary treatment failure of. *Laryngoscope.* 2003 Apr; 113:743-5.
150. Heckmann M, Ceballos-Baumann AO, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). *N Engl J Med.* 2001; 344:488-93.
151. Hirst GR, Watkins AJ, Guerrero K, et al. Botulinum toxin B is not an effective treatment of refractory overactive bladder. *Urology.* 2007;69(1):69-73.
152. Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. *J Am Acad Dermatol.* 2000; 43:249-59.
153. Isaacson SH, Ondo W, Jackson CE, et al; MYSTICOL Study Group. Safety and efficacy of rimabotulinumtoxinB for treatment of sialorrhea in adults: a randomized clinical trial. *JAMA Neurol.* 2020;77(4):461-469. doi:10.1001/jamaneurol.2019.4565
154. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. *N Engl J Med.* 1991; 324:1186-94.
155. Johnson EA. Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. *Annu Rev Microbiol.* 1999; 53:551-75.
156. Jost WH. Botulinum toxin type B in the treatment of anal fissures: first preliminary results. *Dis Colon Rectum.* 2001; 44:1721-2.

157. Klein AW. Complications and adverse reactions with the use of botulinum toxin. *Semin Cutan Med Surg.* 2001; 20:109-20.
158. Lew MF, Adornato BT, Duane DD et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. *Neurology.* 1997; 49:701-7.
159. Lew MF. Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients. *Adv Neurol.* 1998; 78:227-30.
160. Lew MR, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: Summary of three controlled clinical trials. *Neurology.* 2000;55(12 Suppl 5):S29-S35.
161. Lowe NJ, Yamauchi PS, Lask GP et al. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. *J Cosmet Laser Ther.* 2002; 4:15-8.
162. Matarasso A, Deva AK. Botulinum toxin. *Plast Reconstr Surg.* 2002; 109:1191-7.
163. Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. *Dermatol Surg.* 2003; 29:7-13.
164. Moore AP. Botulinum toxin A (BoNT-A) for spasticity in adults. What is the evidence? *Eur J Neurol.* 2002; 9(Suppl 1):42-7.
165. Motegi SI, Uehara A, Yamada K, Sekiguchi A, Fujiwara C, Toki S, Date Y, Nakamura T, Ishikawa O. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis. *Acta Derm Venereol.* 2017 Jul 6;97(7):843-850. doi: 10.2340/00015555-2665. PMID: 28358168.
166. Myobloc (rimabotulinumtoxinB) [prescribing information]. Louisville, KY: Solstice Neurosciences; September 2020.
167. Myobloc(R) IM injection, rimabotulinumtoxinB IM injection. Solstice Neurosciences, LLC, Louisville, KY, Revised March 2021. https://www.myobloc.com/files/MYOBLOC_PI.pdf
168. Nelson L, Bachoo P, Holmes J. Botulinum toxin type B: A new therapy for axillary hyperhidrosis. *Br J Plast Surg.* 2005;58(2):228-232.
169. O'Brien CF. Treatment of spasticity with botulinum toxin. *Clin J Pain.* 2002; 18: S182-90.
170. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. *Neurology.* 2004;62(1):37-40.
171. Pappert EJ, Germanson T; The Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial. *Mov Disord.* 2007;23(4):510-517.
172. Park J, Lee MS, Harrison AR. Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm. *Clin Ophthalmol.* 2011; 5:725-32.
173. Racette BA, Good L, Sagitto S, Perlmutter JS. Botulinum toxin B reduces sialorrhea in Parkinsonism. *Movement Disord.* 2003;18(9):1059-1061.
174. Racette BA, Lopate G, Good L et al. Ptosis as a remote effect of therapeutic botulinum toxin B injection. *Neurology.* 2002; 59:1445-7.
175. Racette BA, Stambuk M, Perlmutter JS. Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024). *Mov Disord.* 2002; 17:1098-100.

176. Ramirez AL, Reeck J, Maas CS. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. *Otolaryngol Head Neck Surg.* 2002; 126:459-67.
177. Regan J, Murphy A, Chiang M, McMahon BP, Coughlan T, Walshe M. Botulinum toxin for upper oesophageal sphincter dysfunction in neurological swallowing disorders. *Cochrane Database Syst Rev.* 2014;(5):CD009968
178. Sadick NS. Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study. *Dermatol Surg.* 2002; 28:817-21.
179. Sadick NS. Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2,400 and 3,000 U for the treatment of glabellar wrinkles. *Dermatol Surg.* 2003; 29:501-7.
180. Sanger TD, Kukke SN, Sherman-Levine S. Botulinum toxin type B improves the speed of reaching in children with cerebral palsy and arm dystonia: An open-label, dose-escalation pilot study. *J Child Neurol.* 2007;22(1):116-122.
181. Sataloff RT, Heman-Ackah YD, Simpson LL et al. Botulinum toxin type B for treatment of spasmodic dysphonia: a case report. *J Voice.* 2002; 16:422-4.
182. Schwartz M, Freund B. Treatment of temporomandibular disorders with botulinum toxin. *Clin J Pain.* 2002; 18(6 Suppl):S198-203.
183. Schwerin A, Berweck S, Fietzek UM, Heinen F. Botulinum toxin B treatment in children with spastic movement disorders: A pilot study. *Pediatr Neurol.* 2004;31(2):109-113.
184. Setler PE. Therapeutic use of botulinum toxins: background and history. *Clin J Pain.* 2002; 18(Suppl):S119-24.
185. Solstice Neurosciences, Inc. Myobloc® (rimabotulinumtoxinB) Injection. Prescribing Information. San Francisco, CA: Solstice Neurosciences; revised May 2010. Available at: https://www.myobloc.com/files/MYOBLOC_PI.pdf.
186. Stein E. Botulinum toxin and anal fissure. *Curr Probl Dermatol.* 2002; 30:218-26.
187. Terranova W, Breman JG, Locey RP et al. Botulism type B: epidemiologic aspects of an extensive outbreak. *Am J Epidemiol.* 1978; 108:150-6.
188. Toni T, Tamanaha R, Newman B, et al. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series. *Neurol Sci* 2021; 42:5373.
189. Trosch RM, Adler CH, Pappert EJ. Botulinum toxin type B (Myobloc(R)) in subjects with hemifacial spasm: Results from an open-label, dose-escalation safety study.
190. Truong DD, Cullis PA, O'Brien CF et al. BotB (Botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study). *Mov Disorders.* 1997; 12:772-5.
191. Tsui JK. Botulinum toxin as a therapeutic agent. *Pharmacol Ther.* 1996; 72:13-24.
192. Tsui JKC, Hayward M, Mak EKM et al. Botulinum toxin type B in the treatment of cervical dystonia: a pilot study. *Neurology.* 1995; 45:2109-10.
193. van Laborde S, Dover JS, Moore M et al. Reduction in injection pain with botulinum toxin type B further diluted using saline with preservative: a double-blind, randomized controlled trial. *J Am Acad Dermatol.* 2003; 48:875-7.
- 194.

Appendix A

General Recommendations for Time to Retreatment and Dosing

Table 1 provides general recommendations for:

- A. the time to retreatment with botulinum toxin agents, assuming that all other clinical criteria remain met. These recommendations may differ for individual members but should not occur more frequently than every three months. If requests for more frequent injection frequency are made, documentation of medical necessity should be provided.
- B. the doses (in units) of botulinum toxin agents, assuming that all other clinical criteria are met. Although the recommended doses may vary by individual member and condition, they should not be exceeded regardless of indication. If injection dosages exceeding the recommended amounts are requested, further review and documentation of medical necessity may be required. The following table is provided for reference purposes only.

Table 1: Dosage and retreatment information for botulinum toxin regimens by indication

Botox (onabotulinumtoxinA)				
Indication	Initial dose	Subsequent Dose	Retreatment	Additional Considerations
Unless otherwise noted in the indication-specific dosing, total maximum dose per 3 months are as follows: <ul style="list-style-type: none"> • In pediatrics <18 years, the maximum cumulative dose is 10 units/kg or 340 units, whichever is less. • In adults ≥18 years treated for 1 or more indications, the maximum cumulative dose should not exceed 400 units (i.e., ≤400 units per 3 months). 				
Achalasia	20 to 25 units to each of the 4 quadrants in the lower esophageal sphincter		3 months	Maximum recommended dose is 100 units/course Residual lower esophageal sphincter tone of less than 18 mmHg after botulinum injection is a predictor of a good response
Blepharospasm	1.25–2.5 units per injection site	maximum dose per site: 5 units	3 months	Dose during subsequent treatment sessions may be increased by up to two-fold if initial response is insufficient (e.g., the duration of effect is <2 months) Cumulative dose: ≤200 units in 30-day period (i.e., maximum dose of 100 units per eye in a three-month period)
	Typically, 4-6 injection sites are used per affected eye.			
Cervical dystonia	50-200 units total	50-300 units total	3 months	Studies have documented a mean dose of 236 units divided among affected muscles (range: 198-300 units).

				Dose should be divided across all injected sites; Max 50 units/site The total dose injected into the sternocleidomastoid muscle should be limited to 100 units or less to decrease the risk of dysphagia.
Chronic anal fissure	5-100 units		2-4 months	Generally injected into the internal anal sphincter, with half on the right and the remainder into the left
Chronic migraine prophylaxis	155 units total		3 months	given as multiple injections divided among 7 head and neck muscles and 31 injection sites (5 units/injection)
Head/Neck Area Muscle(s)		Total Dose Per Muscle	No. of Injection Sites per Muscle	
Frontalis		20 units	4 sites	
Corrugator		10 units	2 sites	
Procerus		5 units	1 site	
Occipitalis		30 units	6 sites	
Temporalis		40 units	8 sites	
Trapezius		30 units	6 sites	
Cervical paraspinal muscle group		20 units	4 sites	
Total dose per treatment session		155 units	31 sites	
Essential tremors, hand	50-120 units		3-4 months	Injected into the affected hand, divided among multiple injection sites
Essential tremors, head and neck	100-200 units		3-4 months	Injected into the affected muscles in the neck and/or head, divided among multiple injection sites
Hemifacial spasm	12-25 units administered into the inferior and superior orbicularis oculi, buccolabial, and/or platysma muscles. Typically, 20-30 injection sites are used on the affected side of the face, with a starting dosage of 2.5-5 units per injection site.		3 months	Cumulative dose: ≤200 units in 30-day period (i.e., maximum dose of 200 units per treatment session)

Hyperhidrosis, Axillary	50 units/axilla		4 months	Injections should be evenly distributed into multiple sites (10 to 15)
Hyperhidrosis, Palmar	100–120 units (or 50-100 units/palm)	100–165 units per palm	3 months	Inject among multiple (e.g., 50–60) sites in the hyperhidrotic area of each palm Studies have used doses of 200 units per palm
Laryngeal dysphonia	1-5 units/muscle	1-5 units/muscle	3 months	Typical doses range from 1-6 units in studies
Oromandibular dystonias (i.e., cranial dystonia)	10-50 units injected into each affected muscle (25-50 units per side)		3-4 months	Total dose not to exceed 100 units per treatment session
Overactive bladder	100 units per treatment		3 months	Dose should be divided across 20 injection sites
Sialorrhea	10-40 units/side	10-40 units/side	3 months	Total dose should be divided across parotid and submandibular if injecting both
Spasticity, Adult Upper Limb	75 Units to 400 Units divided among selected muscles; ≤50 units per site		3 months	Dose listed is total dose administered as divided separate intramuscular injection(s)
	<ul style="list-style-type: none"> ● Adductor pollicis: 20 units (1 site). ● Biceps brachii: 60 to 200 units (divided into 2 to 4 sites). ● Brachialis: 30 to 50 units (divided into 1 to 2 sites). ● Brachioradialis: 45 to 75 units (divided into 1 to 2 sites). ● Flexor carpi radialis: 12.5 to 50 units (1 site). ● Flexor carpi ulnaris: 12.5 to 50 units (1 site). ● Flexor digitorum profundus: 30 to 50 units (1 site). ● Flexor digitorum sublimis: 30 to 50 units (1 site). ● Flexor pollicis brevis/opponens pollicis: 5 to 25 units (1 site). ● Flexor pollicis longus: 20 units (1 site). ● Lumbricals/interossei: 5 to 10 units (1 site). ● Pronator teres: 15 to 25 units (1 site). ● Pronator quadratus: 10 to 50 units (1 site). <p>Stroke-related upper limb spasticity</p> <ul style="list-style-type: none"> ● Adductor pollicis: 20 units (1 to 2 sites) ● Biceps brachii: 100 to 200 units (up to 4 sites) 			

	<ul style="list-style-type: none"> • Flexor digitorum profundus: 15 to 50 units (1 to 2 sites) • Flexor digitorum sublimes: 15 to 50 units (1 to 2 sites) • Flexor carpi radialis: 15 to 60 units (1 to 2 sites) • Flexor carpi ulnaris: 10 to 50 units (1 to 2 sites) • Flexor pollicis longus: 20 units (1 to 2 sites) 		
Spasticity, Adult Lower Limb	300 Units to 400 Units divided among 5 muscles; ≤50 units per site	3 months	Dose listed is total dose administered as divided separate intramuscular injection(s)
	<ul style="list-style-type: none"> • Flexor digitorum longus: 50 units (divided into 2 sites) • Flexor hallucis longus: 50 units (divided into 2 sites) • Gastrocnemius lateral head: 75 units (divided into 3 sites) • Gastrocnemius medial head: 75 units (divided into 3 sites) • Soleus: 75 units (divided into 3 sites) • Tibialis posterior: 75 units (divided into 3 sites) 		
Spasticity, Associated with Cerebral Palsy in Pediatric Patients	Maximum dose per treatment session: 3–6 units/kg for large muscles, 1–2 units/kg for small muscles; maximum dose of 50 units per injection site	3 months	Maximum recommended total dose administered during a single treatment session should not exceed 12 units/kg or 400 units, whichever is less.
	Upper extremity: 3 to 6 units/kg total per session divided up amongst affected muscles; maximum dose per site: 50 units/site; maximum total dose per treatment session in the upper limb: 6 units/kg or 200 units total, whichever is less.		
	<ul style="list-style-type: none"> • Biceps brachii: 1.5 to 3 units/kg divided in 4 sites • Brachialis: 1 to 2 units/kg divided in 2 sites • Brachioradialis: 0.5 to 1 unit/kg divided in 2 sites • Flexor carpi radialis: 1 to 2 units/kg divided in 2 sites • Flexor carpi ulnaris: 1 to 2 units/kg divided in 2 sites • Flexor digitorum profundus: 0.5 to 1 unit/kg divided in 2 sites • Flexor digitorum sublimis: 0.5 to 1 unit/kg divided in 2 sites 		
	Lower extremity: 4 to 8 units/kg total per session divided up amongst affected muscles; maximum dose per site: 50 units/site; maximum total dose per treatment session in the lower limb or visit: 8 units/kg or 300 units total, whichever is less.		
	<ul style="list-style-type: none"> • Gastrocnemius lateral head: 1 to 2 units/kg divided in 2 sites • Gastrocnemius medial head: 1 to 2 units/kg divided in 2 sites • Soleus: 1 to 2 units/kg divided in 2 sites • Tibialis posterior: 1 to 2 units/kg divided in 2 sites 		
Strabismus	<ul style="list-style-type: none"> • Vertical muscles and for horizontal strabismus <20 prism diopters: 1.25 to 2.5 units in any one muscle • Horizontal strabismus of 20 to 50 prism diopters: 2.5 to 5 	3 months	<p>Max dose as a single injection for any one muscle is 25 units.</p> <p>Subsequent doses for patients experiencing incomplete paralysis of the target may be increased up</p>

	units in any one muscle <ul style="list-style-type: none"> Persistent VI nerve palsy ≥ 1 month: 1.25 to 2.5 units in the medial rectus muscle 			to twice the previous administered dose.
Upper extremity focal dystonia	20-80 units/limb	20-200 units/limb	3 months	Total dose should be injected across affected muscles Studies have used doses of 200-360 units per treatment session.
Urinary incontinence due to detrusor overactivity secondary to neurologic condition	Adults: 200 units per treatment		3 months	given as 30 separate injections of approximately 6.7 units each into the detrusor muscle (avoiding the trigone)
	Children ≥ 5 years and < 18 years, weight ≥ 34 kg: 200 units per treatment			administered as 20 injections
	Children ≥ 5 years and < 18 years, weight < 34 kg: 6 units/kg per treatment			administered as 20 injections
Dysport (abobotulinumtoxinA)				
Indication	Initial dose	Subsequent Dose	Retreatment	Additional Considerations
Axillary hyperhidrosis	100-200 units/axilla	100-500 units/axilla	3 months	Injections should be evenly distributed into multiple sites ~1 to 2 cm apart (10 to 20 injections)
Blepharospasm or hemifacial spasm	120 units subcutaneously per eye: 20-40 units/injection	80 units per eye: 20 units/injection	3 months	Cumulative dose: < 60 units/eye or 120 units/both eyes per 3 month period after the initial dose
Cervical dystonia	500 units divided among affected muscles	250-1000 units	3 months	Dose should be divided among all treated muscles, retreatment should be no greater than 250 units more than prior treatment dose
Chronic anal fissure	90 to 150 units in 2 divided doses (up to 250-500 units total)		2-4 months	injected into the internal anal sphincter on each side of the anterior midline Some studies have supported use of two injections of 90 units (180 units total)
Sialorrhea	15 to 75 units injected per gland (submandibular, parotid or both)		4-6 months	Injection should be into parotid and/or submandibular gland.

	either unilaterally or bilaterally		Studies have used a total of 250 units, guided by ultrasound.
Spasticity of upper/lower extremity (Adult)	<p>Maximum recommended total dose (upper and lower limbs combined) is 1,500 units</p> <ul style="list-style-type: none"> • upper limb spasticity, total doses of 500 and 1,000 units divided among selected muscles • lower limb spasticity, total doses of 1,000 and 1,500 units divided among selected muscles 	3-5 months	Maximum total dose (including upper AND lower limbs combined) not to exceed 1500 units per 3 month period.
	<p>Upper limbs:</p> <ul style="list-style-type: none"> • Brachialis: 200 to 400 units (1 to 2 injections per muscle). • Brachioradialis: 100 to 200 units (1 to 2 injections per muscle). • Biceps brachii: 200 to 400 units (1 to 2 injections per muscle). • Flexor carpi radialis: 100 to 200 units (1 to 2 injections per muscle). • Flexor carpi ulnaris: 100 to 200 units (1 to 2 injections per muscle). • Flexor digitorum profundus: 100 to 200 units (1 to 2 injections per muscle). • Flexor digitorum superficialis: 100 to 200 units (1 to 2 injections per muscle). • Pronator teres: 100 to 200 units (1 injection per muscle). 		
	<p>Lower limbs:</p> <ul style="list-style-type: none"> • Flexor digitorum longus: 130 to 200 units (1 to 2 injections per muscle). • Flexor hallucis longus: 70 to 200 units (1 injection per muscle). • Gastrocnemius, medial head: 100 to 150 units (1 injection per muscle). • Gastrocnemius, lateral head: 100 to 150 units (1 injection per muscle). • Soleus: 330 to 500 units (3 injections per muscle). • Tibialis posterior: 200 to 300 units (2 injections per muscle). 		
Spasticity of upper/lower extremity (Pediatric, Children ≥2 years and Adolescents <18 years)	<p>Upper Limb: 8 Units/kg to 16 Units/kg per limb</p> <ul style="list-style-type: none"> • Maximum total dose per treatment session = 16 Units/kg or 640 Units, whichever is lower 	3 months	Maximum total dose per treatment session = 30 Units/kg or 1000 Units, whichever is lower
	<p>Lower Limb: 10 Units/kg to 15 Units/kg per limb</p> <ul style="list-style-type: none"> • Maximum total dose per treatment session for unilateral limb injections = 15 Units/kg or 1000 Units, whichever is lower • Maximum total dose per treatment session for bilateral limb injections = 30 Units/kg or 1000 Units, whichever is 		

	lower			
	Upper extremity <ul style="list-style-type: none"> • Brachialis: 3 to 6 units/kg (up to 2 sites per muscle) • Brachioradialis: 1.5 to 3 units/kg (1 site per muscle) • Biceps brachii: 3 to 6 units/kg (up to 2 sites per muscle) • Flexor carpi radialis (FCR): 2 to 4 units/kg (up to 2 sites per muscle) • Flexor carpi ulnaris (FCU): 1.5 to 3 units/kg (1 site per muscle) • Flexor digitorum profundus (FDP): 1 to 2 units/kg (1 site per muscle) • Flexor digitorum superficialis (FDS): 1.5 to 3 units/kg (up to 4 sites per muscle) • Pronator quadratus: 0.5 to 1 units/kg (1 site per muscle) • Pronator teres: 1 to 2 units/kg (1 site per muscle) Total dose: 8 to 16 units/kg not to exceed 640 units			
	Lower extremity: <ul style="list-style-type: none"> • Gastrocnemius: 6 to 9 units/kg (1 to 4 sites per muscle) • Soleus: 4 to 6 units/kg (1 to 2 sites per muscle) Total: 10 to 15 units/kg divided across both muscles (1 to 6 sites per muscle)			
Upper extremity focal dystonia	15-150 units	15-150 units	3 months	Total dose should be injected across affected muscles. Total doses of 250-350 units have been utilized.
Myobloc (rimabotulinumtoxinB)				
Indication	Initial dose	Subsequent Dose	Retreatment	Additional Considerations
Cervical dystonia	2,500 to 5,000 units divided among the affected muscles in patients previously treated with botulinum toxin; initial dose in previously untreated patients should be lower.		3-4 months	Toxin treatment-naive patients: Use a lower initial dose.
Sialorrhea	1,500 to 3,500 units divided among the parotid (500 to 1,500 units/gland) and submandibular (250 units/gland) glands (1 injection per side of face)		3-6 months	Injection should be into parotid and/or submandibular gland
Xeomin (incobotulinumtoxinA)				
Indication	Initial dose	Subsequent Dose	Retreatment	Additional Considerations
Blepharospasm or hemifacial spasm	25 units per eye (50 units per treatment session)	maximum dose: 50 units per eye (100 units per treatment session)	3 months	
Cervical dystonia	120 units divided into affected muscles	120-400 units	3 months	Maximum cumulative dose per treatment session: 400 units. Initial doses >120 units not shown to provide additional efficacy and

			may be associated with increased incidence of adverse effects.
Sialorrhea	100 units divided among the parotid (30 units/gland) and submandibular (20 units/gland) glands on both sides (ie, 4 injection sites per treatment session)	4 months	divide dose with a ratio of 3:2 between parotid and submandibular glands.
Spasticity of the upper limb	See the below table for dose range for specific muscle group and maximum dose.	3 months	Maximum cumulative dose per treatment session: 400 units.

Dosing of IncobotulinumtoxinA for Upper Limb Spasticity in Adults			
Clinical Pattern/Muscle	Recommended Dose per Muscle	Recommended No. of Injection Sites per Muscle	
Clenched fist; flexor digitorum superficialis	25–100 units	2 sites	
Clenched fist; flexor digitorum profundus	25–100 units	2 sites	
Flexed wrist; flexor carpi radialis	25–100 units	1-2 sites	
Flexed wrist; flexor carpi ulnaris	20–100 units	1-2 sites	
Flexed elbow; brachioradialis	25–100 units	1-3 sites	
Flexed elbow; biceps	50–200 units	1-4 sites	
Flexed elbow; brachialis	25–100 units	1-2 sites	
Pronated forearm; pronator quadratus	10–50 units	1 site	
Pronated forearm; pronator teres	25–75 units	1-2 sites	
Thumb-in-palm; flexor pollicis longus	10–50 units	1 site	
Thumb-in-palm; adductor pollicis	5–30 units	1 site	
Thumb-in-palm; flexor pollicis brevis/opponens pollicis	5–30 units	1 site	
<p>Dosing of IncobotulinumtoxinA for Upper Limb Spasticity in Children ≥ 2 years and Adolescents ≤ 17 years</p> <p><i>NOTE: If a single upper extremity being treated, the total dose should not exceed 8 units/kg divided among affected muscles up to a maximum of 200 units per single upper limb; if both upper limbs are treated, total dose should not exceed 16 units/kg up to a maximum of 400 units.</i></p>			
Muscle	Dosage Range	Maximum Dose (units)	Number of Injection Sites Per Muscle

Adductor pollicis	0.5 units/kg	12.5	1	
Biceps	2 to 3 units/kg	75	1 to 3	
Brachialis	1 to 2 units/kg	50	1 to 2	
Brachioradialis	1 to 2 units/kg	50	1 to 2	
Flexor carpi radialis	1 unit/kg	25	1	
Flexor carpi ulnaris	1 unit/kg	25	1	
Flexor digitorum profundus	1 unit/kg	25	1	
Flexor digitorum superficialis	1 unit/kg	25	1	
Flexor pollicis brevis/Opponens pollicis	0.5 unit/kg	12.5	1	
Flexor pollicis longus	1 unit/kg	25	1	
Pronator quadratus	0.5 units/kg	12.5	1	
Pronator teres	1 to 2 units/kg	50	1 to 2	
Daxxify (daxibotulinumtoxinA-lanm)				
Indication	Initial dose	Subsequent Dose	Retreatment	Additional Considerations
Cervical dystonia	125 to 250 units divided among affected muscles		3 months	Total recommended dosage for a single treatment session: 125 to 250 units. Dose and number of injection sites should be personalized considering previous treatment, response, duration of effect, and any adverse events. The dosage can be modified by increments of 50 to 75 units depending on the individual's response.

Appendix B

Table 1: Diagnostic criteria according to the International Classification of Headache Disorders, 3rd edition (ICHD-3)

Diagnosis	Criteria
Migraine without aura	BOTH of the following: 1. A history of at least FIVE (5) attacks ¹ meeting ALL of the following:

Diagnosis	Criteria
	<ul style="list-style-type: none"> a. Headache attacks lasting at least 4 hours (when untreated or unsuccessfully treated)^{2,3}; <i>and</i> b. Headache is characterized by at least <i>TWO (2)</i> of the following: <ul style="list-style-type: none"> i. Aggravation by or causing avoidance of routine physical activity(e.g., walking or climbing stairs); <i>or</i> ii. Moderate to severe pain; <i>or</i> iii. Pulsating quality; <i>or</i> iv. Unilateral (one-sided) location; <i>and</i> c. During headache, at least <i>ONE (1)</i> of the following: <ul style="list-style-type: none"> i. Nausea and/or vomiting; <i>or</i> ii. Photophobia (sensitivity to light) and/or phonophobia (sensitivity to sound); <i>and</i> <p>2. Provider attestation indicating that other potential causes of headache have been ruled out.</p>
Migraine with aura	<p>BOTH of the following:</p> <ul style="list-style-type: none"> 1. A history of at least <i>TWO (2)</i> attacks meeting BOTH of the following: <ul style="list-style-type: none"> a. At least <i>ONE (1)</i> of the following fully reversible aura symptoms: <ul style="list-style-type: none"> i. Brainstem (e.g., dysarthria, vertigo, tinnitus, diplopia); <i>or</i> ii. Motor; <i>or</i> iii. Retinal (eg, scintillations, scotomata, blindness); <i>or</i> iv. Sensory, including positive features (e.g., pins and needles) and/or negative features (e.g., numbness); <i>or</i> v. Speech and/or language (e.g., loss of ability to express speech); <i>or</i> vi. Visual, including positive features (e.g., flickering lights, spots, lines) and/or negative features (e.g., loss of vision); <i>and</i> b. At least <i>THREE (3)</i> of the following: <ul style="list-style-type: none"> i. At least one aura symptom is positive⁶; <i>or</i> ii. At least one aura symptom is unilateral⁵; <i>or</i> iii. At least one aura symptoms spreads gradually over 5 or more minutes; <i>or</i>

Diagnosis	Criteria
	<ul style="list-style-type: none"> iv. Each individual aura symptom lasts between 5 and 60 minutes⁴; <i>or</i> v. The aura is accompanied or followed within 60 minutes by headache; <i>or</i> vi. Two or more symptoms occur in succession; <i>and</i> <p>2. Provider attestation indicating that other potential causes of headache have been ruled out</p>
Episodic Cluster Headache	<p>ALL of the following:</p> <ul style="list-style-type: none"> 1. A history of at least 5 attacks meeting ALL of the following: <ul style="list-style-type: none"> a. severe or very severe unilateral orbital, supraorbital, and/or temporal pain lasting 15 to 180 minutes⁷; <i>and</i> b. occurring with a frequency between one every other day and eight per day⁸; <i>and</i> c. Headache is accompanied by a sense of restlessness or agitation and/or at least ONE (1) of the following (on the same side of the body): <ul style="list-style-type: none"> i. Eyelid swelling or drooping; <i>or</i> ii. Increased redness or tearing of the eye; <i>or</i> iii. Forehead and facial sweating; <i>or</i> iv. Pupil contraction; <i>or</i> v. Stuffy or runny nose (nasal congestion); <i>and</i> 2. At least TWO (2) cluster periods lasting one week to a year (when untreated), separated by attack-free intervals (i.e. remission) lasting at least 3 months; <i>and</i> 3. Provider attestation indicating that other potential causes of headache have been ruled out

¹ Distinguishing a single migraine attack from a symptomatic migraine-like attack can be challenging. Additionally, the nature of only one or a few attacks may be difficult to ascertain. Therefore, a diagnosis of migraine without aura requires at least five attacks to establish the disease pattern. Patients with fewer than five attacks who otherwise meet diagnostic criteria should be designated as having probable migraine without aura.

² If a migraine attack ends when the patient falls asleep, the duration of the attack should be determined based on the time up until the point of falling asleep.

³ In children and adolescents under 18 years of age, migraine attacks may last from 2 hours up to 72 hours. Evidence has not confirmed untreated attack durations of less than 2 hours in pediatric patients.

⁴ If three distinct aura symptoms occur, the maximum acceptable total duration would be 3 × 60 minutes. Motor symptoms may persist for up to 72 hours.

⁵ Aphasia should always be categorized as a unilateral symptom. Dysarthria may or may not be unilateral.

⁶ Positive aura symptoms include scintillations (a visual disturbance characterized by shimmering or flickering) and pins and needles sensations.

⁷ For less than half of the duration of an active cluster headache period, some attacks may be of lesser severity and/or shorter or longer duration compared to a patient's typical attack pattern.

⁸ For less than half of the duration of an active cluster headache period, some attacks may occur at a lower frequency than is typical for a patient.

Clinical Guideline Revision / History Information

Original Date: 08/07/2017

Reviewed/Revised: 01/18/2018, 07/31/2018, 04/15/2019, 08/6/2020, 03/11/2021, 12/01/2021, 03/17/2022, 06/23/2022, 09/15/2022, 12/08/2022, 03/23/2023, 12/14/2023, 03/21/2024, 07/01/2025, 04/01/2026